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Abstract 
Atypical haemolytic uraemic syndrome (aHUS) is renal disease associated with 
mutations and/or polymorphisms in genes encoding complement proteins, 
including complement factor H (CFH), factor I (CFI) and membrane cofactor 
protein (CD46). Recently, deficiency of CFH-related (CFHR) proteins 1 and 3 
(via loss of the CFHR3/CFHR1 gene block) was linked to the generation of 
autoantibodies to CFH. Around 10% of aHUS patients develop CFH 
autoantibodies, adding aHUS to a growing list of kidney diseases with a defined 
autoimmune component. IgA nephropathy (IgAN) is another such renal disease, 
where autoantibodies target an aberrantly glycosylated IgA1.  
To investigate the role of CFH and CFHR copy number variation in the control 
of complement activation in aHUS and IgAN, I have first generated a full panel 
of recombinant CFHR proteins in mammalian cell culture. These were then 
used to generate unique monoclonal antibodies (mAbs) and ELISA protocols to 
screen for autoantibodies.  
Using carefully optimised immunisation protocols, I used my recombinant CFHR 
proteins to produce several highly-specific CFHR mAbs. One of which targets 
CFHR1 (R1/1037) and three target CFHR4 (R4/244, R4/277 and R4/123). The 
generation of these antibodies have allowed putative ELISA screens to be 
developed to measure the concentration of CFHR4 in healthy individuals and 
aHUS patients. 
My full panel of CFHR proteins also enabled screening of both aHUS and IgAN 
patients for the presence of autoantibodies to CFH and the CFHR proteins. 
Screening of aHUS plasma did not indicate the presence of any novel CFHR 
autoantibodies. However, IgA autoantibodies against CFHR5 (~9%) and CFH 
(~32%) were detected in IgAN patients. Interestingly, 64% of IgAN patients 
show reactivity with bovine CFH. 
During this PhD, I have generated a panel of unique reagents for the study of 
CFHR proteins in health and disease. These have allowed me to demonstrate 
for the first time, the presence of CFH and CFHR5 autoantibodies in a 
preliminary cohort of IgAN patients. 
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Chapter 1 
1. General Introduction 
1.1 Introductory Overview 
The complement system plays a diverse role in the immune response of a wide 
variety of different species. This highlights the ancient origins and evolution of 
complement2-4. The human complement system was initially considered as only 
being part of innate immunity, providing a primary line of defence against 
infection. However, in the last 40 years it has become increasingly evident that 
the complement system also plays a significant supportive role in the 
development of adaptive immunity5,6. 
While complement provides us with an essential first line of defence, there are 
occasions where problems arise and disease ensues. Disease associated with 
complement can be categorised into diseases associated with complement 
deficiency, and diseases associated with issues of complement regulation. The 
former constitutes a lack of complement activation, whereby the basic functions 
of complement are compromised leading to an increased risk from infection, 
while the latter results in unregulated complement activation leading to cell and 
tissue damage. 
Complement is ubiquitous in the body and therefore protection from unwanted 
complement activation in all tissues and organs is required. It is not surprising 
that deficiencies in complement genes/proteins result in a variety of disease 
states. Complement has been implicated in diseases such as asthma7-11, 
systemic lupus erythematosus (SLE)12-14, glomerulonephritis15-17, rheumatoid 
arthritis (RA)18-20, multiple sclerosis21-25, ischemia-reperfusion injury26,27 and 
rejection in organ transplantation28,29. The complement system is also becoming 
increasingly implicated in diseases affecting the central nervous system, such 
as Alzheimer's disease and other neurodegenerative conditions30-32. 
For the purpose of this study, the emphasis will be placed upon inefficient 
regulation of complement activation, and this will be termed ‘dysregulation’ 
throughout.  
 
1 
 
Several human diseases are associated with complement dysregulation, 
including age-related macular degeneration (AMD), membranoproliferative 
glomerulonephritis type 2 (MPGN2), and atypical haemolytic uraemic syndrome 
(aHUS). Herein, I will focus on aHUS as a model disease to probe the 
complexity of complement regulation in disease. The research aims are 
designed specifically to bring a clearer understanding of how failure/deficiency 
of certain fluid-phase complement regulatory proteins may confer an increased 
risk of aHUS. I will also study immunoglobulin A nephropathy (IgAN), a disease 
where the involvement of complement is less well defined, and assess whether 
there is evidence that these fluid-phase complement proteins can directly 
influence the onset and/or progression of IgAN. 
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1.2 The Complement System 
The bactericidal property of human serum was first described in the late 
1800s33-35. Further studies by Ehrlich36,37 demonstrated that this same factor 
was involved in the lysis of erythrocytes by immune serum. It was Ehrlich who 
first used the term 'complement' to indicate that this factor augmented or 
'complemented' the bacterolytic and haemolytic activity of antibodies (Ab). It is 
now established that the complement system consists of over 40 proteins, 
present in fluid-phase, or in association with cell membranes. These 
complement proteins interact in a precise and tightly controlled manner to bring 
about a diverse range of effects, including the promotion of inflammation, 
enhancement of phagocytosis, and lysis of unprotected microbial cells. 
1.2.1 The Pathways of Complement Activation 
The complement system is a major component of the innate immune response, 
with supportive roles within the development of adaptive immunity38,39. There 
are 3 activation pathways, which are triggered via a range of different stimuli 
(Figure 1.1). The classical pathway (CP) is activated both by immune 
complexes (antigen/Ab complexes) and via C1q bound directly to pathogenic 
cell surface. The lectin (LP) pathway is activated through the binding of 
mannose-binding lectin (MBL) or ficolin molecules to unique saccharide 
residues on microbial cell surfaces, and the alternative pathway (AP) is 
activated in response to the unregulated cell surface of microbial cells. All 
complement pathways eventually converge upon the formation of C3 
convertase. Subsequent downstream events lead to the production of the C5 
convertase, which leads to the construction of the membrane-attack complex 
(MAC). The MAC is a polymeric pore which ‘punctures’ unregulated cell 
membranes, resulting in disruption to the osmotic balance of the cell which 
results in cell lysis and death.  
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Figure 1.1: The Pathways of the Complement System 
The complement system is composed of 3 pathways; the classical, the alternative, and the 
lectin pathway. All pathways are activated by different stimuli, but all converge to C3 
convertase leading to a uniform progression to C5 convertase and the construction of the 
membrane attack complex (MAC). 
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1.2.2 The Classical and Lectin Pathways 
The CP and LP pathways are activated via different stimuli (as previously 
described), but after activation the LP merges with the CP. 
The CP is activated via the binding of the C1-complex to Ab bound antigen (i.e. 
immune complexes). The C1-complex comprises one copy of C1q, two copies 
of C1r, and 2 copies of C1s (C1qr2s2). The C1q component binds to both IgM 
and IgG immune complexes, causing a conformational change that leads to 
activation of the serine protease activity of the C1r components. C1r then 
cleaves C1s, activating the serine protease activity of this component. The C1s 
component then cleaves fluid-phase complement component 4 (C4) into C4a 
and C4b. The C4b fragment then associates with cell surfaces via covalent 
thioester bonding, while the C4a fragment is released with weak analphylatoxic 
activity40. C2 is recruited to the cell surface-bound C4b, and is subsequently 
cleaved by C1s into C2a and C2b. The C2a fragment remains in association 
with C4b, building the CP C3 convertase, C4b2a. The C2b fragment is 
released. The function of fluid-phase C2b is unclear, but it has been suggested 
to increase vascular permeability, thus contributing to the proinflammatory 
environment and infiltration of immune cells41 The C3 convertase then recruits 
fluid-phase C3, cleaving it into C3a and C3b. The C3b fragment remains in 
association with the C3 convertase, forming the CP C5 convertase (C4b2a3b). 
The C3a fragment is released into fluid-phase where it serves as a potent 
anaphylatoxin42. C5 convertase then cleaves fluid-phase C5 into C5a and C5b. 
C5b associates with fluid-phase C6 and C7 (C5b-7) at the cell surface. C5b-7 
then binds C8 to form the C5b-8 complex, which results in sequential binding of 
multiple copies of C9, to form the MAC43,44. The MAC is a membrane-spanning 
lytic pore which results in disruption to the osmotic balance of the targeted cell 
and lysis45,46.  
The LP relies upon the presence and recognition of bacterial polysaccharides 
by a group of collectins and ficolins with carbohydrate recognition domains. The 
collectin MBL, was once thought to be the only activator of the LP, but more 
recently a group of ficolins known as filcolin-M (or ficolin-1), ficolin-L (ficolin-2), 
and ficolin-H (ficolin-3) were also found to be potent activators of the pathway47. 
A recent study found another collectin with LP activatory properties, known as 
 
5 
 
CL-1148. Each lectin can bind to bacterial polysaccharides, and other 
glycoconjugates rich in D-mannose, N-acetyl-D-glucosamine and L-fucose. 
Three MBL-associated serine proteases (MASP-1, MASP-2 and MASP-3) are 
found associated with the lectin recognition molecules. MASP-2 is thought to be 
the main activator component of the LP, with MASP-1 and MASP-2 playing 
other up- or downregulatory functions49-54. Additionally, the protein products of 
MASP transcript alternative splicing (sMAP and MAP-1) are also found in 
association with the lectin/MASP complex, but their functional significance 
remains unclear.   
Upon binding of the lectin component to microbial carbohydrate residues, 
MASP components sequentially cleaved into active serine proteases. The 
activated lectin/MASP complex then cleaves C4 and C2, in the same manner as 
the C1-complex. This leads to construction of the CP C3 convertase (C4b2a) 
and subsequent downstream events towards terminal MAC formation.   
1.2.3 The AP of Complement Activation 
The AP of complement activation is the only pathway to exist in a constitutively 
activated state. Approximately 1% of fluid-phase C3 exists in a hydrolysed form 
(C3.H2O), which enables binding of complement factor B (CFB), which in-turn 
initiates activation of the AP. This state of immunological ‘readiness’ is referred 
to as the ‘tick-over’ effect. However, in steady state conditions (i.e. no microbial 
infection), complement activation is closely monitored by a series of regulatory 
proteins which act to decay C3.H2O/CFB interactions. This maintains a balance 
between protective and destructive activation of the AP.  
In the presence of an activator surface (unregulated microbial cell membranes) 
there is enhancement of AP complement activation. However, host tissues are 
protected from complement attack by a tightly controlled mechanism of 
complement regulation. Binding of C3.H2O to CFB is not regulated at the 
microbial cell surface, resulting in the proteolytic cleavage of bound CFB by 
fluid-phase protease complement factor D (CFD), into C3-associated Bb, and 
free Ba. The C3.H2O/Bb complex is the first active C3 convertase in AP 
activation, and functions to cleave inactive C3 into C3a and C3b. C3b interacts 
with unregulated cell surfaces via thioester covalent bonding (as C4b does). As 
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with C3.H2O, C3b complexes with CFB and is cleaved in the same manner to 
form an alternate version of C3 convertase, C3b/Bb. This process continues, 
rapidly creating a positive amplification-loop of complement activation via C3 
convertase formation and C3 cleavage (Figure 1.2).  
C3b/Bb also recruits an additional C3b molecule at the cell surface resulting in a 
C3b2/Bb complex. C3b2/Bb is the C5 convertase of the AP, and functions to 
cleave inactive C5, into the active C5b and C5a components. C5b associates 
with the unprotected microbial cell surface, and triggers formation of the MAC 
(as previously described). C3a and C5a are potent anaphylatoxins with roles in 
promoting inflammation, recruitment of polymorphonuclear (PMN) cells and 
activation/modulation of dendritic cells (DC), macrophages (Mø) and T-cells55. 
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 Figure 1.2: The AP of complement activation 
The AP is constitutively activated due to hydrolysed C3 ‘tick-over’. Therefore, pathway 
activation is closely regulated by complement regulators (see red boxes) at the host cell 
surfaces. On unregulated surfaces (e.g. a bacterial cell surface), AP activation 
progresses, resulting in a positive amplification of self-perpetuating complement 
activation. 
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1.2.4 Regulation of AP Activation 
Binding of C3b at the cell surface is indiscriminate between host tissue and 
pathogenic cells, so there is clearly a requirement for regulatory proteins at the 
host cell surface. The genes coding the complement regulatory proteins are 
grouped together in the ‘Regulators of Complement Activation’ (RCA) gene 
cluster, positioned on chromosome 1 (1q32), along with a selection of other 
immunologically active genes (Figure 1.3). One of the key features of the 
regulatory proteins encoded by genes within the RCA cluster is their unique 
structural presentation. They are composed of a series of short consensus 
repeats (SCR), also referred to as complement control proteins (CCP), or sushi 
domains. For simplicity, they will be referred to as SCR domains throughout.  
Many of the regulatory proteins are membrane bound, and function to 
specifically prevent activation at the cell surface. For example, membrane 
cofactor protein (CD46) and complement receptor 1 (CR1) bind active C3b, 
allowing for fluid-phase regulator complement factor I (CFI) to cleave the 
complement proteins into an inactive state. Another example of a membrane-
associated regulator is decay-accelerating factor (DAF). The regulatory role of 
DAF is to decay the AP C3 convertase (C3bBb), via specific binding to the Bb 
component56. The decay of the C3 convertase results in blocking of the AP 
positive amplification loop. 
There are also fluid-phase regulators that circulate to prevent fluid phase 
activation of complement. Some fluid-phase complement regulators are thought 
to also regulate cell surface complement activation. Complement factor H (CFH) 
is a fluid-phase complement regulator that is recruited to the cell surface upon 
deposition of C3b (a marker of complement activation). CFI is another fluid-
phase regulator, which works in conjunction with CFH, CR1 and CD46. In the 
AP, CFH and CFI are the main regulatory proteins which work in unison to 
prevent complement activation. 
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Figure 1.3: The Regulators of Complement Activation (RCA) gene cluster 
The RCA gene cluster is found located on chromosome 1, at position q32. There are 
several complement regulatory genes found clustered here, including the genes 
encoding the CFH and CFHR1-5 proteins. 
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1.3 Complement and Adaptive Immunity 
The breakdown of complement proteins during complement activation (and 
regulation) results in several bioactive complement protein fragments, or by-
products. These include the C3a and C5a anaphylatoxins as well as the 
C3b/C3d opsonins. These proteins have been shown to be critical in the optimal 
function of the immune system as a whole. Antigen presenting cells, such as 
Møs and DCs, express significantly higher levels of C3a and/or C5a receptors 
(R) on their cell surface. Recent studies have shown that C3aR and/or C5aR 
are expressed on several DC subsets, in response to different stimuli (e.g. 
microbial antigen, inflammatory mediators, complement products)57-61. 
Therefore, C3a and C5a have the potential to alter the differentiation and/or 
activation profile of DCs, which in turn will selectively drive a particular T-cell 
mediated response. Indeed, early studies into the role of C3a and C5a in 
adaptive immunity have highlighted that both anaphylatoxins have immune 
regulatory functions62-64. C3a has been shown to be a potent suppressor of 
antigen-specific and non-specific Ab responses, while C5a was found to 
influence both Ab responses and antigen-induced T-cell proliferation. In recent 
studies, several animal models have been used to demonstrate that blocking 
the ability of C5a to interact with the C5aR is sufficient to impair T-cell 
responses (including Th165-67, Th268-70 and Th1771-73 responses).  
The immune system is highly interlinked and this is never clearer than when 
looking at the interaction of B and T-cells. Productive T-cell responses are 
necessary for full activation of B-cells, as primed B-cells (encountered antigen 
and presenting peptides on cell surface HLA molecules) require T-cell help to 
become fully activated. As C3a and C5a are involved in B and T-cell responses, 
problems or alterations in complement activation/regulation may result in a poor 
adaptive immune response, or even the onset of autoimmunity.  
Systemic lupus erythematosus (SLE) is a prime example where complement 
activation and the presence of complement deposition products are associated 
with disease. Beyond the strong up-regulation of C3aR in lupus prone mice with 
active nephritis, the C3 fragment, C3d and the function of its receptor 
(complement receptor 2, or CR2; expressed on B-cells), are particularly linked 
with disease. C3d is the final breakdown product of C3 and is covalently linked 
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to antigen during complement activation. If the C3d coated antigen is 
recognised by a specific B-cell receptor (BCR) it can also interact with CR2, 
resulting in the cross-linking these B-cell surface receptors. This leads to a 
much stronger intracellular B-cell activation signal, compared to the relatively 
weak signal achieved to an antigen without C3d. Therefore, complement (C3d) 
and CR2 play a critical role in B-cell response74. A key feature in SLE is low 
expression levels of CR2. Subsequent studies using murine models have 
demonstrated that abnormalities in CR2 lead to an SLE-like disease. These 
studies provide a rational for C3d and complement activation being regarded as 
essential in helping to define immune tolerance. Immune tolerance or the ability 
to discriminate between self and non-self is one of the biggest challenges faced 
in the development of a fully functional adaptive immune system.  
Like many diseases with a strongly defined complement component, SLE is 
characterised by the deposition of immune complexes in multiple organs of the 
body, including the kidney, where patients are reported to present with lupus 
nephritis (LN). Key features in the progression of LN, are deposits in the kidney 
and proliferation of the mesangium. Such characteristics are also seen in IgA 
nephropathy (IgAN), where IgA-based immune complexes are found deposited 
within the mesangium. Here, the role of complement remains much less clear 
but evidence is building. 
. 
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1.4 Overview of the pathogenesis of IgAN 
Immunoglobulin (Ig) A nephropathy (IgAN) was first described in 1968, and is 
now recognised as the world’s most common glomerulonephritis75,76. IgAN is 
characterised by IgA1 deposition in the glomerular mesangium, with co-
localised C3 deposits, and immune-complexed IgG and IgM75,77-81. There is also 
a marked increase in circulating IgA levels in over 50% of patients82-84. The key 
features of the IgA1 found increased in circulation and in mesangial deposits 
are that it is polymeric (pIgA1) and contains aberrantly glycosylated side chains 
(galactose deficient O-linked glycans)85-88 that appear to influence proliferation 
of the mesangial cells85. 
1.4.1 The molecular basis of aberrantly glycosylated IgA1 
IgA1 contains a 17 amino acid hinge region, located centrally in the α-heavy 
chain. The hinge region undergoes post-translation modification whereby 6 O-
linked glycan chains can be added (Figure 1.4)89. The primary glycan 
modification is N-acetylgalactosamine (GalNAc), in O-linkage with hinge serine 
or threonine residues. Under normal conditions a galactose residue is attached 
to the GalNAc residue by the enzyme ‘C1GalT1’, which requires the molecular 
chaperone ‘Cosmc’ to ensure its correct folding. Therefore, an issue with either 
the enzyme or chaperone system could be responsible for the galactose 
deficient status of aberrantly glycosylated IgA1 in IgAN. Several sets of results 
have suggested down regulation of ‘C1GalT1’ and/or ‘Cosmc’ as a key event in 
this process90-92. 
1.4.2 IgAN, autoantibodies and complement activation 
IgAN is now considered an immune-complex disease. The aberrantly 
glycosylated IgA1 is one feature of the immune complexes, but there is also 
evidence of autoantibodies targeting the abnormal pattern of glycosylation at 
the hinge region. IgM, IgG and IgA1 autoantibodies have been identified in 
mesangial deposits93,94. Breakdown products of C3 are also found co-localised 
with these immune complexes, suggesting complement activation and localised 
inflammation as another aspect of IgAN pathogenesis. The AP and MBL 
pathways have both been implicated in glomerular injury in IgAN95-99. 
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Figure 1.4: IgA1 is aberrantly glycosylated in IgAN 
IgA1 undergoes O-linked glycosylation at serine or threonine residue at the α-heavy-
chain hinge region. Glycosylation begins with the addition of O-linked GalNAc via the 
action of GalNAcT2. Galactose residues are then added via the action of C1GalT1 and 
its molecular chaperone Cosmc, to ensure correct folding and stability. In aberrantly 
glycosylated IgA1 It is unclear whether galactose is sialylated during healthy 
glycosylation by ST3,2. In aberrantly glycosylated IgA1, sialic acid residues may be 
added directly to GalNAc via the action of ST6,2, in circumstances where 
galactosylation is deficient. Evidence suggests sialylation may prevent the addition of 
galactose to this glycosylation profile. It is the absence of galactose, and presence of 
sialylation that is reported in IgAN. 
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Diseases associated with complement dysregulation are often found to result in 
some form of glomerular injury, as previously described with aHUS and 
MPGN2. This suggests a potential for a complement dysregulation in IgAN, 
where glomerular injury occurs and complement deposition is found. There has 
been some evidence to suggest a potential role of regulators of the AP in 
IgAN100,101. Additionally, certain HLA alleles have been linked with increased 
risk of developing IgAN102-104. This implicates an adaptive immune response in 
this disease.  
Complement activation is undoubtedly involved in glomerular injury in IgAN. The 
localised deposition of complement proteins in the mesangium was at first 
poorly understood; as deposited IgA1 was considered ineffective at triggering 
complement via the CP activation. Subsequently, IgA1 has been shown to 
activate the AP97. Additionally, CP complement activation is expected with the 
presence of IgG or IgM autoantibodies against aberrantly glycosylated IgA1 
containing immune complexes. Therefore, it may be that complement is merely 
being activated under normal circumstances; with detrimental secondary effect 
to patients with IgAN. 
With the increasing evidence of complement dysregulation in association with a 
number of kidney diseases (including aHUS and MPGN2), IgAN is a prime 
candidate for screening for deficiency in complement genes/proteins. Deficiency 
of CR1 has been linked with IgAN, suggesting complement dysregulation could 
be an important factor in the pathogenesis in IgAN105. In order understand the 
complexity of complement dysregulation in disease, the pathogenesis of aHUS 
will now be discussed in detail. 
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1.5 Haemolytic Uraemic Syndrome 
Haemolytic Uraemic Syndrome (HUS) is a renal disease, and one of the 
thrombotic microangiopathies (TMA), characterised by the presentation of 
haemolytic anaemia, thrombocytopenia and acute renal failure. It was first 
described and characterised in 1955 by Conrad Von Gasser, where he 
encountered five patients with renal failure, who also presented with 
thrombocytopenia and haemolytic anaemia106. 
HUS is often described after an enteric infection with verocytotoxin-producing 
strains of Escherichia coli, or Shiga-toxin secreting Shigella species107-111. 
Verocytotoxin is known as Shiga-like toxin due to the structural and functional 
similarities with Shiga-toxin. There are other strains of bacteria that carry the 
toxin, as the gene originates, and is readily transmitted by a bacteriophage112-
115. In all infected bacteria, this toxin becomes the primary virulence factor. 
Verocytotoxin is a 2-part cytotoxin designed, to break through the gut epithelial 
barrier, inhibit protein synthesis and ultimately allow infection to enter the 
bloodstream. The toxin causes damage to the glomerular endothelium, resulting 
in platelet activation and the initiation of the coagulation cascade. This results in 
thromocytopenia, the formation of localised thrombi in the renal 
microvasculature, and damage to erythrocytes (haemolytic anaemia). Patients 
affected with HUS generally complain of an associated infection, generally 
giving rise to diarrhoea, so the disease is also referred to as diarrhoea positive 
HUS (d+HUS). This aids in distinguishing it from the 5-10% of HUS cases that 
present with symptoms of haemolytic anaemic, thrombocytopenia and renal 
failure, but show no evidence on enteric infection or diarrhoeal illness116. This 
group of patients are referred to as having ‘atypical’ HUS (aHUS).  
1.5.1 aHUS 
When aHUS was first being described, causative factors behind the disease 
were unknown. However, there was evidence of a hereditary component as 
members of the same family were being hit by the disease, often generations 
apart117. This became known as familial aHUS. It also emerged that the disease 
was presenting randomly within the population. This is referred to as ‘sporadic’ 
aHUS. The terms familial and sporadic are commonly used to categorise aHUS 
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patients, and are essentially terms to describe the origin of the components that 
contribute toward disease onset and progression.  
The presentation of aHUS is strongly associated with complement 
dysregulation, resulting from a range of abnormalities with complement 
regulatory and activator proteins. In particular, problems involving the AP of 
complement activation. From a genetic perspective, mutations in complement 
genes are found in ~51% of aHUS patients118. In the past 20 years, several 
complement components have been identified as posing an increased risk of 
developing aHUS. The complement genes/proteins shown to predispose to 
aHUS will now be addressed.  
1.5.1.1 The role of CFI in aHUS 
CFI is fluid-phase regulator of complement activation. It functions to inactivate 
surface bound C3b and C4a, thus preventing progression of the C3 convertase 
amplification loop. CFI exists in an active state in the circulation, but requires a 
different compliment of cofactors to inactive each of these convertase 
components. AP C3b inactivation requires CFH as a cofactor, and C4b requires 
C4-binding protein (C4BP). CD46 serves as a cofactor for inactivation of both 
components. Therefore, CFI serves as complement regulator across all 
activation pathways, and is integral for permanent inactivation of convertase 
components C3b and C4b. A 2008 study was able to characterise mutations in 
the serine protease domain of the light chain of CFI (CFI is composed of a 
heavy and light chain), which resulted in a lack of C3b and C4b cofactor 
activity119. Additionally, they found a mutation leading to an issue with protein 
secretion. There was also a risk-associated mutation located in the heavy chain. 
However, the exact function of the heavy-chain domain is unclear, so how the 
mutation affects the function of CFI is unknown. Mutations in CFI are found in 
~17% of aHUS patients119. Those with CFI mutations respond poorly to plasma 
therapy118.  
1.5.1.2 The role of CD46 in aHUS 
CD46 is widely expressed on the surface of all cells, with the exception of 
erythrocytes. CD46 serves as a cofactor for CFI to inactivate surface bound 
C3b and C4b, thus regulating the AP and CP of complement activation. CD46 
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mutations are present in ~15% of aHUS patients, however despite this high 
frequency (relative to mutations in the other complement regulatory proteins), 
CD46 mutations offers the best prognosis. In particular, after renal 
transplantation, those with a CD46 mutation rarely experience a recurrence of 
aHUS118. 
1.5.1.3 The role of CFB in aHUS 
CFB is a fluid-phase zymogen that carries the convertase protease catalytic 
subunit (Bb) required for activation of the AP C3 convertase. Mutations on CFB 
are present in less than 3% of aHUS patients120. Functional analysis of mutants 
suggests some CFB mutations confer an increased level of resistance to the 
decay of C3 convertase, which is because complement regulators cannot bind 
as efficiently to exert their decay-accelerating activity.  
1.5.1.4 The role of C3 in aHUS 
C3 is the central component of complement activation, enabling the 
construction of the C3 convertase and the pivotal downstream production of the 
positive amplification loop of activation121. Mutations in C3 have been described 
in ~10% of aHUS patients118,122. In functional analysis of these mutations, five 
resulted in inefficient binding of complement regulators so were gain of function 
mutations. However, there were two mutations resulting in a decrease of C3 
secretion, but the mechanism of which is unclear122.  
1.5.1.5 The role of thrombomodulin in aHUS 
Thrombomodulin (TMBD) is a glycoprotein located on the surface of endothelial 
cells, is a key component of the protein C anticoagulation pathway. It functions 
as a cofactor in the thrombin-induced activation of protein C. Additionally, it 
functions to enhance thrombin-mediated activation of an inhibitor of fribrinolysis, 
procarboxypeptidase B (pro-CPB). Therefore, under normal conditions, TMBD 
functions to regulate blood coagulation via these two regulatory processes. 
When activated by TMBD, pro-CPB also acts to inactivate anaphylatoxins C3a 
and C5a, thus counteracting the proinflammatory actions of these complement 
components. TMBD has been shown to regulate the AP by binding to cell 
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surface bound C3b, and accelerating the cofactor activity of CFH or C4BP, in 
the presence of CFI.  
In a recent study, the THBD gene was screened in 152 aHUS patients, and 
compared to a group of normal controls. Six different heterozygous missense 
mutations were found in 7 unrelated patients123. Functional analysis using cell 
coated with mutant TMBD displayed a diminished capacity to either inactivate 
C3b, or activate pro-CPB. The net result was less protection against 
complement mediated cell damage. Mutations in the gene encoding TMBD 
have also been shown to result in a loss of cofactor activity.  
1.5.1.6 The role of CFH in aHUS 
CFH is a 155 kDa single-chain serum glycoprotein, primarily secreted by the 
liver. CFH is the principle regulator of the AP. The circulating concentration 
ranges from 200-800 µg/ml124, but how circulating levels are maintained within 
this homeostatic range is currently unknown. CFH is found ubiquitously 
throughout the body, both in circulation and in tissue interstitium to facilitate 
rapid regulation of the AP ‘tick over’.  
The CFH mRNA transcript is composed of 23 exons, which are translated into a 
chain of 20 domains, known as short consensus repeats, or SCR domains. 
Each SCR domain consists of ~60 amino acids, each containing two disulphide 
bonds between cysteine residues. Upon translation, the pro-protein is led by an 
18 amino acid N-terminal signal peptide, which is cleaved prior to secretion. To-
date, only the secondary structure of individual or small fragment groups of 
SCR domains have been investigated. However, based upon these structural 
and functional data, a hypothesis has been proposed as to how CFH chain may 
arrange at the cell surface during recruitment by surface bound C3b125.  
CFH has two main binding domains for C3b, in SCR domains 1-4, and domains 
19-20125-127. The regulatory domain lies at the N-terminal end of the extended 
CFH chain, and is responsible for binding C3b to promote decay-acceleration of 
C3 convertase (C3b/Bb), and the cofactor activity for CFI-mediated inactivation 
of C3b128-131. The other C3b binding region lies at the opposite end of the chain 
(SCR domains 19-20), which binds to C3b with a high degree of affinity. It is 
well documented that SCR domains 19-20 also bind to polyanionic structures 
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such as glycosaminoglycans (GAGs) like heparin sulphate, and also to sialic 
acid residues in proteoglycans, glycoproteins and the extracellular matrix126. It 
was once considered that due to the affinity for cell surface glycans and 
extracellular matrix components that CFH was found anchored to these 
surfaces/structures, and therefore immediately available for regulation of 
alterative pathway activation. However, it is now generally accepted that the 
high affinity binding to C3b is a way of recruiting CFH to the cell surface when 
required, and multiple sites of electronegative attraction (particularly in SCR 20) 
help to anchor the CFH chain into position to function as a regulator125. The net 
effect of CFH binding to C3b is the rapid disruption and inactivation of the 
complement cascade. As previously described, this appears to be accelerated 
by the action of TMBD/C3b binding at the cell surface123. 
Mutations in CFH have been described in multiple studies, and are found in 
~30% of patients16. The majority of mutations associated with aHUS are 
heterozygous missense, and do not affect the circulating levels of CFH. 
Considering the assumed structural arrangement of CFH in fluid-phase (as a 20 
SCR chain, without tertiary structure), point mutations appear to only exert 
localised minor effect132. However, heterozygosity means functional effects will 
be experienced in 50% of the circulating CFH. Interestingly, the observed 
mutations appear to cluster to the C-terminal end of CFH (Figure 1.5), 
suggesting an issue with binding to cell and extracellular matrix surfaces as a 
key component to the complement-mediated pathogenesis of aHUS.  
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Figure 1.5: Mutations in CFH cluster to the C-terminus in aHUS patients 
CFH contain 20 SCR domains which are arranged in a chain. The regulatory domain lies at 
the N-terminus, and is responsible for decay-accelerator and cofactor activity against the AP 
C3 convertase. The recognition domain is located at the C-terminus, and is responsible for 
CFH binding to polyanionic residues (e.g. heparin sulphate) at the cell surface. In aHUS, at-
risk mutations cluster to the CFH C-terminus recognition domain. Therefore, abnormalities in 
the recognition domain are associated with an increased risk of developing aHUS. 
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Subsequent to these findings, in vitro assays using mutant proteins showed no 
change in fluid-phase complement regulatory activity. However, studies using 
protein crystallography and nuclear magnetic resonance (NMR) showed that 
mutations in SCR 20 do have a negative effect on GAG (used as a surrogate for 
cell surface interaction) binding125. Therefore, aHUS-associated mutations in 
the C-terminus of CFH result in impaired cell surface binding. This leads to 
dysregulation of complement on host cells. Additionally, CFH has also been 
shown to bind to the cell surface of platelets via interaction with thrombospodin-
1, and this interaction in reduced to a significant degree in CFH with C-terminal 
mutants133.  
Further evidence for the consequences of C-terminal clustering was 
demonstrated in a mouse model of aHUS. Mice were made transgenic for a 
truncated version of the murine Cfh gene, which lacked exons 19-23, resulting 
in a protein lacking SCR domains 16-20 (CfhΔSCR16-20). Without this surface 
recognition domain, the mice developed a renal thrombotic microangiopathy 
analogous to aHUS. There was also evidence of erythrocyte fragmentation, 
disruption to the endothelium and C3 deposition along the capillary 
endothelium, arterial smooth muscle and mesangium. Additionally, the 
endothelium was coated with platelets134. However, the CfhΔSCR16-20 mice 
were still able to regulate fluid-phase AP activation, as indicated by normal 
levels of C3 in vivo. In contrast, mice with complete CFH deficiency (Cfh-/-) 
develop a renal disease similar to MPGN2, characterised by very low levels of 
C3, extensive C3 deposition in the glomerulus and dense deposits at the 
glomerular basement membrane (GBM)134. 
CFH deficiency is also associated with AMD and MPGN2. In particular, at-risk 
genetic elements have been shown to correlate with each disease. Studies in 
AMD have shown common CFH haplotypes to be associated with disease135-
138. In particular, a common polymorphism that results in an amino acid change 
(Y402H) in SCR 7 of CFH and CFHL-1, is found to segregate with disease. In a 
recent study, we were able to show that the Y402H variant is in some way 
protective against the development of a CFH autoantibody response in AMD 
patients (compared to age-matched normal controls)139. As with aHUS, other 
complement genes have also been linked as predisposing factors in AMD140-145. 
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In AMD, dense deposits, or ‘drusen’, are found deposited along the Bruch’s 
membrane in the macular region of the eye, resulting in gradual loss of central 
vision. These dense deposits have been shown to contain C3 breakdown 
products, suggesting dysregulation of the AP. 
Similar complement containing dense deposits are also found in MPGN2, or 
dense deposit disease (DDD) as it is also known. Dense deposits were first 
identified in the GBM, as resolved by electron microscopy. However, in recent 
studies deposits have also been detected along the Bruch’s membrane, as 
seen in AMD. Interestingly, MPGN2 is also associated with CFH deficiency, as 
previous discussed. CFH mutations primarily cluster to the N-terminal region of 
the protein, thus affecting CFH regulatory function (i.e. decay-accelerator and 
cofactor activity). Therefore, aHUS is associated with deficiency of cell surface 
recognition, thus affects regulation of AP activation. However, MPGN2 is 
associated with compromised cell surface and fluid-phase AP complement 
activation.  
Other than deficiency in complement regulatory components, ~80% of MPGN2 
patients test positive for C3 nephritic factor (C3NeF), an autoantibody that 
targets and stabilises the AP C3 convertase. This results in unregulated AP 
complement activation and consumption of C3 (low C3 is a diagnostic marker of 
MPGN2). Complement dysregulation in MPGN2 is progressive and destructive, 
so spontaneous remission is rare. Most patients will progress to end-stage renal 
failure, with impaired visual acuity146.  
The CFH-associated deficiencies in aHUS, MPGN2 and AMD not only suggest 
genotype similarities between these diseases, but also a phenotypical 
relationship.  
1.6 The role of CFHR proteins in health and disease 
Downstream of CFH in the RCA gene cluster are a group of genes with a high 
degree of sequence homology to CFH (Figure 1.6). These are referred to as 
the CFH-related (CFHR) genes. The sequence homology between CFH and the 
CFHR genes is thought to be a result of genomic rearrangements occurring 
within this region, potentially stemming from a single progenitor gene sequence. 
Therefore, rearrangements of the progenitor gene sequence eventually, through 
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a period of evolution, resulted in the birth of a family of genes coding for the 
CFH and the CFHR proteins. Clearly, the evolutionary selection of this final 
repertoire of CFH family proteins suggests each family member has a 
significant role (or multiple roles) to play in the maintenance and survival of the 
species. 
There are five CFHR genes (CFHR1-5), which result in six mature circulating 
proteins, CFHR1, CFHR2, CFHR3 CFHR4A, CFHR4B (a truncated CFHR4 
splice-variant), and CFHR5. Functional analysis has demonstrated that all 
CFHR proteins, (except CFHR2) exhibit varying degrees C3b and GAG binding. 
Whether this is biologically significant is being investigated for each protein. 
1.6.1 CFHR1 
CFHR1 comprises 330 amino acids, including an 18 amino acid signal peptide. 
The mature protein is composed of 5 SCR domains and is post-translationally 
modified with N-linked glycosylation. In human sera, there are two CFHR1 
isoforms, CFHR1α (37 kDa) which is non-glycosylated, and CFHR1β (42 kDa) 
which is glycosylated.  
CFHR1 was first discovered when two antigenically related proteins were 
identified on screening human serum with a CFH pAb147. The proteins were 
purified directly from human sera, and the amino acid sequences of the two 
were found to be identical. This suggested both proteins were translated from a 
single mRNA transcript. After deglycosylation with N-glycosidase F, both bands 
migrated into a single band, suggesting the molecular weight difference was 
due to N-linked glycosylation. Decay-acceleration was investigated, and 
cofactor activity assessed using a C3b and CFI is fluid-phase cofactor assay. 
However, CFHR1 exhibited no evidence of decay-acceleration or cofactor 
activity. 
Subsequent to the identification of this CFH-related protein in human serum, a 
single cDNA transcript was identified which was directly related to the 
previously reported protein148-151. When nomenclature for the CFH proteins was 
decided, this protein became known as FHR-1152, which was later changed to 
CFHR1. 
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The functional significance of CFHR1 remained unclear for several years after 
its initial discovery. However, a recent study demonstrated that CFHR1 is a 
potent C5 convertase inhibitor153 and can thus be classified as a complement 
regulatory protein. Besides acting as a regulatory protein, CFHR1 also plays a 
role in the defence against infection. It has been shown that both CFH and 
CFHR1 can associate with neutrophils via complement receptor 3 (CR3) to 
mediate attachment to Candida albicans and enhances neutrophil antimicrobial 
activity154. Additionally, CFHR1 has been shown to bind to cell surface proteins 
(BbCRASP3-5) of Borrelia burgdorferi, therefore reducing bacterial virulence155. 
1.6.2 CFHR2 
Shortly after the discovery of CFHR1, CFHR2 was identified using the same 
methodology156. CFHR2 has four SCR domains and like CFHR1, exists in two 
isoforms; non-glycosylated (24 kDa) and glycosylated (29 kDa). There is no 
evidence to suggest CFHR2 has any complement regulatory activity, and very 
little is known about potential ligands. However, like other CFHR proteins, it is 
found associated with lipoproteins in circulation. The CFHR2 gene was found to 
be highly homologous to the adjacent gene coding for coagulation factor 
XIIIb157, suggesting a further link between complement and the coagulation 
cascade. Dual roles have already been identified with TMBD, as a regulator of 
thrombin in the coagulation cascade, and C3b in AP complement activation 
(Section 1.5.1.5). Sequence homology between CFHR2 and XIIIb also provides 
further evidence for evolution of the RCA gene cluster via intragenic 
recombination events, resulting in shuffling of SCR encoded elements.  
1.6.3 CFHR3 
After previously identifying three mRNA transcripts with significant levels of 
sequence homology to CFH, cDNA probes were created to search for further 
gene expression of other potential CFHR transcripts. Another transcript was 
found, which resulted in the discovery of CFHR3158. 
CFHR3 contains 5 SCR domains, each with respective homology to SCR 
domains -6, -7, -8, -19 and -20 in CFH. When human plasma is probed via 
western blot, CFHR3 appears in multiple glycosylated isoforms159. 
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The functional characteristics of CFHR3 have been investigated, but despite 
C3b, C3d and heparin binding capacity, the protein is unable to regulate 
complement activation160. Despite this finding, the CFHR3/1 gene deletion has 
been implicated as a risk factor in aHUS, correlating with the presentation of a 
CFH autoantibody response161-164.  
1.6.4 CFHR4 
CFHR4 protein was first identified in association with triglyceride-rich 
lipoproteins165. The 86 kDa protein was isolated, digested into 6 fragments and 
the amino acid sequence determined for each fragment. All fragments shared 
variable levels of sequence homology to CFH, CFHR1, CFHR2 and CFHR3. In 
parallel the cDNA transcript for CFHR4 was also identified, and matched to the 
amino acid sequence. 
Functional characterisation showed CFHR4 binds to C3b via the C-terminus in 
a dose-dependent manner, suggesting it may have complement regulatory 
activity at the level of C3 convertase160,166. However, like all CFHR proteins, 
CFHR4 lacks the complement regulatory domain found in CFH (SCR domains 
1-4). On an SDS-PAGE separation, bands of 43 kDa and 86 kDa were seen, 
the latter of which was considered a CFHR4 homodimer.  
To assess the function of CFHR4, the protein was expressed recombinantly in a 
baculovirus/insect cell system160. Recombinant expression led, as in vivo, to 
both the monomeric and homodimeric forms of CFHR4. CFHR4 was shown to 
be post-translationally glycosylated, and also to bind C3b. It was later 
determined that CFHR4 was a splice-variant of a larger cDNA transcript. In 
serum, the size of the larger CFHR4 protein is 86 kDa, suggesting the 
previously reported CFHR4 homodimer may actually have been this larger 
protein167. The two proteins became respectively known as CFHR4A (86 kDa) 
and CFHR4B (45 kDa). 
A recent study examined the functional significance of the C3b binding 
capability of CFHR4 because it is unable to regulate C3 convertase formation. 
CFHR4 was shown to bind C3b at the cell surface and reduce the decay 
accelerating activity of CFH168. This suggested a novel role for CFHR4 in 
promoting rather than regulating complement activation. 
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1.6.5 CFHR5 
CFHR5 (65 kDa) was the final CFHR protein to be discovered, as reflected by 
its nomenclature. The protein was first identified in the analysis of complement 
deposits in the glomerulus169,170. A mAb was raised against CFHR5 using 
pathological human glomerular preparations as the immunogen. CFHR5 was 
subsequently purified via affinity chromatography and shown to bind C3b in 
vitro. The CFHR5 gene was mapped to the RCA gene cluster and is located 
between the genes encoding CFHR2 and Factor XIIIb171. CFHR5 was 
eventually shown to bind heparin, have cofactor activity, inhibit C3 convertase 
and bind CRP and lipoproteins172. This suggests that CFHR5 may have multiple 
roles in complement regulation/activation. Genetic variants of CFHR5 have 
been associated with aHUS173, MPGN2174 and the recently characterised 
CFHR5 nephropathy175.  
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 Figure 1.6: Comparison of sequence homology in CFH family proteins 
CFH and the CFHR proteins share a high degree of sequence homology. The SCR domains of 
the CFHR proteins are aligned according to their homology to CFH SCR domains 1-20. Above 
each CFHR SCR domain is the % sequence homology to the corresponding CFH SCR domain 
located above. 
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1.6.6 NAHR within the RCA gene cluster 
The RCA gene cluster is scattered with regions of sequence homology that 
span the CFH family of genes. Under normal conditions, regions of sequence 
homology line-up (allele to allele), and recombination events occur leading to an 
alternative arrangement of haplotypes (alleles) within the population. However, 
within the RCA gene cluster, the region is scattered with repeats of sequence 
homology. This has the potential to result in regions of sequence homology 
lining-up in a non-allelic fashion. This can allow recombination to occur that 
results in an alternative arrangement of genes on each chromosome. This 
process is known as non-allelic homologous recombination (NAHR). When 
NAHR occurs in the non-coding regions spanning genes, one chromosome 
loses genes, and the other chromosome gains them, leading to an increase in 
gene copy number (Figure 1.7). When NAHR occurs within the coding 
sequence, the resulting gene product will either be a truncated gene/protein or 
create a novel fusion gene/protein176,177. Within the normal population, CFHR 
copy number variation is common with CFHR3, CFHR1 and CFHR4. However, 
due to the location of non-allelic regions of sequence homology, CFHR3 and 
CFHR1 are found deleted together in a single block. Based upon the theoretical 
understanding of how CFHR3/1 is deleted, there should also be an equal 
frequency of chromosomes with two copies of CFHR3 and CFHR1. In aHUS 
patients, ~10% have a homozygous deletion of CFHR3/1. This implicates both 
CFHR3 and CFHR1 as risk factors in the presentation of aHUS. It soon became 
clear the CFHR3/1 deletion correlated with the presentation of an IgG CFH 
autoantibody response in ~90% of these CFHR3/1 deficient patients162,163,178. 
After several reports of the CFHR3/1 deletion and CFH autoantibody 
phenotype, Zipfel et al., (2010) proposed these patients as representative of a 
novel aHUS subtype, referred to as ‘Deficiency of CFHR plasma proteins and 
Autoantibody Positive form of HUS’, or DEAP-HUS179.  
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Figure 1.7: NAHR in the RCA gene cluster 
(a) The CFH genes are arranged in tandem (grey arrows), and regions of high DNA 
sequence homology are highlighted in colour, and labelled A-D. Additional labelling with ’ 
or ‘’ indicates the position of each segment of sequence homology. (b) B shares 
sequence homology with B’ so they align and NAHR occurs. The red line indicates which 
genes will be carried forward on the first chromosome. NAHR has resulted in a deletion 
of CFHR3 and CFHR1 in one block. (c) The blue line demonstrates what genes will be 
carried forward onto the second chromosome. NAHR has resulted in the duplication of 
CFHR3 and CFHR1, essentially taken from the first chromosome.  
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That the CFHR3/1 deletion is associated with CFH autoantibodies suggests that 
CFHR proteins may have a role to play in maintaining immunological tolerance 
to CFH. Therefore, measuring CFHR plasma concentration may be a disease 
marker for an autoimmune subtype of aHUS. A common methodology for 
measuring plasma protein concentration is the use of sandwich ELISA, where 
the sensitivity of detection can reach pg/ml. While there are commercially 
available kits for measuring plasma CFH concentration, there are no such kits 
for CFHR1, CFHR3 or CFHR4. Additionally there were no CFHR1-specifc (no 
cross-reactivity with other CFH family proteins) mAbs available at the start of 
this study. Commercially available CFH mAbs/polyclonal Abs (pAbs) inevitably 
cross-react with the CFHR proteins due to the high levels of sequence 
homology between the proteins. From the outset of this research project, there 
were two commercially available CFH mAbs which bound to CFH SCR 20 
(C18/3 and L20/3; Santa Cruz Biotech). As CFH SCR 20 has >97% amino acid 
sequence homology with CFHR1 SCR domain 5, both Abs cross-react with 
CFHR1. These Abs could therefore not be used to specifically measure the 
concentration of either CFH or CFHR1. Additionally, there were no mAbs 
available at the start of this research against CFHR3 or CFHR4. Therefore, 
there was a need for the production of a panel of CFHR-specific mAbs. 
Having mAbs targeting different regions of the CFHR proteins would also be 
useful in the investigation of patients in whom genetic analysis identifies copy 
number variants in the CFH family of genes. Having a repertoire of Abs to target 
particular regions of interest is a powerful research tool. 
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1.7 Complement and Autoantibodies 
In MPGN2 autoantibodies have been described against CFH, CFB180, and more 
importantly, against C3 convertase. Approximately 80% of MPGN2 patients 
present with C3NeF, which functions to stabilise C3 convertase into an 
activated state181,182. The result is continuously unregulated activation of the C3 
amplification loop. The origin of this Ab response is still unknown.  
In a recent study from our research laboratory, a cohort of AMD patients was 
tested for CFH autoantibodies. These were compared to a group of age-
matched controls. The results demonstrated that AMD patients with a CFHR3/1 
deletion, had a lower level of CFH autoantibodies, compared to the control. This 
suggested the CFHR3/1 deletion was in some way protective against forming a 
CFH autoantibody response. Additionally, it highlighted that developing CFH 
autoantibodies may be related to old age. 
In aHUS, autoantibodies have been described targeting CFH and CFI. As 
previously described, CFH autoantibodies were discovered in the plasma of 
90% aHUS patients with homozygous deficiency of CFHR3/1. In the remaining 
10% with the deletion, there was no evidence of CFH autoantibodies. When 
investigating an autoantibody response, it is important to consider that Ab titres 
are going to be variable in any one individual, based upon the proposed 
requirement for the immunological response (i.e. the antigen availability with the 
immune-sensitised individual). As CFH is consistently available, it seems 
paradoxical that the CFH autoantibody response would not be switched on 
continuously. Instead, aHUS patients have shown variability in their 
autoantibody titres over time. Transplantation and pregnancy are key triggering 
events for the activation of increased levels of CFH autoantibodies.  
To date the functional consequences of having CFH autoantibodies remains 
unclear. Certainly, cell surface blockade has been shown in vitro and treatment 
of patients with CFH autoantibodies with B-cell depleting therapy has been 
advocated by several reports. It is not clear whether autoantibodies can induce 
disease on their own by either directly blocking CFH function or forming immune 
complex in the kidney. Therefore, understanding any similarities to other 
immune complex kidney diseases may elucidate this. IgA Nephropathy (IgAN) 
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is a disease where significant immune complex deposition is seen and it would 
be interesting to determine whether autoantibodies to CFHR proteins are 
present in this disease. Furthermore, CFHR5 nephropathy has demonstrated 
that CFHR5 may be an important complement regulator in the glomerulus. In 
aHUS, CFH deficiency from genetic mutation causes, or contributes towards the 
onset of disease. This is also suggested by the IgG autoantibody response to 
CFH. In IgAN, Ab mediated autoimmunity is present so there may be other 
autoantibody-mediated events occurring with regards to complement activation 
(i.e. targeting complement regulatory proteins, like CFHR5). Should CFHR5 
autoantibodies be discovered, this would provide further evidence for CFHR5 as 
a major complement regulator in the kidney. 
1.8 aHUS: a multiple hit disease 
There are a range of potential risk-factors involved in the pathogenesis of 
aHUS. Based upon the predisposing factors (as previously presented), these 
can be summarised as rare genetic variants (mutations or gene 
rearrangements), common genetic variants (SNPs), and complement-targeted 
autoantibodies. The onset of disease appears to require several of these risk 
factors, in combination with a trigger, such as infection, pregnancy or 
transplantation. This has been described as a ‘multiple-hit’ theory183 (Figure 
1.8).  
When considering ‘a multiple hit’ hypothesis, it is important to consider this in 
relation to all diseases associated with complement dysregulation. Additionally, 
all complement proteins involved in the AP must be considered. In a recent 
study investigating high risk SNPs in AMD, it was demonstrated that a 
combination of common polymorphisms in C3, CFB and CFH (from one 
individual) was associated with the onset of disease184. Heuric et al., tested the 
functionality of each polymorphism and confirmed that each risk-associated 
SNP did result in reduced complement regulation. When combining all 3 risk-
associated proteins in a haemolytic assay, haemolysis was increased 6-fold 
providing evidence that the risk-associated polymorphisms were having a 
negative effect on AP complement regulation. They referred to this as a high-
risk ‘complotype’ (or combination of polymorphisms). 
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A similar mechanism has been described within individual genes, whereby 
groups of risk-associated polymorphisms can be inherited together, resulting in 
risk-associated haplotypes. These have been shown in aHUS, AMD and 
MPGN2134. 
It was recently reported that a female post-transplant patient had developed 
postpartum aHUS, five years after receiving a donor liver. After screening 
several complement genes in both the donor and recipient, it was discovered 
that the donor liver was heterozygous for a CFH nonsense mutation leading to a 
premature stop codon in SCR 6. The recipient had a homozygous CD46 at-risk 
haplotype (termed CD46GGAAC). This combination of donor/recipient genes (or 
complotype) did not result in the presentation of aHUS. However, in this case 
pregnancy appears to have served to trigger aHUS, in combination with the 
native and acquired aHUS risk alleles. This is prime example of multiple hits 
resulting in the onset of aHUS.  
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Figure 1.8: Multiple risk factors are required to develop aHUS  
In aHUS it has been proposed that multiple risk factors within AP complement 
components are required to trigger the onset of disease. This hypothesis is represented 
diagrammatically above, demonstrating that when risk-factors overlap aHUS is likely to 
ensue. Disease predisposing risk factors have been grouped into rare genetic 
abnormalities (e.g. point mutations, gene rearrangements), common genetic features 
(e.g. SNPs, haplotype variants), autoantibody presentation (e.g. targeting CFH and CFI) 
and trigger incidents (e.g. pregnancy, infection, transplantation).  
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1.9 Aims of this research project 
The primary aim of this research project is to produce a set of recombinant 
human CFHR proteins, to be utilised in the investigation of CFHR involvement 
in the disease pathogenesis of autoimmune aHUS and IgAN.  
After producing the proteins, the aim is to establish a set of quantification 
assays to measure CFHR levels in human plasma. CFHR1, CFHR3 and 
CFHR4 deficiency are linked to the production of CFH autoantibodies. However, 
deficiency is measured first by assessing gene copy number, followed by 
analysis of protein in plasma. While this methodology has proved useful, it has 
not enabled us to conclude on which of these CFHR deficiencies is the 
triggering element. CFHR1 is the common deficiency between the two block 
deletions (CFHR3/1 or CFHR1/4), so it is assumed to be the triggering element. 
However, further clarification is required. Additionally, plasma CFHR deficiency 
may result from issues other than gene deletions, like promoter or regulatory 
element mutations. Therefore, screening CFHR levels at the level of secretion is 
more representative. 
Due to the lack of suitable commercially available mAbs, the second major aim 
of this thesis is to produce a set of CFHR-specific mAbs, for use in the 
development of the quantification assays. Therefore, the recombinant CFHR 
proteins will be utilised to illicit an Ab response in mice, followed by the 
production of CFHR-specific Ab-secreting hybridomas. 
The final aim of this thesis is to establish the autoantibody status of a cohort of 
aHUS and IgAN patients, using the recombinant CFHR proteins as candidate 
coating antigens in optimised ELISA screens. 
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Chapter 2 
2. Materials and Methods 
2.1 DNA Manipulation and Cloning 
2.1.1 DNA plasmids and primers 
The DNA expression vector pDEF(nMCS) (Figure 2.1) has been commonly 
used in conjunction with CHO cells to produce a range of human proteins, 
including human complement proteins185-188. The vector contains an elongation 
factor 1α (eF1α) promoter region 5’ of the multiple cloning site (MCS) which 
results in constitutive protein expression when transfected into a mammalian 
cell system. The vector also contains the hygromycin B resistance gene 
(hyg)189,190, which allows selection of transfected cells using hygromycin B 
supplemented media. This was chosen as our base construct, but modified to 
include a 6x poly-histidine motif (HisTag).  
Single stranded oligonucleotide primers were designed to produce a clone of 
each rCFHR cDNA (Table 2.1). For CFHR1, CFHR2, CFHR3, and CFHR4B, 
XbaI and BamHI restriction endonuclease sites were selected/introduced as the 
most suitable for insertion of each clone into pDEF/L5H6. Due to an internal 
XbaI site in the CFHR5 sequence, an alternative RE site was selected for the 
CFHR5 forward primer. Therefore, SpeI and BamHI RE sites were selected for 
cloning of CFHR5. Primers were synthesised by Eurofins MWG Operon 
(Eisberg, Germany). 
  
 
 
 
 
 
 
Table 2.1: CFHR primers 
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Figure 2.1: An illustration of the expression vector pDEF/nMCS 
The pDEF/nMCS cloning vector contains multiple features which are important for plasmid 
selection and replication in bacteria, and gene transcription and protein expression in 
mammalian cells. 
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2.1.2 DNA Sequencing 
Complementary forward (pDEF_NF) and reverse (pDEF_NR) primers were 
designed to anneal upstream (1326-1346bp) and downstream (1495-1518bp) of 
the MCS. DNA was sequenced by Eurofins MWG Operon (Eisberg, Germany). 
2.1.3 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) was used to amplify DNA in the cloning of 
CFHR cDNA, and also in the screening of transformation colonies via ‘Colony 
PCR’. 
2.1.3.1 CFHR cDNA PCR Amplification 
CFHR cDNA was obtained from multiple sources (Table 2.2), and used as the 
template in a standard PCR recipe (used for all CFHR cloning,Table 2.3). Pfu 
DNA polymerase (Fermentas, UK) was used for amplification as it possesses 
3’-5’ proof-reading activity. Using Taq DNA polymerase would result in a 6-fold 
increase in the number of mutations introduced per duplicated base pair, when 
compared to the mutation rate of Pfu. This reduces the frequency of point 
mutations introduced into each CFHR cDNA sequence. CFHR-specific primers 
were used, as previously described (Section 2.1.1). PCR condition are 
summarised below (Table 2.4). All PCR results were assessed on 1% agarose 
gels, supplemented with 0.5 μg/ml ethidium bromide. UV emissions were 
visualised using the AlphaImager® Gel Documentation system (ProteinSimple; 
Santa Clara, USA). After PCR, amplified products were purified using a 
‘QIAquick PCR Purification Kit’ (QIAGEN, UK), following the manufacturer’s 
instructions. 
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cDNA 
Clone 
Storage 
 Vector
Antibiotic 
 Resistance
 Vector/cDNA Source
CFHR1  pDNR-LIB  Chloramphenicol  IMAGE Consortium
CFHR2  pUC-19  Ampicillin  Synthesised by ‘Genscript’
CFHR3  pDNR LIB  Chloramphenicol  IMAGE Consortium
CFHR4B  pCR4-Topo  Kanamycin  IMAGE Consortium
CFHR5  pGEM-easy  ?? M. Pickering; Imperial College 
 London, UK
 
Table 2.2: Sources of CFHR cDNA 
Recipe Volume 
Template (1ng/μl) 1μl 
Forward Primer (50μM) 1μl 
Reverse Primer (50μM) 1μl 
dNTP mix (25mM each) 1μl 
10x Pfu Buffer with MgSO4 5μl 
Pfu DNA polymerase (2.5u/μl) 1μl 
dH2O 40μl 
Final Volume: 50μl 
 
Table 2.3: Standard PCR Recipe 
Recipe Volume 
Bacterial Lysate* 5μl 
Forward Primer (50μM) 1μl 
Reverse Primer (50μM) 1μl 
dNTP mix (25mM each) 1μl 
10x Thermo Buffer 5μl 
Taq DNA polymerase (2.5u/μl) 1μl 
dH2O 35μl 
Final Volume: 50μl 
 
Table 2.4: Colony PCR Recipe 
Step Temperature Duration Cycles 
Melting 95°C 5 mins 1 
Melting 95°C 1 min  
35 Annealing 55°C 1 min 
Extension 72°C Taq: 1 min/kb 
Pfu: 1.5 min/kb 
Extension 72°C 7 mins 1 
Storage 4°C ∞ - 
 
Table 2.5: Standard and Colony PCR Thermo Cycler Conditions 
Ampicillin 
Ampicillin 
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2.1.3.2 Colony PCR Amplification 
After DNA plasmid transformation into bacterial cells, ampicillin-resistant 
colonies were selected and screened for the presence of the correct CFHR 
insert. 
Bacterial colonies were picked using a sterile filter-tip, and resuspended in 20 μl 
dH2O and boiled at 100°C for 5 min. The lysed samples were micro-centrifuged 
for 5 min at 13,000 x g, to pellet the cell debris from the sample lysate. The 
supernatant (SN) was collected, and 5 μl used as template DNA in a colony 
PCR (Table 2.5). pDEF_NF and pDEF_NR primers were used to amplify the 
contents of the pDEF/L5H6 MCS.  
As colony PCR amplification products were not used after screening, a proof-
reading polymerase was not required. Therefore, Taq DNA polymerase (New 
England Biosciences, UK) was used in colony PCR reactions. 
2.1.4 DNA Digestion & Ligation 
To produce a CFHR expression construct, PCR amplified CFHR cDNA was RE 
digested and inserted into the pDEF/L5H6 expression plasmid. The PCR 
product will be referred to as the ‘insert’ and the expression plasmid as ‘vector’. 
The insert and vector were double-digested using XbaI/BamHI (CFHR1-4B), or 
SpeI/BamHI (CFHR5), following the manufacturer’s instructions (New England 
Biosciences, UK) for double digestions. Sufficient insert and vector DNA was 
used so that 100% would digested within 1-2 hr, incubating in a thermocycler at 
37°C. Following digestion, insert and vector DNA were purified using a 
‘QIAquick PCR Purification Kit’ (QIAGEN, UK). 
Purified insert and vector DNA concentrations were determined via 
spectrophotometry at 260 nm, and a 1:1 molar ratio of each was used for the 
ligation reaction. T4 DNA ligase (Fermentas) was used in conjunction with the 
manufacturer’s guidelines 
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2.1.5 Bacterial Strains  
2.1.6 Plasmid Transformation and Purification  
‘OneShot® Top10’ E.coli were used for DNA transformation using the 
manufacturer’s ‘heat-shock’ protocol (Invitrogen, UK). Transformed bacterial 
cells were selected using Luria-Bertani (LB) broth or agar, supplemented with 
50 μg/ml ampicillin. Plasmids were purified from bacterial cells using a ‘QIAprep 
Miniprep Kit’ (QIAGEN, UK) following the manufacturer’s instructions. Plasmids 
were stored frozen at -20°C, until required.  
2.2 Tissue Culture 
2.2.1 Cells, Media and Maintenance 
Chinese Hamster Ovary (CHO) cells were the selected cell line for the 
expression of rCFHR proteins. The cell line had previously been used in-
conjunction with the pDEF(nMCS) vector for expression of complement 
proteins. CHO cells were maintained in Ham’s F12 media, supplement with 
10% FCS, 2 mM L-glutamine, 0.1 Units/ml penicillin and 100 μg/ml streptomycin 
(PAA, UK). CHO and all other mammalian cell lines used were incubated at 
37°C, 5% CO2, with humidity.  
CHO cells were split once they reached 70-80% confluence on the flask base. 
Being an adherent cell line, trypsin-EDTA was used detach cells from the plastic 
followed by splitting cells 1/10.  
NS0 cells were selected as the fusion-partner cell line (Section 1.3.3) for 
production of immortalised hybridomas. NS0 cells were cultured in RMPI media 
supplemented with 10% IgG stripped FBS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 1x MEM amino acids (1/100 v/v; PAA, UK), 1 mM kanamycin and β-
mercaptoethanol (1/1000 v/v).  
As NS0 cells were incubated with phenol supplemented RPMI media, the 
requirement to split cells was monitored by the growth media changing colour 
from red/pink, to orange/yellow, indicating an increase in the environmental pH. 
Cells were generally split 1/10 or 1/20, depending on density of cells.  
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Post-fusion hybridomas cells were cultured using the same media and 
conditions as the NS0 cells, with the addition of HAT supplement (0.5 mM 
hypoxanthine, 0.4 μM aminopterin, and 16 μM thymidine; Gibco, UK).  
2.2.2 Cell Transfection and Selection 
2.2.2.1 CHO cell transfection 
CHO cells were transfected with pDEF/rCFHR plasmid DNA using transfection 
reagent jetPEI® (Polyplus Transfection, France). The jetPEI® transfection 
reagent is a polyethelenimine (PEI) reagent with an abundance of protonated 
nitrogen residues which interact with the negatively charged DNA phosphate 
backbone to form DNA/jetPEI® complexes191. The ratio of jetPEI® to DNA is 
calculated to confer a net positive charge to the surface of the DNA complexes, 
resulting in the electrostatic interaction with anionic cell surface proteoglycans. 
Complexes are then internalised via endocytosis, into endosome 
compartments. Endocytosed material is usually subjected to a low pH 
environment, resulting in degradation of ‘exogenous’ material. However, the 
nitrogen-rich jetPEI® acts as a “proton-sponge”, therefore buffering the 
endosomal compartment and protecting DNA degradation. Disruption of the 
compartmental pH causes a disruption to the osmotic balance leading to 
endosome rupture. The subsequent release of DNA into the cell cytoplasm 
thereby facilitates nuclear transport of DNA into the nucleus for genome 
integration and transcription. 
The transfection of all pDEF/rCFHR plasmids was completed using 24-well 
tissue culture plates. CHO cells were seeded 24 hours prior to transfection, 
seeding 5*104 trypsinised cells per well (surface area = 1cm2) in 0.5 ml volume 
of CHO cell media.  
The pDEF/rCFHR plasmid DNA and jetPEI® were individually diluted in 150 
mM NaCl (Table 2.6). The two solutions were then combined by adding the 
jetPEI®/NaCl solution to the DNA/NaCl solution, followed by vortexing for 15 
seconds and incubating at room temperature (RT) for 30 minutes (min). With 
complexes now formed, the total volume of the DNA/jetPEI® was added ‘drop-
wise’ to each culture well, homogenising by gently agitating the plate in a 
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‘swirling’ motion. Plates were incubated for 24 hr using conditions described for 
CHO cells. 
Further details on nitrogen/phosphate ratios can be referenced in the 
manufacturer’s instructions (CPT 101Vn; last updated March 2012). 
 
Controls were included to monitor the effect of antibiotic selection on wild type 
verses transfectant CHO cells. These included a no DNA negative control, to 
monitor cell death when under antibiotic selection pressure. A pDEF(nMCS) 
transfection was also included to act as a positive control for antibiotic selection 
and a negative control for recombinant protein production. Untransfected CHO 
tissue culture SN was also used as a negative control in downstream screening 
of pDEF/rCFHR transfected cultures. 
Screening of pDEF/rCFHR1, pDEF/rCFHR3, pDEF/rCFHR4B and 
pDEF/rCFHR5 transfectants was achieved by sandwich ELISA (Section 
2.3.4.2), and pDEF/rCFHR2 by western blot (Section 2.3.6). 
2.2.2.2 Selection of CHO cell transfectants using hygromycin B 
CHO cells transfected with pDEF/rCFHR plasmids are under the selective 
pressure of hygromycin B. However, prior to selection of transfectants, a 
suitable concentration of hygromycin B was ascertained by running a ’cell death 
curve’.  
CHO cells were seeded to individual wells of a tissue culture plate and 
incubated for 24 hr in CHO cell media. This media was then exchanged for 
CHO cell media supplemented with a serial dilution of hygromycin B (1000-0 
μg/ml). Cultures were incubated for 10 days (d), with trypsin-EDTA stripping and 
reseeding of all cells every 2 d. From previous experience, CHO cells appear to 
maintain some sense of resistance to the detrimental effects of antibiotic 
pressure if left in their adherent state. This is most likely not resistance to the 
Plate Amount 
of DNA 
(μg) 
Volume of 
jetPEI® (μl) 
Volume 150mM 
NaCl per DNA and 
jetPEI® (μl) 
Total volume of 
complexes added 
per well (μl) 
24-well 1 2 50 100 
 
Table 2.6: Complex preparation from transfection using jetPEI® reagent 
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antibiotic, but rather maintenance of the adherent morphology due to cell 
surface protein interaction with the culture vessel surface. Stripping CHO cells 
under hygromycin B selection conditions appears to be a more effective 
approach, as the inhibition of protein synthesis prevents CHO cells from 
reattaching as efficiently to the vessel surface. Therefore, no adherent cells are 
maintained in the culture. 
At each stage of stripping and reseeding (d +2, +4, +6, +8, and +10), cells were 
counted using a haemocytometer using the manufacturer’s instructions 
(Abcam). 
The results suggest using hygromycin B at 200 μg/ml would result in clearance 
of non-transfected CHO cells within 10 d (Figure 2.2). At 400-600 μg/ml this is 
reduced to approximately 6-8 d. The most efficient concentration is between 
800-1000 μg/ml, taking 4 d until CHO viability is no longer present. These 
results are based upon wildtype CHO cells, but cannot inform on how 
transfected cells may respond to different concentrations of hygromycin B. 
Therefore, using a hygromycin B concentration in the lower range will increase 
the chances of transfectant cell survival, especially as the transfected cells 
adapt to their transgenic status under the selective pressure of the hygromycin 
B antibiotic. Therefore, 400 μg/ml was chosen to facilitate transfectant selection 
within 7 d.  
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 Figure 2.2: CHO cell death curve using hygromycin B 
CHO cells were seeded onto plates and treated with an increasing concentration of 
hygromycin B. Cells were trypsinised every 2 d counted using a haemocytometer. 
After counting, all cells were returned to the well with fresh CHO cell media 
supplemented with the relevant concentration of hygromycin B.  
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2.2.3 Cryogenic Storage of Mammalian Cells 
For long-term storage of mammalian cells, cell cultures were pelleted at 300 x 
g, and resuspended in foetal calf serum (FCS) supplemented with 10% 
dimethyl-sulphoxide (DMSO). Cells were immediately placed in a polystyrene 
box and stored overnight at -80°C, to facilitate gradual freezing. Cells were then 
transferred to liquid nitrogen (LN2) for long-term storage. 
To revive cryogenically frozen mammalian cells, culture vials were rapidly 
defrosted by incubation in a pre-heated 37°C water bath for 5 min. Defrosted 
cells were then diluted with pre-warmed sterile phosphate buffered saline (PBS; 
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) and 
pelleted at 300 x g. The SN was discarded, and the pellet resuspended in at 
least 10 ml of pre-warmed supplemented media (Section 2.2.2). Cells were 
allowed to revive for at least 48 hr before being used in experimental 
procedures. 
2.3 Protein Purification and Identification 
Proteins were purified using HiTrap™ Chelating HP, HiTrap™ Protein G HP 
and HiTrap™ NHS-activated HP columns (GE Healthcare, UK). All buffers, 
tissue culture SNs and serum solutions were adjusted to pH 7.4 (unless 
specified otherwise) and filter sterilised using 0.22 μM Corning® Filtration 
System units (Corning, UK), prior to running over each chromatography column. 
When running samples over each column, an AKTAprime purification system 
was used to regulate flow-rate, concentration gradients and the monitoring of 
protein elution. AKTAprime was supported by UNICORN version 5.0 software 
(GE Healthcare, formerly Amersham Biosciences). 
After eluting column matrix bound proteins, elution fractions were initially 
assessed via SDS-PAGE and Coomassie staining (Section 2.3.5).  
2.3.1 HisTag Purification 
All rCFHR proteins were designed with a C-terminal HisTag to enable rapid 
purification via a nickel-coated chromatography column. ‘HiTrap™ Chelating 
HP’ columns (GE Healthcare, UK) were coated with 0.5 ml of 0.1 M nickel 
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sulphate, as described by the manufacturer’s instructions. The column was 
primed with ‘His Binding Buffer’ (20 mM sodium phosphate, 500 mM NaCl, 20 
mM imidazole). 
CHO cells transfected with pDEF/rCFHR expressions plasmids were cultured 
using the conditions used previously described (Section 2.2.1), until 500 ml of 
culture SN was collected. SN was centrifuged at 4,500 x g for 10 min to remove 
cell debris, followed by a 1:1 dilution with ‘2x His Binding Buffer’ (40 mM sodium 
phosphate, 868 mM NaCl, 40 mM imidazole). 
The SN solution was passed over the primed nickel-coated ‘HiTrap™ Chelating 
HP’ column at a constant flow rate of 1 ml/min. The column was then washed 
with ‘His Binding Buffer’ to wash unbound SN protein, prior to the elution step. 
The column was washed until the protein absorbance trace (A280) had returned 
to baseline. 
The column was then eluted using a concentration gradient from 100% ‘His 
Binding Buffer’, to 100% ‘His Elution Buffer’ (20 mM sodium phosphate, 500 
mM NaCl, 500 mM imidazole), set to run at a flow rate of 1 ml/min for 10 min.  
2.3.2 mAb Purification 
Monoclonal IgG Abs were purified from hybridoma cultures using ‘HiTrap™ 
Protein G HP’ columns (GE Heathcare, UK). Hybridomas were cultured using 
the conditions previously described (Section 2.2.1), until 300 ml of culture SN 
was collected. SN was centrifuged at 4,500 x g for 10 min to remove cell debris, 
followed by a 1:1 dilution with PBS and the addition of 0.01% NaN3.  
A 1 ml ‘HiTrap™ Protein G HP’ column was primed with PBS/NaN3 0.01%, to 
prime the column ready for running the SN solution. The diluted SN ran over the 
column at a rate of 1 ml/min. The column was then washed with 5 ml PBS/NaN3 
0.01% to wash unbound SN protein, prior to the elution step.  
The column was eluted using 0.1 M glycine HCl (pH 2.5), collecting 1 ml elution 
fractions until all bound protein had eluted. To neutralise the acidic elution 
buffering, 100 μl of 1 M Tris base (pH 11.0) was added to each fraction tube 
before Ab elution.  
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2.3.3 Purification of native CFHR proteins 
‘HiTrap™ NHS-activated HP’ columns (GE Heathcare, UK) were covalently 
coated with R1/1037 or R4/244, following the manufacturer’s instructions (GE 
Healthcare). Human donor serum was collected, and 30 ml was diluted 1/10 
with PBS/NaN3. After running the 300 ml of diluted serum over the column, the 
column was eluted and analysed as previously described (Section 2.3.2).  
2.3.4 Enzyme-linked Immunosorbent Assay 
2.3.4.1 Direct ELISA 
Direct ELISA was used in several methods for the detection of protein ‘directly 
coated’ on the surface of the plate. Standard conditions were used in direct 
ELISA tests, and included using PBS buffer (pH 7.4) and carbonate buffer (pH 
9.0), in conjunction with flexiplate ELISA plates. Plates were coated with antigen 
at concentrations ranging from 1-5 μg/ml, and test, control and Ab samples 
loaded at a volume of 50 μl. Plates were blocked using BSA blocking buffer 
(PBS/BSA 1%) for 1 hr, as standard, and washed in-triplicate after each 
incubation with Ab (primary and secondary) with PBS/Tween20 0.01%. Primary 
mAbs were generally used at a dilution of 1/2,000-5,000 of the stock 
concentration (0.8-1 mg/ml, as standard). Secondary Abs were used at a 
dilution of 1/5,000-10,000.  
Secondary Abs were always HRPO-conjugates, so ELISA were developed 
using a 3,3,5,5,-tetramethylbenzidine (TMB) solution. TMB is a peroxidase 
sensitive substrate, which when enzymatically cleaved turns blue at a neutral 
pH. The TMB solution was prepared a minimum of 30 min prior to an ELISA 
development, by adding 100 μl TMB stock (10 mg/ml TMB diluted in DMSO), 
and 3 μl H2O2 (30% solution) to 9.9 ml phosphate-citrate buffer (51.4 mM 
Na2HPO4, 24.3 mM anhydrous citrate). TMB stock was stored at 4°C between 
uses. At this temperature, the solution crystallises, so prior to use it must be 
allowed time to melt at RT. After incubating with the TMB solution for 5-10 min 
(dependent on the signal from positive and negative controls), reactions were 
stopped using 10% H2SO4 (samples change from blue to yellow, at a low pH). 
Plates were then read at 450 nm using either ‘Labsystems Multiscan Spectrum’ 
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microplate spectrophotometer (Thermo, USA), or ‘SpectraMAX 190’ microplate 
reader (Molecular Devices, USA). 
When screening for CFHR-specific Ab responses in murine tail bleed sera 
(Chapter 4), serum samples were diluted (a 1/2 serial dilution with PBS, starting 
from 1/5,000) and used instead of a standard primary detection Ab. Therefore, a 
positive signal would indicate the presence of an Ab positive serum sample. 
Screening for autoantibodies used the same methodology, but serum was 
diluted 1/50 with PBS. 
Hybridoma screening used the same premise, but instead of sera, tissue culture 
well SN was applied as the primary detection reagent (diluted 1/2 with PBS). 
Hybridomas secreting antigen-specific mAbs would be highlighted as positive in 
the ELISA development. 
2.3.4.2 Sandwich ELISA 
When attempting to detect soluble proteins in a mixed protein samples (e.g. 
sera or tissue culture SN), sandwich ELISA was considered the most 
appropriate method to use. However, sandwich ELISA was only possible when 
at least two antigen-specific Abs were available. The same conditions were 
used in this ELISA, as previously described (Section 2.3.4.1). However, due to 
the nature a sandwich ELISA, one of the antigen-specific Abs (the monoclonal) 
was coated to the plate surface at 5 μg/ml. Secondary detection of the captured 
antigen was achieved by an antigen-specific pAb. Some secondary Abs were 
HRPO-conjugated, while others required a tertiary HRPO-conjugate. Secondary 
(and tertiary) Abs were used at a dilution of 1/5,000-10,000.  
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2.3.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SDS-PAGE gels were used to separate protein samples by molecular weight. 
Gels were produced in-house using the ‘Mighty Small II Gel System’ (GE 
Healthcare, formerly Amersham Biosciences), following the standard method 
proposed by Laemmli192. Stacking and separating gels were made as described 
in Table 2.7. Before the addition of TEMED, solutions were filtered using a 0.22 
μM syringe filter. 
 
Protein samples were diluted with ‘5x Protein Loading Buffer’ (0.313M Tris-HCl 
at pH 6.8, 10% SDS, 0.05% bromophenol blue, 50% glycerol), as non-reduced 
samples. Reduced samples included 100 mM dithiothreitol (DTT). Reduced and 
non-reduced samples were boiled at 100°C for 2 min, prior to running. 
‘PageRuler™ Plus Prestained Protein Ladder’ (Fermentas, UK) was loaded as 
a molecular weight protein marker on each gel. 
SDS-PAGE gels were electrophoresed using ‘SDS Running Buffer’ (25 mM Tris 
base, 192 mM Glycine, 0.01& SDS, pH 8.3), and running at 30 mA per gel. Gels 
were stopped when the ‘dye-front’ reached the bottom of the gel.  
2.3.6 Coomassie Staining 
Coomassie staining of SDS-PAGE gels was used as a rapid method of 
visualising all proteins within a given sample. SDS-PAGE gels were incubated 
with Coomassie blue stain (50% methanol, 10% acetic acid, 0.1% Coomassie 
brilliant blue) for 30 min, followed by brief washing with dH2O to remove excess 
Table 2.7: SDS-PAGE gel recipe 
^Ammonium Persulphate; *N,N,N’,N’-Tetramethylethylenediamine 
Stacking Gel 4% 
1M Tris pH 6.8 0.5ml 
30% bis/acrylamide (29:5:1) 0.67ml 
dH2O 2.4ml 
10% SDS 40μl 
10% APS^ 30μl 
TEMED* 3μl 
Separating Gel 10% 
1.5M Tris pH 8.8 2.5ml 
30% bis/acrylamide (29:5:1) 3.3ml 
dH2O 4.1ml 
10% SDS 100μl 
10% APS^ 50μl 
TEMED* 5μl 
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stain. The stained SDS-PAGE gels were then destained (10% methanol, 10% 
acetic acid) until the gel was clean and the proteins of interest were visible. 
Destain incubation time, and destain repeats were specific to each Coomassie 
stain procedure. 
2.3.6 Western Blot 
SDS-PAGE separated protein samples were transferred to ‘Hybond HCL 
nitrocellulose’ (GE Healthcare) via electrophoresis using ‘Transfer Buffer’ (25 
mM Tris base, 192 mM Glycine, 20% Methanol) and running at 100 volts for 1 
hr. After transferring, nitrocellulose membranes were blocked for 1 hr with ‘Non-
fat dried milk (NFDM) Blocking Buffer’ (5% NFDM/PBS/0.01% Tween20).  
Nitrocellulose membranes were then incubated with primary Ab diluted 1/2000-
5000 in ‘NFDM Blocking Buffer’. Membranes were then washed for 10 min, in-
triplicate, with ‘Wash Buffer’ (PBS, 0.01% Tween20, pH 7.4). After washing, 
membranes were incubated with an HRPO-conjugated secondary Ab diluted 
1/4,000-10,000 in ‘NFDM Blocking Buffer’, and incubated for 1 hr. Membranes 
were then washed as previously described.  
The membrane was then immersed in ‘Peirce® ECL Western Blotting 
Substrate’ (Thermo Scientific) for 1 min, then wrapped in standard cling-film. 
The blot was exposure to light-sensitive X-OMAT film in the dark, for increments 
of time.  
When testing for autoantibodies via western blot, a ‘Strip Blot’ methodology was 
developed. This involved running the antigen of interest in all test wells of the 
SDS-PAGE gel, and transferring to nitrocellulose as previous described. Once 
transferred, the nitrocellulose was treated with ‘Ponceau Stain’ (0.1% Ponceau 
S w/v, 5% acetic acid) to instantly visualise the protein lanes on the 
nitrocellulose. The lanes were then cut into strips, placed into in a test tube (with 
lids) and washed with PBS until the stain had been removed. Strips were then 
individually blotted with primary and secondary Abs. The ‘primary Ab’ was 
patient or control plasma, diluted 1/50 in PBS/0.01% Tween20. After the final 
wash, strips were lined-up in their original order, with reference to the protein 
marker. The blot was then developed as previously described.  
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2.4 Animal Work and Hybridoma Fusions 
2.4.1 Murine Immunisations 
Female C57BL/6 mice aged 12-16 weeks were selected for immunisation, with 
the aim of producing an antigen-specific IgG Ab response.  
2.4.1.1 Immunisation Protocol and Antigen-Adjuvant Emulsification 
Mice were immunised as outlined in Table 2.8. The initial CFHR immunisations 
were administered using Freund’s Complete Adjuvant (FCA), followed by 
subsequent immunisations at week 2 with Freund’s Incomplete Antigen (FIA). 
Antigen was diluted to 0.4 mg/ml in sterile PBS, and a 100 μl volume (40 μg 
CFHR antigen) was combined with an equal volume of either FCA or FIA. The 
two solutions were emulsified using two luer-lock glass syringes immediately 
prior to immunisation. 
FCA and FIA emulsions (weeks 0 and 2, respectively) were administered 
subcutaneously (SC) at either the ‘scruff’ of the neck, or lower flank. Each 
antigen-adjuvant immunisation was injected at two sites (100 μl per site). The 
remaining immunisations were administered intraperitoneally (IP). 
 
2.4.1.2 Murine Spleen and Blood Collection 
Prior to each immunisation, tail bleeds were taken to assess anti-CFHR serum 
levels. Tail bleeds were taken as previously described193. Approximately 50-100 
μl of blood was collected per tail bleed. Collected blood was incubated for 1 hr 
at RT, followed by micro-centrifugation at 13,000 x g for 5 min. Serum was 
collected, stored on ice and tested on the same day. Sera was then stored at -
20°C. 
Week 
No. 
Immunisation Buffer/Adjuvant Injection 
site 
Volume Antigen 
load 
0 1st PBS/FCA SC 200μl 40μg 
2 2nd PBS/FIA SC 200μl 40μg 
4 3rd PBS/- IP 200μl 40μg 
6 4th PBS/- IP 200μl 40μg 
8 5th PBS/- IP 200μl 40μg 
 
Table 2.8: Murine immunisation protocol 
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The coagulated blood pellets were discarded. Sera collected prior to the first 
immunisation served as negative control sera for subsequent tail bleed tests. 
Murine sera were screened via direct ELISA (Section 2.3.4.1). 
5 d after the final immunisation (week 8), total blood volume was collected via 
cardiac puncture and terminal exsanguination. Blood sera was isolated and 
stored, as previously described. Spleens were collected and stored on ice in 
sterile PBS (pH 7.4), and processed within 1 hr of collection.  
2.4.2 Hybridoma Fusion 
Spleens were transferred to 1 well of a 6-well tissue culture plate (surface area 
9.6cm2), with 5 ml sterile PBS. Spleens were crushed using two frosted glass 
slides, releasing the splenocytes into solution. Splenocytes were resuspended 
by gentle aspiration with a pipette, and transferred to a 50 ml tube, followed by 
the addition of 20 ml ice cold unsupplemented RPMI 1640 media (PAA, UK). 
The cell suspension was stored on ice for 5 min, to allow large debris to settle to 
the bottom of the tube. The cell suspension was carefully aspirated (leaving 
unwanted debris behind) and transferred to a new 50 ml tube. At this stage 107 
NS0 cells were collected from standard incubation treated following the same 
protocol as the splenocytes.  
Splenocytes and NS0 cells were centrifuged at 500 x g for 5 min at 4°C. After 
centrifugation, the SN were discarded and pellets resuspended into a further 20 
ml of ice cold unsupplemented media. The cell suspension was centrifuged as 
before. This wash procedure was repeated in-triplicate. The final cell pellets 
were resuspended in 20 ml pre-warmed (37°C) unsupplemented RPMI media. 
The cell suspensions were then combined and centrifuged at 500 x g for 5 min 
at RT. The SN was discarded. The mixed cell pellet was gently resuspended by 
repeatedly tapping the bottom of the tube. At this stage, the cells were ready for 
the fusion procedure. 
A sterile 50% PEG 1500 solution was pre-warmed to 37°C, and 1.5 ml loaded 
into a 2 ml syringe, with needle. The warm 50% PEG 1500 solution was then 
added ‘drop-wise’ over 2 min to the NS0/splenocyte mixture, with continuous 
gentle tapping of the tube. After 2 min, the cells were immediately resuspended 
with pre-warmed 20 ml supplemented RPMI media, centrifuged at 500 x g for 5 
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min at RT, the SN discarded and the pellet resuspended again. This was 
repeated in-triplicate, to remove excess PEG 1500. The final pellet was 
resuspended in 195 ml supplemented RPMI media, with the addition of HAT 
supplement for hybridoma selection (Section 2.2.1). The hybridoma fusion cell 
suspension was transferred to 10 x 96 well tissue culture plates (200 μl per 
well). The remaining ‘excess’ culture was split across the final plate to ensure all 
potential hybridomas were included. The remaining subcloning protocol is 
summarised later in this chapter (Figure 2.3), and the ELISA specificity 
screening was completed as previously described (Section 2.3.4.1).  
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Figure 2.3: Hybridoma screening protocol 
 (a) An immunised C57BL/6 mouse spleen is collected and splenocytes are released 
into suspension. Splenocytes and NS0 cells are then counted and prepared for PEG-
fusion. Splenocytes and NS0 fusion-partner cells are fused using 50% PEG-1500. (b) 
Following the fusion procedure, the hybridoma fusion culture is plated out across 10 x 
96-well tissue culture plates. The hybridoma cultures are incubated for 7-10 d. (c) All 
hybridoma wells are visually screened and wells containing clone colonies are selected 
and condensed into individual wells of a 96-well plate (using fresh media). The selected 
colonies plate is incubated for 3 d, the screened via direct ELISA to identify rCFHR-
specific Ab secretion. (d) Positive hybridoma wells are selected and subjected to a 
limiting dilution across a 96-well plate. The selected positive hybridoma limiting dilution 
cultures are incubated for 7-10 d, and re-screened as before. This procedure is repeated 
until 3 limiting dilutions have been completed for each original positive well selected 
from stage (c). 
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2.5 Autoantibody Screening 
2.5.1 Patient and Control Plasma 
To assess the presence of CFH family autoantibodies in the normal population, 
human plasma was collected from 100 ‘normal’ blood donor controls. Blood 
samples were supplied by the Blood Transfusion Service (Newcastle-upon-
Tyne, UK), and plasma and genomic DNA collected courtesy of the NHS 
sample reception at the Centre for Life (Newcastle-upon-Tyne, UK). These 
samples will be referred collectively as ‘BTS’ control plasma. 
The BTS controls are made up of a 1:1 ratio of male to female donors. The 
ethnicity of donors was 98% white and 3% black Afrocarribean. Donor age 
ranged from 17-72 years. The aHUS plasma samples came from the Newcastle 
patient cohort 139,162, and IgAN samples were collected as part of a new cohort 
IgAN patients. Ethical approval for the use of these samples was given by the 
NRES Committee North East – Northern and Yorkshire (Genetic factors 
predisposing to the haemolytic uraemic syndrome, MREC 01/3/083) and NRES 
Committee North East – Newcastle and North Tyneside 1 (Complement and 
glomerulonephritis – genetic factors, 05/Q0905/158).  
2.5.2 Preliminary ELISA Testing 
The generation of a robust and sensitive ELISA screen for autoantibodies in 
patient samples requires comprehensive optimisation. Therefore, preliminary 
testing of ELISA parameters was undertaken, including ELISA plate surface, 
antigen coating buffer, antigen coat concentration and plate surface blocking. 
These parameters were evaluated in a multiplex testing process (Figure 
2.4).This enabled rapid production of a stable ELISA screen for each CFHR 
antigen used, and for each autoantibody isotype being tested (IgG and IgA). 
Multiplex testing was done in 2 stages, as will now be described. 
Stage 1 is designed to determine the most appropriate conditions for optimal 
coating of the antigen, assessing coat surface x coat buffer x coat antigen 
concentration. A primary Ab was used to assess the efficiency of antigen 
binding, where the highest signal is an indication of the best conditions for the 
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specific coating antigen. The blocking reagent used in ‘Stage 1’ is kept 
consistent across all conditions. 
Stage 2 is designed to determine the most appropriate conditions when BTS 
control plasma (assumed negative) is included as in the position of ‘primary Ab’, 
as autoantibodies will essentially serve as ‘primary’ in the final ELISA screen. 
The aim of ‘Stage 2’ is to choose conditions where the mean BTS control value 
(from 10 samples) approaches zero, while maintaining a high positive control 
value. The positive control is an autoantibody positive plasma sample, 
previously determined (if available). This control is available for rCFHR1 
screening, due to the identification of positivity from CFH autoantibody testing 
(IgG isotype), and fragment analysis highlighting C-terminal binding of CFH and 
CFHR1162. However, when screening rCFHR2-5, or for IgA autoantibodies to all 
CFH family proteins, no known positive control was available.  
‘Stage 2’ uses the best conditions for antigen coating, as determined by ‘Stage 
1’ results. These conditions primarily include coat buffer, and coat antigen 
concentration. Plate surface is reassessed in ‘Stage 2’ as different blocking 
reagents are tested. Therefore, it is important to reassess the influence of plate 
surface on each of the blocking reagents. Therefore, ‘Stage 2’ assesses coat 
surface x blocking reagent x donor plasma. 
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Figure 2.4: Testing parameters for the autoantibody screening ELISA  
The various parameters of each autoantibody ELISA were tested to select the most 
suitable parameters for each screen. This optimisation process was split into two 
stages. (a) Stage 1 involved testing ELISA plate surface (Flexiplate, Perkins Elmer 
and Maxisorb), antigen coating buffer (PBS pH 7.4), ‘Coating Buffer’ pH 7.4, and 
Carbonate buffer pH 9.0) and a range of CFHR coating concentrations (0.1-10 μg/ml). 
(b) Stage 2 involved testing plate surface (as before), blocking buffer (PBS/BSA 1%, 
‘Ultrablock’ diluted 1/5, and PBS/Tween20 0.1%) and a cohort of 10 BTS normal 
controls (plasma diluted 1/50). All BTS plasma was duplicate-tested on no coat control 
plates to assess background level binding to the blocking buffer. The background 
binding was then subtracted from the coated plate result.  
(a) 
(b) 
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2.6 Statistical Analysis 
2.6.1 General Analysis 
When conducting ELISA, samples were loaded in-duplicate/triplicate and the 
mean value established for presentation of results. Under these circumstances, 
the standard deviation was applied to measure the spread around the mean 
(presented as positive error bars). The standard deviation values were 
calculated using the follow equation. 
 
2.6.2 Analysis of autoantibody data 
The disease and control data from autoantibody screening was not analysed 
statistically to assess the significance of a change between the two groups. The 
design of the experiment was optimised towards creating a base-line negative 
result, whereby the distribution of data due to positive results would skew the 
data to the right of a Gaussian distribution. If the data were to be analysed, a 
Fisher’s exact test would be considered due to the quadranted presentation of 
results (i.e. patient and control groups x positive or negative results).  
2.6.3 Analysis of CFHR4 plasma levels 
CFHR4 concentration levels were assessed in small preliminary populations of 
aHUS and BTS controls. Each population consisted of 10 samples, so a 
Gaussian distribution could not be determined. Therefore, a nonparametric 
Mann-Whitney test was selected to analyse the statistical significance of a 
change between the two populations. Data was analysed using GraphPad 
Prism® version 5.0 (GraphPad Software Inc.) 
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Chapter 3  
3. Production & Purification of Recombinant CFHR Proteins 
3.1 Introduction 
CFH and the CFHR proteins are a group of highly homologous proteins, of 
which CFH and CFHR1 are considered to exhibit potent complement regulatory 
activity153,194-196. CFHR4 has recently been shown to play a supportive role in 
the activation of C3 convertase168. The functional role of CFHR2, CFHR3 and 
CFHR5 remain to be elucidated. However, there is sufficient evidence to 
suggest potential roles for CFHR3, CFHR4 and CFHR5 in the pathogenesis of 
renal diseases such as aHUS162 and CFHR5 nephropathy197. 
The role of the CFHR proteins remains poorly understood, in contrast to our 
knowledge of CFH in health and disease198-200. At the beginning of this research 
project, there were no commercially available CFHR proteins, or mAbs for 
specific detection or isolation of CFHR proteins from human serum. Therefore, 
in order to study CFHR proteins, a full panel of recombinant proteins was 
deemed essential, with the subsequent aim to use these to generate new mAbs 
and pAbs. These combined reagents would allow a complete and thorough 
characterisation of the role of CFHRs in health and disease. 
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3.2 Chapter 3 Aims 
To produce five DNA plasmid constructs containing cDNA for each of the five 
rCFHR genes, followed by production in mammalian cell culture. 
To generate highly pure rCFHR proteins to enable future studies, including the 
development of mAbs. 
3.3 Results 
3.3.1 Modification of pDEF(nMCS) Expression Vector 
The DNA expression vector pDEF(nMCS) has been commonly used in 
conjunction with CHO cells to produce a range of human proteins, including 
human complement proteins185-188. The vector contains an elongation factor 1α 
(eF1α) promoter region upstream of the multiple cloning site (MCS) which 
results in constitutive protein expression when transfected into a mammalian 
cell system. The vector also contains the hygromycin B resistance gene 189,190, 
which allows selection of transfected cells using hygromycin B supplemented 
media. Thus, pDEF(nMCS) was chosen as our base construct.  
Before the insertion of the rCFHR cDNA insert, pDEF(nMCS) was modified to 
include a sequence coding for a 5 amino acid linker, followed by a 6 histidine 
purification tag (HisTag). The linker-HisTag (L5H6) sequence was incorporated 
immediately downstream of the restriction enzyme (RE) site used for ligation of 
each rCFHR insert.  
The aim of the modification was to facilitate the addition of L5H6 to the 3’ end of 
each inserted rCFHR construct. Two complementary single stranded DNA 
(ssDNA) oligomers were designed encoding for the L5H6 sequence, with the 
addition of BamHI and NheI RE sites at either end. The complementary 
oligomers were designed to anneal leading to BamHI and NheI overhangs, as 
would be achieved after a RE digestion of pDEF(nMCS) (Figure 3.1a). 
After insertion of the annealed L5H6 fragment into pDEF(nMCS), OneShot® 
Top10 E.coli (Invitrogen) were transformed with 5 μl of the ligation reaction and 
propagated as previously described (Section 2.1.6).  
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Positive colonies were selected on ampicillin 200 μg/ml supplemented LB agar 
plates, picked and cultured overnight. Plasmid DNA was isolated via standard 
column DNA preparation according to manufacturer’s instruction (QIAprep 
Miniprep Kit, Qiagen). Correct insertion of L5H6 was confirmed via DNA 
sequencing of the pDEF(nMCS) (Section 2.1.2). The DNA sequencing results 
show successful insertion of the L5H6 fragment into one of the positively 
selected bacterial clones (Figure 3.1b). The modified vector will be referred to 
as pDEF(L5H6). 
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 Figure 3.1: Construction of pDEF(L5H6) 
(a) Illustration of the annealed complementary single stranded DNA oligonucleotides that were 
designed to produce a double stranded DNA fragment (L5H6) with BamHI and NheI 
overhangs. (b) DNA sequencing data of the newly generated pDEF(L5H6) vector showing the 
successful insertion of the L5H6 fragment (purple shaded area). The BamHI and NheI sites 
are listed and highlighted by boxes.  
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3.3.2 PCR Amplification of rCFHR cDNA 
Plasmids containing cDNA for each of the CFHR genes were obtained from 
different sources (Table 2.2). Upon receipt of each clone, DNA sequencing was 
completed to clarify the correct DNA sequence had been supplied. These 
sequencing results are discussed further in Section 3.3.4.  
Template DNA for each rCFHR construct was amplified using specifically 
designed primers (Table 2.1). Amplified cDNA was visualised on an ethidium 
bromide supplemented 1% agarose/TAE gel (Figure 3.2). The results show 
successful PCR amplification of rCFHR1 (990bp), rCFHR2 (810bp), rCFHR3 
(990bp), rCFHR4B (991bp), and rCFHR5 (1707bp). The PCR primers were 
designed specifically for cloning of CFHR cDNA so no specific positive control 
for primer function (under these specific PCR conditions) could be included with 
these PCR reactions. However, negative controls (excluding primers and/or 
DNA template) were included in all PCR reactions and remained negative as 
expected (control results not shown). PCR cloned rCFHR cDNA was purified 
from the PCR mixture (QIAquick PCR Purification Kit, Qiagen) and DNA 
concentration was determined via UV spectrophotometry. 
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 Figure 3.2: rCFHR cDNA PCR 
Samples from various PCR cloning reactions were ran on 1% TAE/agarose gels, 
supplemented with ethidium bromide. Shown are examples of the PCR reactions for (a) 
rCFHR1 (expected size 990bp), (b) rCFHR2 (expected size 810bp), (c) rCFHR3 (expected 
size 990bp), (d) rCFHR4B (expected size 993bp), and (e) rCFHR5 (expected size 1707bp). 
These results are representative of many such reactions. Negative controls lanes remained 
completely blank and have been omitted. 
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3.3.3 Construction of pDEF/rCFHR 
Purified rCFHR DNA was double digested and ligated into linearised 
pDEF(L5H6), as before. Again, 5 μl of ligation reaction was transformed into 
One Shot® Top10 E.coli. Single colonies were selected and whole cell DNA 
was collected as previously described (Section 2.1.3.2) and used as template 
DNA in a colony PCR procedure. The colony PCR results for pDEF/rCFHR1, 
rCFHR3 and rCFHR4B show amplification of a product of the expected size for 
each rCFHR cDNA insert (Figure 3.3). Negative results show a band of 192bp, 
the distance between the pDEF(nMCS) forward and reverse primers. 
Bacterial colonies identified as positive via colony PCR were cultured overnight 
in 5 ml LB broth, supplemented with 200 μg/ml ampicillin. Plasmid DNA was 
isolated and purified, as previously described, and each pDEF/rCFHR plasmid 
was double digested using XbaI and BamHI (rCFHR1-4), or SpeI and BamHI 
(rCFHR5). Restriction endonuclease digested plasmids were electrophoresed 
as previously described. Linearised DNA bands of the expected sizes; 
pDEF(L5H6) vector (~7kb), and the linearised rCFHR inserts: rCFHR1 (990bp), 
CFHR2 (810bp), CFHR3 (990bp), CFHR4B (991bp), and CFHR5 (1707bp) are 
clearly visible in the respective panels (Figure 3.4). Each panel contains a 
restriction endonuclease digestion of pDEF(L5H6), loaded as a negative 
control. This negative results show a linearised vector band of ~7kb, without a 
MCS rCFHR ‘drop-out’ product. 
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 Figure 3.3: Colony PCR 
Single bacterial colonies (10 clones per pDEF/rCFHR transformation) were selected and 
total cell DNA collected and used as template in colony PCR. Primers were designed to 
amplify the contents of the MCS. PCR reactions were electrophoresed on 1% agarose 
gels, supplemented with ethidium bromide. Colony PCR results are shown for 
transformations for pDEF/rCFHR1, rCFHR3 and rCFHR4B as indicated above the lanes. 
Each lane represents a colony PCR result from a single bacterial colony. Positive controls 
for each construct (CFHR1+, CFHR3+ & CFHR4B+), using purified pDEF/rCFHR plasmid 
DNA as template. These data are a representative of the pDEF/rCFHR colony PCR runs. 
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 Figure 3.4: pDEF/rCFHR DNA construct digestions 
Plasmid DNA was isolated from small batch cultures of ampicillin resistant bacterial 
tranformant colonies, and restriction enzyme digested with XbaI and BamHI 
(pDEF/rCFHR1-4), or SpeI and BamHI (pDEF/rCFHR5). In panels a-e, lanes 1-3 is 
plasmid DNA isolated from randomly selected positive colonies, and lane 4 is double 
digested pDEF(L5H6), as a negative control. (a) pDEF/rCFHR1; (b) pDEF/rCFHR2, (c) 
pDEF/rCFHR3, (d) pDEF/rCFHR4B, and (e) pDEF/rCFHR5. 
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3.3.4 DNA Sequencing of pDEF/rCFHR constructs 
PCR rCFHR templates were initially sent for DNA sequencing (Section 3.3.2) to 
validate the correct cDNA insert had been supplied. Results from forward and 
reverse sequencing of template DNA were aligned alongside rCFHR reference 
sequences obtained from the NCBI nucleotide database 
(www.ncbi.nlm.nih.gov/nucleotide). The CFHR cDNA reference accession 
numbers are as follows: rCFHR1; NM_002113, rCFHR2; NM_005666, rCFHR3; 
NM_021023.4, rCFHR4B; NM_006684, and rCFHR5; NM_030787. Sequence 
alignments were completed using Vector NTI v.10 (Invitrogen). Sequence 
alignments for rCFHR1, rCFHR2, and rCFHR3 (Appendix I) share 100% 
homology between the reference sequence and template sequencing results. 
However, the alignments for rCFHR4B and rCFHR5 highlighted nucleotide 
sequence variants (Figure 3.5). Sequencing of rCFHR4B showed 6 nucleotide 
sequence variants (156T>C, 171T>C, 216T>C, 231T>G, 243G>A, 237A>G). 
These variants do not result in translational amino acid substitutions, so from a 
functional perspective, these are ‘silent’ nucleotide variants. However, the 
rCFHR4B sequence also contained a sequence variant (236C>T) which 
translated to a 79Ser>Leu amino acid change. All sequence variants were 
assessed using Alumut v.6 database, courtesy of the Institute of Genetic 
Medicine, Newcastle University. 
From a genetic perspective, it is interesting that all rCFHR4B nucleotide 
changes cluster to a 10% region of the rCFHR4B cDNA sequence (mapping to 
SCR1). Whether there is anything significant to note from this observation is 
currently unclear. 
Sequencing of rCFHR5 showed two nucleotide sequence variants (609A>G, 
1122A>G) which did not result in any amino acid substitutions. The 1122A>G 
variant is located 2bp from the 5’ splice site of exon 7, which may have an effect 
on RNA splicing of the CFHR5 transcript. However, this should not cause 
difficulty for this construct as transcript splicing is already complete (working 
with rCFHR5 cDNA). 
To validate the correct insertion of each rCFHR clone into pDEF/L5H6, each of 
the pDEF/rCFHR constructs were also DNA sequenced using the same primers 
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as used previously for colony PCR. The pDEF/rCFHR sequencing results were 
aligned with the reference and template sequences. The results were identical 
to the template sequence, indicating that no sequence changes had been 
introduced during the bacterial cloning process. 
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 Figure 3.5: DNA sequencing of rCFHR constructs 
rCFHR cDNA was DNA sequenced prior to PCR amplification (sequencing of PCR 
template), and again after bacterial transformation (final pDEF/rCFHR construct). A cDNA 
reference sequence was used for each rCFHR (NCBI database). The reference, template 
and pDEF/RCFHR sequences were aligned and nucleotide variants analysed. Sequence 
homology and nucleotide variant are highlighted (yellow and cyan, respectively). (a) DNA 
sequence alignment using Vector NTI software for regions of rCFHR4B where nucleotide 
variants were found, when comparing the reference and template sequences. (b) DNA 
sequence alignment for the regions of rCFHR5 where nucleotides variants were found when 
comparing the reference and template sequences.  
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3.3.5 Protein expression and CHO transfectant sub-cloning 
After transfecting the pDEF/rCFHR constructs into wildtype CHO cells using 
jetPEI® transfection reagent (Section 2.2.2.1), tissue culture growth media was 
collected after 10 d and tested for the presence of each rCFHR protein. For 
each rCFHR transfection, 12 individual clone colonies were selected, and 
growth media from each clone was tested via sandwich ELISA. An anti-HisTag 
Ab was coated to ELISA plates, followed by the addition of cell culture SN. 
HisTag-bound rCFHR proteins were detected using a goat anti-CFH pAb, with 
subsequent detection using a HRPO-conjugated donkey anti-goat IgG, as 
previously described (Section 2.3.4.2).  
A positive result was considered as a UV absorbance reading of more than 3 
times the signal of the negative control cell culture SN (wild type CHO cell 
growth media). The results indicate 9 of the 12 clones analysed in the rCFHR1 
transfected clones yielded a positive result (Figure 3.6a). Clone R1.4 yielded 
the highest absorbance reading, suggesting this clone as producing the highest 
levels of rCFHR1. Therefore, R1.4 was selected for further analysis and carried 
forward for large batch culturing.  
Using the same approach, clones R3.2, R4.2 and R5.5 were selected and 
carried forward for large batch culturing (Figure 3.6b-d). 
The expression of rCFHR2 could not be detected in tissue culture growth 
media, either via ELISA or western blot (Figure 3.7). This was compounded by 
the lack of a suitable positive control. Human serum is a source of native 
CFHR2, but detection using the anti-CFH pAb had previously been 
unsuccessful in western blot analysis (data not shown). Detection of rCFHR2 
was attempted via sandwich ELISA using an anti-HisTag mAb coated plate (as 
previously described to capture rCFHR3, rCFHR4B and rCFHR5), but no 
positive signal could be detected in any of the R2.1-12 monoclonal cell clones 
(Figure 3.7a). However, the positive control protein (a recombinant CFH 
fragment, consisting of SCRs 16-18, with 6*HisTag at the N-terminus) was 
clearly detectable in the sandwich ELISA. It is unclear whether this is due to a 
deficiency in rCFHR2 protein expression, or a result of poor binding affinity of 
the anti-CFH polyclonal. The anti-HisTag monoclonal was also used as a 
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primary Ab in a western blot analysis, but the anti-HisTag mAb was 
unsuccessful at detecting rCFHR2 in tissue culture SN (Figure 3.7b). The anti-
HisTag Ab was functional in the western blot, as a HisTag positive control signal 
was present. However, this primary Ab was unable to detect any of the 
histidine-tagged rCFHR proteins produced.  
As a result of the issues with detection (or expression) of rCFHR2, work on 
rCFHR2 was placed on hold until a suitable detection reagent became 
available.  
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 Figure 3.6: CHO/rCFHR transfectant colony testing 
12 clones were selected for each of the four CHO/rCFHR (1, 3, 4B and 5) and d +7 growth 
media applied to ELISA plates coated with a capture Ab. For rCFHR1 detection, the plate 
was coated with C18/3 mAb (100 μl at 5 μg/ml), and plates for rCFHR3, rCFHR4B or 
rCFHR5 were coated with anti-HisTag mAb (100 μl at 5 μg/ml). All plates were then 
probed with an anti-CFH pAb (1/5,000 dilution), followed by probing with a HRPO-
conjugated anti-goat IgG. A positive signal was determined as being 3 times the signal of 
the CHO SN negative control. Clones with the highest signal, which were selected and 
carried forward for large batch production of each rCFHR protein, are marked with an 
asterix (   ).  
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Figure 3.7: rCFHR2 protein detection in CHO/rCFHR2 transfectants  
(a) 12 CHO/rCFHR2 clones were selected and d +7 SN applied to ELISA plates coated with 
an anti-HisTag mAb (100 μl at 5 μg/ml). The ELISA was then probed with an anti-CFH pAb 
(1/5,000 dilution), followed by probing with a HRPO-conjugated donkey anti-goat IgG. A 
positive signal was determined as being 3 times the signal of the CHO SN negative control. 
(b) CHO/rCFHR2 transfectant SNs were separated using Tris-Glycine SDS-PAGE (10% gel) 
and transferred to nitrocellulose membrane. Membranes were incubated with an anti-HisTag 
mAb, followed by detection using an HRPO-conjugated sheep anti-mouse IgG secondary 
pAb. Lane 1: 10 μl rCFHR2 tissue culture SN; lane 2: 20 μl rCFHR2 tissue culture SN; lane 3: 
HisTag positive control protein (1618his; CFH fragment consisting of SCR domains 16-18); 
lane 4: CHO cell tissue culture SN (CHO SN) as a negative control. 
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3.3.6 Purification of rCFHR Proteins 
As previously discussed, all rCFHR proteins were designed with a C-terminal 
HisTag for rapid purification via a nickel coated chelate chromatography 
column. Tissue culture SN from each clone (CHO/rCFHR1.4, CHO/rCFHR3.2, 
CHO/rCFHR4.2 and CHO/rCFHR5.5) was collected (1-2 litres) and diluted in ‘2x 
His Binding Buffer’ (Section 2.3.1). Pilot purification established that 20 mM 
imidazole in the binding buffer was sufficient to restrict non-specific protein 
binding to the nickel chelating column, with the exception of rCFHR1 
purification; this protein preparation favoured a 40 mM imidazole in the binding 
buffer. rCFHR proteins were then eluted using an imidazole gradient from 20 or 
40 mM (His Binding Buffer) to 500 mM imidazole (His Elution Buffer). 1 ml 
fractions were collected throughout the elution, and examples of the UV 
absorbance readings for each rCFHR protein are presented (Figure 3.8).  
A double absorbance peak is visible during the imidazole gradient elution of 
rCFHR1 (Figure 3.8a), suggesting at least two species of protein were being 
eluted in this process. To assess the purity and uniformity of the proteins in the 
various fractions the elution fractions were applied to a 10% SDS-PAGE gel and 
Coomassie stained. The data suggests the earlier peak (fractions 7-10) 
contains predominately non-specifically bound protein (Figure 3.9a), whilst the 
later peak (fractions 11-14) corresponds to the elution of rCFHR1. Fraction 11 
also contains some higher molecular weight contaminant proteins so were 
excluded from further analysis. Fractions 12-14 were pooled, buffer exchanged, 
filter-concentrated, and the final concentration determined as outlined below 
(Section 3.3.7)  
In the remaining clone (rCFHR3, rCFHR4B and rCFHR5), a single absorbance 
peak is observed on each UV trace of the eluted fractions (Figure 3.9b-d). The 
Coomassie stained SDS-PAGE gels confirmed this single peak was 
predominately the rCFHR proteins of interest with low levels of contamination 
proteins present. Thus, from the rCFHR3 elution, fractions 3-6 were selected, 
from rCFHR4B, fractions 6-9, and from rCFHR5, fractions 3-6.  
During the purification process samples were collected from each stage of the 
protocol to assess the progress on HisTag purification. These samples were 
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analysed via western blot (Figure 3.10). An anti-CFH mAb C18/3 (Santa Cruz) 
to detect rCFHR1, followed by secondary detection with an HRPO-conjugated 
sheep anti-mouse IgG pAb (Figure 3.10a). Sample 1 is positive for rCFHR1, 
indicating successful production of the protein in the tissue culture growth 
media. Sample 2 shows that when diluting the tissue culture SN 1/2 in ‘2x His 
Binding Buffer’, the conformation of rCFHR1 is not affected (e.g. no aggregation 
products detected). In sample 3, there is no evidence of rCFHR1, suggesting all 
detectable rCFHR1 is bound to the column. This is further confirmed by the 
positive result from sample 4, containing the eluted rCFHR1 protein. Samples 5 
is a post-column growth media sample, and is negative for rCFHR1. This again 
confirms all detectable rCFHR1 has been purified.  
In reviewing the western blot data for rCFHR1, identical conclusions can also be 
drawn from the data for rCFHR5 (Figure 3.10d); all available rCFHR5 protein is 
purified from the growth media (probing with an anti-CFH pAb). However, the 
data for rCFHR3 (Figure 3.10b) and rCFHR4B (Figure 3.10c) suggests there is 
an excess of recombinant protein still available in post-column sample 5. 
Further clarification comes from the positive result in sample 3 (pre-elute wash), 
for both proteins.  
The success of this method, (i.e. high yield and low levels of non-specific 
protein contamination) indicated that additional purification steps such as Gel 
Filtration and Ion Exchange chromatography were not necessary.
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Figure 3.8: HisTag purification of rCFHR proteins 
CHO/rCFHR tissue culture SNs were applied to a nickel-coated 5ml HiTrap™ Chelating 
column. Shown is the read out or trace of A280 nm (blue line), % imidazole in the gradient 
elution (green line) and the elution fraction number (denoted in red) from a representative 
HisTag purification using the ÄKTA prime (GE Healthcare) for (a) rCFHR1, (b) rCFHR3, 
(c) rCFHR4B and  (d) rCFHR5.  
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 Figure 3.9: SDS-PAGE analysis of elution fractions from HisTag purifications 
Fractions from the imidazole elution of each rCFHR protein were subjected to SDS-PAGE 
(12% gels). (a) rCFHR1, (b) rCFHR3, (c) rCFHR4B, and (d) rCFHR5. Gels were subsequent 
staining with Coomassie blue. Red boxes indicate the fractions which were pooled and 
buffer exchanged into PBS/NaN3 0.01%. Data is representative of several purifications. 
 
80 
 
Figure 3.10: Detection of rCFHR proteins via western blot 
Samples collected at each stage of the HisTag purification procedure were subjected 
SDS-PAGE (10% gels) and transferred to a nitrocellulose membrane. (a) rCFHR1, 
(b) rCFHR3, (c) rCFHR4B, and (d) rCFHR5. After blocking with PBS/milk (5%), the 
nitrocellulose was probed with (a) L20/3 (1/2,000 dilution) followed by HRPO-
conjugated anti-mouse IgG polyclonal (1/10,000 dilution) and (b-d) anti-CFH pAb 
(1/5,000 dilution) followed by HRPO-conjugated anti-goat IgG (1/10,000 dilution). 
Sample 1: CHO/rCFHR growth media (pre-column). Sample 2: 1/2 dilution of sample 
1, diluted with ‘2x His Binding Buffer’. Sample 3: pre-elution PBS column wash. 
Sample 4: a sample taken from the most concentrated elution fraction. Sample 5: 
CHO/rCFHR growth media after column run (post-column).  
 
81 
 
3.3.7 Determination of rCFHR protein concentration 
The selected rCFHR elution fractions were pooled, buffer exchanged into 
PBS/0.01% NaN3 (pH 7.4), and concentrated to a volume of 0.5-1 ml 
(10,000MWCO Vivaspin20, Sartorius). The rCFHR3-5 proteins were 
successfully buffer exchanged and concentrated without any observable 
negative effects on protein composition. However, the rCFHR1 protein showed 
evidence of precipitation in response to buffer exchange and/or the effect of 
being concentrated. The removal of this precipitate was important for 
downstream work involving the induction and detection of Abs (Chapters 4 and 
5). Aggregated or precipitated rCFHR proteins are highly likely to result in 
unique epitopes, which could result in an unwanted antigenic response (i.e. 
false positive results). Therefore, while removal of aggregates was necessary, it 
meant losing a portion of the purified rCFHR1. To remove the protein 
aggregates, the sample was centrifuged, followed by 0.2 μM filtration (0.2 μM 
Vivaspin6, Sartorius).  
rCFHR protein concentration was determined via BCA Protein Assay (Thermo 
Scientific) and UV spectrophotometry (NanoDrop™ 8000, Thermo Scientific). 
The final protein concentrations were measured as follows: rCFHR1 at 0.2 
mg/ml, rCFHR3 at 2.1 mg/ml (Figure 3.11), rCFHR4 at 3.4, and rCFHR5 at 0.5 
mg/ml. 
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 Figure 3.11: Determination of rCFHR protein concentration 
(a) shows the ‘line of best fit’ plot from the BSA standard curve generated using a ‘BCA Protein 
Assay’ kit (Thermo Scientific) following manufacturer’s guidance. The red dashed line denotes 
the intersect from the reading generated by 1/4 diluted rCFHR3 (clone rCFHR3.2) sample in 
this assay. (b) A representative UV spectrum is shown for the rCFHR3.2 protein as noted by 
spectrophotometry using the NanoDrop™ 8000. In-triplicate rCFHR3 A280 nm reads (refer to 
table) were taken compared to the protein storage buffer (PBS/NaN3 0.01%, pH 7.4) and 
internal software used to calculate protein concentration (being set at 1 absorbance unit = 
1mg/ml). 
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3.4 Discussion 
The overall aims of this chapter were to produce a full set of rCFHR proteins. 
With the exception of rCFHR2, these aims were achieved. I have successfully 
cloned, expressed and purified sufficient quantities of rCFHR1, rCFHR3, 
rCFHR4B and rCFHR5 using a mammalian protein expression system. 
Construction of the rCFHR2 protein expression plasmid was successful, and 
hygromycin B resistant DNA transfected CHO cell clones were selected. 
However, there was a difficulty in detecting, or confirming the presence of 
rCFHR2 protein in tissue culture growth media. As previously discussed, this is 
likely to be the result of a lack of cross-reactivity between the anti-CFH pAb and 
CFHR2. In previous western blot analysis of human sera (the only source of 
CFHR2 at the time of the experiment) and this polyclonal, there was no 
evidence of cross-reactivity with CFHR2. However, the native serum CFHR2 
concentration is unknown so a poor performance via western blot may have 
been due to low levels of antigen availability. As previously described, western 
blot analysis using the anti-HisTag mAb failed to detect rCFHR2 or the other 
rCFHR proteins in the panel.  
If the problem was related to an issue with rCFHR2 protein expression, it is 
important to consider which factors may be involved. For all CFHR cDNA 
clones, the native secretion signal peptides were maintained for expression in 
the CHO cell system. The native CFHR2 signal peptide is identical to the 
sequence for CFHR1 (UniProtKB Database; CFHR1: Q03591; CFHR2: P36980; 
amino acids 1-18: MWLLVSVILISRISSVGG), and the rCFHR1 protein was 
successfully produced. Therefore, a problem with rCFHR2 expression is 
unlikely to be related to an issue with signal sequence incompatibility with the 
CHO cell expression system. In addition, the same forward primer was used for 
cloning rCFHR1 and rCFHR2, so the recombinant Kozak201 sequences for both 
mRNA transcripts would be identical. The remaining expression technology was 
contained in the pDEF(L5H6) expression vector, which was ubiquitously utilised 
by all rCFHR constructs. 
In consideration of post-translational issues related to intracellular rCFHR2 
processing, it is more difficult to hypothesise where problems may have arisen. 
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In light of the difficulties presented with rCFHR2 expression, it highlights the 
importance of adopting a more robust expression screening protocol that can be 
used to detect the expression of any recombinant protein (regardless of the 
availability of Abs for downstream protein detection). The use of reporter gene 
technology would be a useful addition to the current CHO cell/pDEF(L5H6) 
expression system. For example, the insertion of a GFP sequence upstream of 
the signal peptide is a viable consideration202. This would allow rapid 
identification of CHO cell transfectant colonies actively expressing the 
recombinant protein of interest. However, this particular methodology could only 
report on intracellular expression; it cannot provide confirmation protein 
secretion into the extracellular tissue culture media. Human CFHR2 has been 
successfully produced recombinantly in non-mammalian eukaryotic systems203, 
so production in a mammalian system should be equally as suitable an 
expression environment, if not more so. 
The CHO/rCFHR2 transfectant clones were cryogenically frozen and stored in 
LN2 until a suitable detection reagent became available that could provide a 
positive control detection signal. 
The experience with rCFHR2 illustrates the importance of both a good detection 
method and a specific means to purify the protein when generating novel 
recombinant proteins. From the outset, several key decisions had to be taken. 
These included the choice of expression vector, in concert with a suitable 
expression system (e.g. bacteria, yeast, insect, mammalian), the purification 
methodology (e.g. affinity, ion-exchange, PEG cuts, gel filtration, heparin). We 
chose to include a HisTag to the C-terminus of the rCFHR proteins to enable 
rapid purification via a nickel coated metal chelate column because it is a rapid 
method for purifying protein from a mixed batch of other proteins (i.e. FCS 
containing tissue culture media). The imidazole gradient elution in particular 
serves to resolve out non-specifically bound proteins based upon their relative 
affinity for the nickel surface, compared to that of the HisTag interaction. This 
method of purification has resulted in a single-step purification procedure, 
leading to the production of relatively pure recombinant protein stocks.  
Using the HisTag has also served in providing an additional antigenic epitope 
that was utilised in detection screening of rCFHR1, rCFHR3, rCFHR4B and 
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rCFHR5 (Figure 3.6). However, as previously described, this failed to detect 
rCFHR2.   
It was decided to incorporate the HisTag directly into the pDEF(nMCS) MCS, as 
this was deemed more efficient than inducing the HisTag into the initial PCR 
primer design. To insert the L5H6, a careful review of the available restriction 
enzyme sites led to the use of BamHI. The BamHI sequence (GGATCC) 
contains codons which translate to a glycine and serine, which made this a 
suitable candidate for linking the HisTag to each rCFHR protein. The amino 
acids have simple, non-reactive side-chains so often used for linker regions in 
recombinant fusion proteins. Another 3*glycine residues were added 
downstream of the BamHI contribution, followed by the 6*histidines and an 
introduced recombinant stop codon. Linker regions are often used in 
recombinant fusion proteins, and in particular, a linker made up of amino acids 
that will maintain a primary protein structure due to their small, non-reactive side 
chains204. In producing these linker-HisTags in this way, the aim was to ensure 
the HisTag and terminal SCR domain of each rCFHR protein were spaced 
sufficiently far apart that the chance of steric hindrance would be reduced with 
respect to either the HisTag, or the terminal SCR functionality. 
Sequence analysis of all the rCFHR cDNA sequences revealed several single 
nucleotide polymorphisms or changes, but the most notable sequence variant 
was in CFHR4B. A Ser79Leu change was identified at the end of SCR1, which 
has the potential to affect the native hinge-region between SCR1 and SCR2. 
There is currently no data available regarding mutations or SNPs within the 
coding region of CFHR4, so it is unclear whether this change is a natural variant 
within the population, or a mutation introduced through bacterial cloning (before 
the cDNA came into our possession). I chose to proceed and produce this 
protein with this variant as there was no evidence suggesting it may cause 
downstream difficulties. It is possible that the amino acid change may confer a 
modification in the native structure and/or function of the protein. Production of 
the CFHR4 with a Leu at position 79, should also be carried out to assess 
whether there are any notable functional differences between these variants. All 
future work with the rCFHR4 Ser79Leu must be cautiously regarded, 
particularly with respect to cell/protein binding or functional analysis. Recent 
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data suggests CFHR4 is involved in the modulation of C-reactive protein (CRP). 
However, the CRP-binding data does not make reference to the importance of 
this region in the structure or other functions of this protein205. 
The advantage of the inclusion of HisTag quickly became evident during the 
purification of the rCFHR proteins. In particular, rCFHR3-5 were rapidly purified 
from cell culture SN at relatively high yields and excellent purities. However, 
purification of rCFHR1 was problematic. When initially purifying rCFHR1, the 
‘His Binding Buffer’ concentration was set at the commonly used concentration 
of 20 mM. SDS-PAGE gel results from this approach showed a high level of 
background binding with CFHR1 and there was no evidence of the 
characteristic double banding of rCFHR1153,198,200. Furthermore, western blotting 
of these samples using C18/3 as the primary Ab indicated that very little of the 
‘purified’ protein was rCFHR1. The concentration of imidazole in the ‘His 
Binding Buffer’ was increased to 40 mM with the aim of reducing the high level 
of non-specific background binding. This approach simply increases the 
imidazole coating the nickel column matrix, and therefore reduces the effect of 
non-specific interactions of other proteins. Only the HisTag protein, with 
significant affinity for the nickel coated column matrix (rCFHR1 in this case) 
should have the ability to displace the imidazole from the nickel and remain 
bound. This change was sufficient to markedly improve protein purification, both 
with respect to yield and overall purity.  
The purity of the rCFHR proteins was very important, especially considering 
how they would be utilised in the next stage of work. The proteins would be 
essentially used as immunogenic substrates in two strands of work; (1) the 
generation of novel mAbs, with a high level of specifically for the rCFHR protein 
with which they had been raised, and (2) to screen whole serum for the 
presence of anti-CFHR autoantibodies in a cohort of aHUS patients.  
In conclusion, the successful production of rCFHR1, rCFHR3, rCFHR4B and 
rCFHR5 enabled progression to the next strand of research; the production of 
mAbs and pAbs to specifically target each rCFHR protein. 
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Chapter 4 
4. CFHR mAb production and development of CFHR detection assays 
4.1 Introduction 
In aHUS patients with a complete deficiency of CFHR3/1 or CFHR1/4, there is a 
90% increased risk of developing an IgG CFH autoantibody response. This 
suggests that the plasma concentration of CFHR1, either alone or in 
combination with CFHR3 or CFHR4, has an impact of the development of a 
CFH-targeted autoantibody response. To assess the role CFHR concentration 
has in disease phenotype, a specific sensitive assay is required. A commonly 
used methodology for detecting protein concentration in a mixed protein sample 
is a sandwich ELISA. This requires the use of a capture and detection Ab, both 
of which target the CFHR protein of interest. 
There are several commercially available CFH monoclonal and pAbs, but a 
restricted availability of Abs to specifically target CFHR proteins. CFH Abs are 
commonly used to detect CFHR proteins, by taking advantage of natural cross-
reactivity of this highly homologous protein family159,162,203. However, using 
ELISA to measure CFHR concentration in human sera requires at least one Ab 
specific to the CFHR protein of interest. Therefore, to measure the individual 
concentration of each CFHR protein in human sera, production of CFHR-
specific mAbs was a requirement. 
Deficiency of CFHR1, CFHR3 and CFHR4 have previously been implicated in 
conferring an increased risk of developing CFH autoantibodies. Therefore, 
CFHR-specific ELISA tests would be developed against these proteins. 
CFHR5 had also been implicated in disease, so testing CFHR5 levels was also 
an important piece of work. However, there was already a CFHR5-specific 
commercially available mAb available that could be used for this work (R&D 
Systems, UK; MAB3845). 
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4.2 Chapter 4 Methodology: Hybridoma Technology 
4.2.1 Discovery of Hybridoma Technology 
The first discovery of Abs of a defined specificity began with the discovery that 
mAbs are produced in fairly high quantities in multiple myelomas, a disease 
caused by the cancerous growth of a B-cell clone that secretes Abs206-208. In the 
1960s, Potter induced myelomas in mice by administering intraperitoneal 
injections of mineral oil209. Although these myeloma Igs produced were 
monoclonal and long-lived, their antigenic specificity was unknown. In contrast, 
immunised mice produced sera of known antigenic reactivity, yet the sera was a 
polyclonal mixture of Abs and the B-cells were short-lived in vitro. Milstein and 
Kohler combined the advantageous properties of these two types of Ab-
secreting cells and revolutionised immunology with the development of 
hybridoma technology210. They fused the non-secretor variants of the murine 
mineral-oil induced myelomas with antigen-primed B-cells in vitro, making 
immortalised Ab-secreting cells called ‘hybridomas’. 
4.2.2 Producing Hybridomas 
Primed B-cells are obtained from experimental animals (usually mice, rats or 
hamsters) immunised with the designated antigen. The myeloma cells that the 
B-cells are fused with are mutant cell lines that fail to secrete their own Igs and 
carry a selectable trait. After fusion, the cells are grown in a culture media that 
allows the growth of the hybridomas, but inhibits the growth of the unfused 
myeloma that carry the selectable trait. Hybridomas are then cloned and the 
specificity of their Abs is established an antigen-binding assay. Finally, the 
hybridoma cells generating the Ab of the desired specificity are cloned and 
expanded. 
4.2.3 Myeloma Fusion Partner Cell Lines 
Two myeloma variants that have defects in nucleotide synthesis pathways are 
commonly used as fusion partners. One of these lacks the gene for 
hypoxanthine guanine phosphoribosyl transferase (HGPRT), an enzyme that is 
essential in the salvage pathway of purine synthesis (adenosine 
monophosphate, AMP; guanosine monophosphate, GMP). Under normal 
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conditions, myelomas can continue to make purines by the alternative de novo 
pathway. 
The other myeloma variant lacks the thymidine kinase (Tk) gene that is required 
for making thymidylate from thymidine. Tk variants can usually still synthesise 
thymidylate from uridylate de novo. Following fusion, the cells are grown in a 
culture medium containing a supplement known as ‘HAT’, containing 
hypoxanthine, aminopterin and thymidine. Aminopterin is a dihydrofolate analog 
that blocks the reactivation of tetrahydrofolate, which is critical for the de novo 
synthesis of GMP, AMP and thymidine monophosphate (TMP). Cells grown in 
HAT supplemented media that have HGPRT and Tk genes can survive since 
exogenous hypoxanthine and thymidine are supplied in the media. If a myeloma 
fusion partner lacking one of these genes fuses with a B-cell, the B-cell supplies 
the vital gene and the hybridoma will survive. However, unfused myelomas that 
are HGPRT or Tk deficient will die, as aminopterin blocks the de novo synthesis 
pathway and the cells are unable to utilise the salvage pathways. 
To generate hybrimomas, experimental animals are immunised with the antigen 
of interest. Generally the mice are primed with an antigen that has been 
emulsified in an adjuvant (e.g. complete Freund’s adjuvant) in order to enhance 
the immunogenicity of the antigen. After an appropriate period of time, their 
spleens (or lymph nodes) are removed and a cell suspension is made. 
Polyethelene glycol (PEG) allows the cell membranes of the antigen–specific B-
cells and the non-secretor HGPRT-/- (or Tk-/-) myeloma fusion partners to fuse. 
After fusion, cells are grown in HAT supplemented media that contain 
aminopterin. Because aminopterin inhibits de novo purine synthesis, the 
HGPRT-/- (or Tk-/-) myeloma cells that must synthesise their nucleotides de 
novo will die off. Unfused B-cells (and other splenocytes) also die, despite their 
ability to synthesise purines in the presence of aminopterin, as their life-span is 
restricted when outside of their native environment. Hybridomas have inherited 
longevity from the myeloma cells and the ability to synthesise purines (or 
thymidylate) via the salvage pathways in the presence of aminopterin.  
In a fusion, only 1% of the starting cells fuse, and only 0.001% form stable 
hybrids. The hybridoma cells are cloned under limiting-dilution conditions to 
guarantee the monoclonality of the Ab-producing cell. 
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4.2.4 Hybridoma Screening 
Various techniques have been used to find and select the hybridoma producing 
the desired Ab. Assays commonly used to find and select the hybridoma 
producing the desired Ab. Assays commonly used include ELISA, 
radioimmunoassay (RIA), immunofluorescence, cytotoxicity assays, and 
immunoprecipitation. Simple procedures have been worked out to screen 
hybridomas for both the Ab specificity and class. The class of the Ab is 
particularly important if using the mAb in partnership with a secondary Ab which 
must have specificity to the isotype and species of the monoclonal. Cloned 
hybridoma cells are grown in in vitro culture or in murine ascites to yield virtually 
unlimited amounts of a mAb. The concentration of mAb in culture SN in 
approximately 1-100 μg/ml, verse 1 mg/ml in ascites211. 
The selected screening protocol is summarised in Chaper 2 (Figure 2.3). 
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4.3 Chapter Aims 
The aim of this chapter was to produce specific mAbs against CFHR1, CFHR3 
and CFHR4, to be used to develop a CFHR-specific detection ELISA and 
measure protein concentration in healthy and disease sera. 
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4.4 Results 
4.4.1 Preliminary Hybridoma Production and Screening 
To optimise and gain valuable experience in hybridoma production, several 
initial attempts were made at producing mAb-secreting hybridomas, prior to the 
recombinant production of CFHR1, CFHR3 and CFHR4B. Therefore, truncated 
CFH fragments were used to immunise mice with the aim of targeting an Ab 
response to CFH SCR domains 19-20 (fragment: rCFH19-20), and CFHR1 
domains 4-5 (fragment: rCFHR14-5). Between these fragments there are only 2 
amino acids difference; S1191L and V1197A changes located in CFH SCR 20, 
and CFHR1 SCR 5. The main aim of choosing these fragments was to try and 
raise Abs to the amino acids variants, thus raising either a CFH-specific mAb, 
with specificity for the SCR 20, or a CFHR1-specific mAb with specificity for 
SCR 5. Both potential Abs could then be used to build highly specific detection 
ELISA screens.  
Two groups of mice were immunised with each antigen, and assuming a 
successful adaptive immune response, both groups of mice should produce Abs 
that cross-react with both antigens, and also produce variant specific Abs. 
After incubating the hydridoma fusions in HAT supplemented selection media 
for 10 d, tissue culture SN was collected and tested via direct ELISA (Section 
2.3.4.1) for the presence of antigen-specific IgG Abs; 960 wells were screened 
on antigen coated ELISA plates. To determine a threshold for positivity, the 
population mean plus two standard deviations (mean+2SD) was applied to the 
data. Detection results that were above, around, and below the threshold were 
considered, positive, borderline positive, and negative, respectively. ELISA 
plates were coated with equimolar concentrations of rCFH19-20 and rCFHR14-5, 
and SN from the rCFH4-5 hybridomas loaded into coated wells. The results from 
each antigen screen were aligned, rCFH19-20 in blue and rCFHR14-5 in red 
(Figure 4.1). 
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Figure 4.1: ELISA screen of rCFHR14-5 hybridoma SN 
After incubation the post-fusion hybridomas for 10 d, 96 wells containing hybridoma 
colonies were selected and transferred to a single 96 well plate. After incubating for 3 d, 
culture SN was collected and applied to an ELISA plate coated with equimolar 
concentrations of rCFH19-20 and rCFHR14-5 to screen for IgG Ab production. Bound 
murine IgG was detected using an HRPO-conjugated goat anti-mouse IgG. Each 
hybridoma well SN was screened against both antigen fragments, and results aligned for 
comparison. rCFH19-20 is shown in red, and rCFHR14-5 . 
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The results show 4 positive results, 3 with cross-reactivity for both proteins 
(hybridoma wells 1, 54, and 67), and one with specificity for rCFHR14-5 only 
(well 44). These hybridoma wells were selected and subjected to a limiting 
dilution to isolate monoclonal populations of Ab producing hybridomas. The 
cultures were re-screened as before, and positive wells were carried forward. 
However, once the final positive clones had been selected and carried forward 
to large batch culturing, Protein G purification failed to purify IgG from the tissue 
culture SN, despite a positive signal from the ELISA screen.  
Upon investigation, it was discovered the secondary Ab being used was 
manufactured to detect murine IgG, but the sample had not been adsorbed to 
IgG resulting in potential cross-reactivity with other immunoglobulin isotypes. 
From the remaining positive clones, tissue culture SN was tested using a 
murine IgG-specific secondary, alongside an IgM-specific secondary. The 
results indicated that all hybridomas were producing IgM Abs (Figure 4.2). 
Subsequent to this discovery, all remaining hybridomas either ceased secreting 
Abs, or were lost due to cell death. 
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Figure 4.2: CFHR14-5 hybridoma screening reveals IgM subclass 
SN from 4 rCFHR14-5 hybridoma clones (1-4) was screened on rCFH19-20 and rCFHR14-
5 coated ELISA plates, with subsequent detection using, (a) HRPO-conjugated goat 
anti-mouse IgG, and (b) HRPO-conjugated goat anti-mouse IgM. 
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From this first round of hybridoma production and screening, the two main 
issues that arose were production of an IgM response rather than IgG, and the 
loss of Ab secretion by selected hybridoma cultures. Hybridoma cell death is a 
routine part of hybridoma production212. It was decided that the antigen load per 
immunisation was not enough to drive an IgG immune response, so after a 
literature review210,213,214 the antigen load for the next round of immunisations 
was increased to 40 μg per immunisation. 
The next attempt at producing Ab-secreting hybridomas was completed using a 
different antigen. The immunising antigen was changed because previous 
fragments were no longer available at the levels required for the newly 
optimised immunisation protocol. Therefore, a fragment consisting of CFH SCR 
domains 10-12 (rCFH10-12) was selected. When comparing all CFH family 
proteins for SCR sequence homology, this region has the lowest level of 
homology with SCR domains of the CFHR proteins (CFHR1-4, in particular). 
However, the region does share ~60% homology with CFHR5 SCR domains 3-
5, so there is still potential for cross-reactivity at least one other CFH family 
protein. If we are to consider the remaining non-homologous sequence between 
the two regions of CFH and CFHR5, there is a ~40% chance of producing a 
CFH-specific response. 
The splenocytes were collected from CFH10-12 challenged mice, and hybridoma 
fusions completed, as before (Section 2.4.2). Previously collected tail bleeds 
were screened against rCFH10-12 and an Ab response was assessed. The 
results indicate that when immunising mice with 40 μg rCFH10-12 per 
immunisation, an IgG response is raised against rCFH10-12 (Figure 4.3). 
Hybridomas were screened as previously described (Section 2.3.4.1 and 
Figure 2.3), and initial screening results identified 3 positives results 
(hybridoma wells: 16, 17 and 24), and 3 borderline positives (Figure 4.4; 1st 
screen). The second round of screening on these cultures showed hybridoma 
clones 17 and 24 maintaining positivity (Figure 4.4; 2nd screen). However, in 
clone 16 the level of positivity reduced to a borderline result. The third round of 
screening (before selecting individual monoclonal hybridomas) shows clones 
16, 17 and 24 maintaining a positive result, while other selected clones 
continued to test negative (Figure 4.4; 3rd screen). Positive clones 16, 17 and 
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24 were subjected to a limiting dilution, as previously described (Figure 2.3) to 
select individual CFH10-12-specific hybridomas. However, all positive clones 
failed to grow under limiting-dilution conditions. The original ‘stock’ cultures also 
failed to grow after being transferred to fresh media (Figure 4.4; 4th screen). 
Therefore, all CFH10-12 hybridoma clones were eventually lost.  
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Figure 4.3: IgG response detected in CFH10-12 tail bleed 
C57BL/6 mice were immunised fortnightly over 8 weeks. Prior to each immunisation, a 
tail bleed was taken. Sera was collected and diluted to 1/5000 in BSA blocking solution 
(1% BSA/PBS, pH 7.4), followed by a 1/2 serial dilution (1/5,000-160,000). A 96-well 
ELISA plate was coated with 100ng CFH10-12 per well and diluted murine sera was 
applied in-triplicate to the CFH10-12 coated wells. After blocking the plate with BSA 
blocking buffer, an HRPO-conjugated goat anti-mouse IgG secondary Ab was applied. 
Pre-bleed: d +0 (blue), 2nd: d +14 (red). 3rd: d +28 (green), 4th: d +42 (purple), 5th: d 
+56 (cyan).  
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Figure 4.4: CFH10-12 hybridoma screening 
After incubation the post-fusion hybridomas for 10 d, 84 wells containing hybridoma 
colonies were selected and transferred to a single 96 well plate. After incubating for 3 
d, culture SN was collected and applied to an ELISA plate coated with 100ng rCFH10-12 
to screen for IgG Ab production. Bound murine IgG was detected using an HRPO-
conjugated sheep anti-mouse IgG. The graph shows 4 rounds of screening, 
highlighting the progression of viable hybridomas, with emphasis placed on 3 
consistently positive clones (16, 17 and 24). 
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4.4.2 Detection of rCFHR1 Ab response from murine tail bleeds 
After successful production and purification of rCFHR1, mice were immunised 
using the optimised protocol, as previously described (Section 2.4.1.1). Tail 
bleeds taken from mice immunised with rCFHR1 indicate a positive IgG anti-
rCFHR1 response after each immunisation (Figure 4.5).  
The results from rCFHR1 hydridoma production will be presented as 
representative of this methodology. Therefore, rCFHR4B hybridoma production 
and screening results will not be shown, but will be commented upon. However, 
results for testing of all mAbs will be shown. 
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Figure 4.5: Detection of rCFHR1 Ab response from murine tail bleeds 
C57BL/6 mice were immunised fortnightly over 8 weeks. Prior to each immunisation, a tail 
bleed was taken. Sera was collected and diluted to 1/5000 in BSA blocking solution 
(PBS/BSA 1%, pH 7.4), followed by a 1/2 serial dilution (x-axis; 1/5,000-160,000). A 96-well 
ELISA plate was coated with 100 ng rCFHR1 per well. The diluted murine sera was applied 
in-triplicate to the rCFHR1 coated wells, followed by detection of bound IgG with an HRPO-
conjugated goat anti-mouse IgG secondary Ab. Pre-bleed: d +0 (blue), 2nd: d +14 (red). 3rd: 
d +28 (green), 4th: d +42 (purple), 5th: d +56 (cyan).  
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4.4.3 Hybridoma Screening: rCFHR1 
The first round of screening was completed on all 960 hybridoma fusion wells 
(10 x 96 well plates). Previously, the first round of hybridoma screening was 
completed only on wells with evidence of hybridoma colony formation. The SN 
from these wells was discarded, and colonies condensed from 10 x 96-well 
plates, to a single plate. However, due to a change in the hybridoma fusion 
protocol (increasing fusion partner cell count to 107 and using all splenocytes), 
the number of hybridomas colonies also increased. On each plate, there was on 
average 80% of wells with colony growth, with approximately 1-3 colonies per 
well. From previous experience, screening SN from the initial fusion cultures 
leads to a high level of background signal. However, due to the high volume of 
resulting hybridomas, it was deemed essential to screen all culture wells. As 
expected, the first round of screening yielded a high level of background signal. 
The previous method for creating a threshold for positivity was applied to these 
results (i.e. mean+2SD), resulting in the selection of 74 hybridoma culture wells 
with a positive or borderline positive detection signal (Figure 4.6). 
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Figure 4.6: ELISA Screen of rCFHR1 Hybridomas (1st screen) 
960 hybridoma fusion wells were screened for the presence of rCFHR1-specific mouse 
IgG Abs. Plates were coated with 100ng rCFHR1 per well, followed by the addition of 
hybridoma well SN. Bound murine IgG was detected using an HRPO-conjugated sheep 
anti-mouse IgG. The results from the hybridoma cohort were used to calculate a 
threshold between a positive and negative result (indicted by the red dashed line; 
mean+2SD). 74 positive wells were selected as positive and carried forward for further 
testing.  
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 The 74 selected hybridoma cultures were transferred to fresh media and 
condensed to a single 96-well plate. The second round of screening was 
completed after culturing for 4 d, and included antigen screening for rCFHR1, 
native CFH and a HisTag control protein (Figure 4.7). There were 7 observable 
positive results (7, 12, 18, 27, 63, 67, and 70) from the 74 hybridomas 
screened, all of which tested positive for the rCFHR1 antigen. Clones 7 and 63 
appear to exhibit cross-reactivity with CFH, and clones 12, 18, 67 and 70 
appear to bind to rCFHR1 exclusively (when compared to the antigens tested in 
this particular screen). Clone 18 appears to cross-react with the HisTag control, 
suggesting this culture well contains an anti-HisTag producing hybridoma. The 
HisTag control protein is a CFH fragment consisting of SCR domains 16-18, so 
there is potential for cross-reactivity between rCFHR1 and rCFH16-18, especially 
between rCFHR1 SCR domain 3, and rCFH domain 18, as they share 100% 
amino acid sequence homology. However, native CFH serves as a negative 
control protein in this analysis; there are no positive clones with cross-reactivity 
for both native CFH and rCFH16-18. Additionally, native CFH does not have a 
recombinant HisTag, and therefore serves as a negative control for HisTag 
cross-reactivity in this ELISA analysis.  
After a further round of screening these positive controls, only hybridoma clones 
18, 67 and 70 survived and maintained positivity (Figure 4.8). However, only 
clone 70 survived to be taken forward to the stages of monoclonal selection via 
limiting dilution. The final hybridoma clone selected came from clone 
rCFHR1.10.37, resulting in the mAb being named ‘R1/1037’. 
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Figure 4.7: ELISA Screen of rCFHR1 Hybridomas (2nd screen)  
The selected 74 positive hybridoma wells (1-74) were resuspended into 500 μl HAT-supplemented tissue culture media and cultured for 7 d. 
Tissue culture SN was then screened against rCFHR1, CFH and 1618his (HisTag negative control) as before.   
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Figure 4.8: ELISA Screen of rCFHR1 Hybridomas (3rd screen) 
Positive clones 7, 12, 18, 27, 63, 67 and 70 were carried forward from the previous screen, 
re-cultured for 3 d and screened as before. Clones 18, 67 and 70 were selected as positive.  
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The same methodology was used to screen for CFHR4B hybridomas, but using 
CFHRB coated plates to screen. 64 positive clones were identified after the 1st 
screen, 12 of which were selected for the 2nd screen. After the 3rd and final 
screen, three viable positive clones remained, referred to as R4/244, R4/277 
and R4/123. 
4.4.4 Purification of mAbs R1/1037 and R4/244 
All selected hybridoma clones were transferred to individual large batch 
cultures, and after 10 d 300 ml of tissue culture SN was collected. The 
purification results of R1/1037 and R4/244 will be now be shown. The R1/1037 
SN was prepared as previously described (Chapter 2) and ran through a 
Protein G coated chromatography column to purify murine IgG Abs. After 
running, the column was eluted using a Glycine-HCl (pH 2.4) acid elution, 
followed by neutralisation of eluate fractions with 1 M Tris base (pH 11.0). The 
elution was completed using the AKTA prime system, with partnered Unicorn 
software. The results show a protein absorbance peak across fractions 1-4 
(Figure 4.9a). Elution fractions were reduced and separated on 10% SDS-
PAGE gels, followed by Coomassie staining as previously described (Chapter 
2). The results of the Coomassie stain show the characteristic heavy and light 
chains of a reduced murine IgG (Figure 4.9b). These samples were selected, 
pooled, buffer exchanged and concentrated using Vivaspin 20 (30,000MW)  
R4/244 was purified using the same methodology (Figure 4.10).  
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Figure 4.9: Purification of R1/1037 mAb  
The R1/1037 hybridoma clone was cultured for 10 d, and 300ml of the culture SN was 
diluted 1/2 with PBS (adjusted to pH 7.4). Diluted SN ran over a 1ml Protein G affinity 
chromatography column, followed by a PBS (pH 7.4) wash, then a Glycine-HCl (pH 
2.5) acid elution. (a) Chromatogram of the Glycine-HCl elution. The x-axis shows 1ml 
elution fractions (red; 1-10). The y-axis shows protein absorbance at 280 nm. (b) 
Fractions 1-4 were reduced (to heavy and light chains) and electrophoresed on a 10% 
SDS-PAGE gel, followed by staining with Coomassie blue. A reduced IgG positive 
control mAb was loaded into the final well (OX24 IgG+).   
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Figure 4.10: Purification of R4/244 mAb 
The R4/244 hybridoma clone was cultured for 10 d, and 300ml of the culture SN was 
diluted 1/2 with PBS (adjusted to pH 7.4). Diluted SN ran over a 1ml Protein G affinity 
chromatography column, followed by a PBS (pH 7.4) wash, then a Glycine-HCl (pH 
2.5) acid elution. (a) Chromatogram of the Glycine-HCl elution. The x-axis shows 1ml 
elution fractions (red; 1-10). The y-axis shows protein absorbance at 280 nm. (b) 
Fractions 1-8 were reduced (to heavy and light chains) and electrophoresed on a 
10% SDS-PAGE gel, followed by staining with Coomassie blue. A reduced IgG 
positive control mAb was loaded into the final well (OX24 IgG+).   
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4.4.5 Ab Isotype Testing of R1/1037, R4/244, R4/277 and R4/123 
To further clarify the R1/1037 heavy and light chain isotypes, R1/1037 and 
R4/244 were coated to ELISA plates and screened using HRPO-conjugated 
anti-murine IgG1, IgG2a, IgG2b, IgG3, IgM and IgA detection Abs, as previously 
described (Chapter 2). The light-chains were also determined using HRPO-
conjugated anti-murine kappa and lambda light chain detection Abs. The results 
show R1/1037 and R4/244 to both have an IgG1 heavy chain, and kappa light 
chain (Figure 4.11). OX24 was included as a positive control for IgG1 and 
kappa. 
4.4.6 Cross-reactivity testing of R1/1037, R4/244, R4/277 and R4/123 
The hybridoma screening highlighted R1/1037 as having rCFHR1-specificity, 
when cross-reactivity tested against CFH and a HisTag control. However, it was 
unclear whether this mAb cross-reacted with CFHR2, CFHR3, CFHR4 or 
CFHR5. The rCFHR proteins produced in Chapter 3, could now be utilised for 
cross-reactivity screening.  
ELISA plates were coated with equimolar concentration of native CFH, rCFHR1, 
rCFHR3, rCFHR4B, rCFHR5 and the HisTag control protein (rCFH16-18). 
R1/1037, R4/244, R4/277 and R4/123 were all screened across all coated 
antigens. The results indicate R1/1037 binds exclusively to rCFHR1, with no 
evidence of cross-reactivity with the other coated CFH family proteins (Figure 
12). R4/244 and R4/277 bind exclusively to rCFHR4B. However, R4/123 binds 
to rCFHRB, but also cross-reacts with CFH. These data do not include rCFHR2 
screening because of the protein production issues, as previously described 
(Chapter 3). 
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Figure 4.11: Ab isotype testing R1/1037, R4/244, R4/277 and R4/123 
ELISA plates were coated in-triplicate with equal concentrations R1/1037, R4/244, 
R4/277, R4/123 and OX24 (IgG1 positive control). Isotypes were detected using HRPO-
conjugated Abs against murine heavy chains IgG1, IgG2a, IgG2b, IgG3, IgM and IgA. 
HRPO-conjugated Abs against murine kappa and lamda light chains were also detected. 
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Figure 4.12: Specificity testing of R1/1037, R4/244, R4/277 and R4/123 
ELISA plates were coated in-triplicate with equimolar concentrations of CFH, rCFHR1, 
rCFHR3, rCFHR4B and rCFHR5. R1/1037, R4/244, R4/277 and R4/123 were diluted 
1/2000 and applied to each set of coated wells. Bound murine IgG was detected using 
a HRPO-conjugated sheep anti-mouse IgG secondary pAb. 
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4.4.7 Ab-specificity testing against native CFH family proteins  
Due to the lack of purified CFHR2 for use as an ELISA coating antigen, human 
plasma was the only source of CFHR2. However, coating an ELISA plate with 
plasma was not a viable option due to the presence of native CFHR1. In 
addition, capturing CFHR2 was not possible due to the lack suitable Abs. 
Therefore, western blot analysis of human serum was used to assess the 
potential cross-reactivity of R1/1037 with CFHR2. This would enable separation 
of the CFH family proteins by size, and give CFHR1 and CFHR2 distinct and 
separate positions in the detection results. 
Human serum was collected from CFHR1-/- aHUS patients to use as CFHR1 
negative controls in the western blot analysis, in comparison to a positive 
control serum (CFHR1+/+). The CFHR2 status of these patients was unknown 
at the time of testing. When probing human serum via western blot, R1/1037 
binds to CFHR1 in the positive control serum. However, in the CFHR1 
homozygous gene deficient aHUS patients, R1/1037 is not detecting CFHR1 
(Figure 4.13). This confirms that R1/1037 can be used in western blot to detect 
native serum CFHR1. However, the results also indicated R1/1037 is cross-
reacting with a lower molecular weight pair of proteins which sit either side of 
the 25 kDa protein marker. This is evident in all serum samples. This double 
banding is characteristic of two isotypes of CFHR2 found in human serum, 
suggesting R1/1037 cross-reacts with native CFHR2, and therefore is not 
CFHR1-specific. 
The same methodology was used to screen R4/244, R4/277 and R4/123. The 
results show R4/244 binds exclusively to a protein with the region of CFHR4A 
(48 kDa), but fails to highlight the native CFHR4B (45 kDa) protein (Figure 
4.14a). R4/123 binds the CFHR4A (86 kDa) band, but also cross-reacts with 
CFH (155 kDa) protein (Figure 4.14b). There is an additional band highlighted 
between MW markers 35-55 kDa. Patients 1-6 are CFHR3 deficient, therefore 
ruling out CFHR3 cross-reactivity. This protein is either CFHR4B (45 kDa) or 
CFHL-1 (47 kDa). As CFHL-1 lacks N-linked glycosylation sites (Asn-X-
Ser/Thr), the spread of this band is unlikely to be a non-glycosylated protein. 
This suggests the band to be CFHR4B, although there is absence of the protein 
in patient 1, and the control sample.  
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R4/277 was shown to bind CFHR4A exclusively (Figure 4.14c). However, in a 
subsequent repeat of this screen, R4/277 showed evidence of cross-reactivity 
with a lower MW band, assumed to be CFHR4B. As previously observed with 
R4/123 screening, patient 1 and the control serum were negative for this protein 
band. This suggests the same protein is being detected by both mAbs. It is 
currently unclear why the lower MW band signal intensity is so different 
between the R4/123 and R4/277 screens, especially as the CFHR4A signals 
appear similar. Further categorisation is required to confirm this protein is 
CFHR4B. 
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Figure 4.13: R1/1037 cross-reactivity with human serum proteins 
Human serum was diluted 1/10 and electrophoresed on a 10% SDS-PAGE gel. 
Proteins were transferred to a nitrocellulose membrane and blocked with 5% 
NFDM/PBS. This blot was stained with R1/1037 (diluted 1/5,000), followed by 
detection with HPRO-conjugated sheep anti-mouse IgG, diluted (1/10,000). 
Serum samples 1-6 are from aHUS patients with a CFHR1 homozygous gene 
deficiency, and serum sample 7 is a BTS control with two copies of CFHR1. 
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Figure 4.14: R4/244, R4/277 & R4/123 cross-reactivity with human sera 
Human serum was diluted 1/10 and electrophoresed on 10% SDS-PAGE gels. Proteins 
were transferred to a nitrocellulose membrane and blocked with 5% NFDM/PBS. (a) This 
blot was stained with R4/244 (diluted 1/5,000) followed by detection with HPRO-conjugated 
sheep anti-mouse IgG (diluted 1/10,000). Serum samples 1-6 are from aHUS patients with a 
CFHR3 homozygous gene deficiency, and serum sample 7 is a BTS control with two copies 
of CFHR3. (b) This blot was stained with R4/123 (diluted 1/5,000), followed by the same 
detection reagent as before. (c) This blot was stained with R4/277 (diluted 1/5,000), followed 
by the same detection reagent as before. (d) This is a repeat of (c).  
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4.4.8 Purification of native CFHR1/CFHR2 from human sera 
To further clarify the binding potential of R1/1037, the Ab was covalently coated 
to a HiTrap™ NHS-activated column (Section 2.3.3). Human serum was 
collected from a blood donor control, known to have a least one gene copy of 
each of CFHR1, CFHR3 and CFHR4. Again, the CFHR2 status was unknown. 
40 ml of serum was collected and diluted in 1/10 with PBS. The diluted serum 
solution was filter purified (0.2 μM) and the final pH confirmed as 7.4. After 
running through the column and washing with filter-sterilised PBS, R1/1037 
bound serum proteins were eluted using an acid elution, as previously 
described in the Protein G purification protocol (Section 2.3.2). The elution was 
completed and monitored using the AKTA primer system and related Unicorn 
software.  
Elution fractions were separated on a 10% SDS-PAGE gel, followed by 
Coomassie staining (Figure 4.15). The results show the characteristic double 
banding for CFHR1 and CFHR2147,150. There were other observable bands, 
again suggesting the R1/1037 mAb binds CFHR1, but also has cross-reactivity 
for CFHR2. These results also show R1/1037 binds to these proteins in their 
native form, as previous analysis via ELISA and western blot dictated that 
CFHR1 (via direct ELISA and western blot) and CFHR2 (via western blot only) 
were presented to R1/1037 in a potentially denatured form (coated directly to an 
ELISA plate, or treated with SDS and boiling). 
Additionally, NHS-columns were made for R4/244, R4/277 and R4/123. 
However, CFHR4 mAb-coated columns failed to purify defined protein bands, 
and contained a high level of contamination. It is unclear why each CFHR mAb 
was unable to specifically purify native CFHR4.  
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Figure 4.15: R1/1037 column purification of native CFHR1 and CFHR2  
R1/1037 was covalently coated to a HiTrap NHS-activated column (GE Healthcare). 
10ml human serum was diluted 1/10 in PBS/NaN3 0.01% (pH 7.4) and run over the 
R1/1037 coated column. After washing with PBS, bound protein was eluted using 0.1 
M glycine HCl (pH 2.5). Lanes 1-4 represent the corresponding elution fractions. 
Purified rCFHR1+ was loaded as a positive control.  
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4.4.9 Detection of rCFHR2 in CHO/rCFHR2 Tissue Culture SN 
As R1/1037 cross-reacts with CFHR2, we now had a suitable Ab reagent to 
detect the recombinant production of CFHR2 in CHO/rCFHR2 cell tissue culture 
SN. A new transfection was completed using pDEF/rCFHR2 and wildtype CHO 
cells, as previous described (Section 2.2.2.1). Post-transfection, 28 x 
CHO/rCFHR2 transfectant single clones were selected and tissue culture SN 
collected after 14 d of culturing from a single cell. Direct ELISA was still not an 
option for testing, but western blot offered potential due to the separation of 
protein (as previous described). After testing all 28 clones via western blot, 
R1/1037 was able to detect rCFHR2 production in all clones (Figure 4.16 
shows a sample of 7 of these clones). In all 28 clones tested, the western blot 
signals were assessed via densitometry, and the highest signal was deemed to 
be the clone producing rCFHR2 with most abundance. However, all clones 
were producing the protein at level <5%+/- the mean densitometry value of the 
clone population. Clone R2.2 was selected and carried forward for large batch 
culturing of rCFHR2.  
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Figure 4.16: rCFHR2 detection in tissue culture SN 
rCFHR2 tissue culture SN from 7 monoclonal cultures of CHO/rCFHR2 (clones 
R2.1-7) were separated on a 10% SDS-PAGE gel and transferred to 
nitrocellulose. The nitrocellulose was stained with R1/1037 at 1/2000 dilution, 
followed by detection with an HRPO-conjugated sheep anti-mouse IgG. Positive 
(rCFHR2+SN) and negative (CHO-SN) control tissue culture SN were also 
loaded. The clone with the highest signal (  ) was selected and carried forward 
for large batch production. 
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4.4.10 Purification of rCFHR2 via HisTag purification 
Clone R2.2 was cultured for 10 d, and 300 ml tissue cultures was collected and 
prepare as previously described for HisTag purification (Section 2.3.1). An 
imidazole concentration of 20 mM was selected as a starting concentration in 
the ‘HisTag Binding Buffer’ (as used for purification of rCFHR3, rCFHR4B and 
rCFHR5). The AKTA purification chromatogram shows elution of protein in 
fractions 6-17 (Figure 4.17a), spaced over two elution peaks, the latter of which 
is most likely rCFHR2.  
Elution fractions were separated on 10% SDS-PAGE gels, followed by 
Coomassie staining as previously described (Figure 17b). The results of the 
Coomassie stain show non-specific binding of protein in fractions 7-12, and 
rCFHR2 in fractions 12-17. Fraction 12 appears to be the interchange between 
non-specifically bound proteins and rCFHR2. Therefore, fractions 13-17 were 
selected, pooled, buffer exchanged and concentrated using Vivaspin 20 
(10,000MW) columns (Sartorius).  
This completes the panel of rCFHR proteins required to undertake the 
autoantibody screening of aHUS and IgAN patients. 
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Figure 4.17: HisTag Purification of rCFHR2 
(a) CHO/rCFHR2 tissue culture SN ran over a nickel-coated 5ml HiTrap™ 
Chelating columns, followed by an imidazole gradient elution (20-500mM). 
Columns were eluted in conjunction with the ÄKTA prime purification system 
(GE Healthcare). (b) Elution fractions 7-17 were electrophoresed by SDS-PAGE 
(10% gel), with subsequent staining with Coomassie blue. The red box indicates 
the elution fractions containing rCFHR2. These were collected, pooled and 
buffer exchanged into PBS/NaN3 0.01%. 
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4.4.11 Quantification of CFHR4 in human sera  
CFHR4 mAb R4/244 was selected to screen a preliminary population of aHUS 
and BTS control plasma. The primary aim was to determine whether a 
sandwich ELISA could detect CFHR4 in human plasma, and ascertain what 
variation exists within, and between, aHUS and normal controls. After setting up 
a CFHR4B standard curve, serum samples were loaded into the sandwich 
ELISA at a 1/20 dilution. The results show consistent levels of CFHR4 in the 
BTS and aHUS populations (Figure 4.18). The data from each group were 
compared using a Mann-Whitney test, as previously described (Section 2.6.3). 
The results indicate that the change between the 2 groups is not significant (p = 
>0.05%)  
The aHUS population contained 3 serum samples heterozygous for the novel 
CFHR1/4 deletion. It was hypothesised these patients would have 50% less 
CFHR4 than the other patients who all have 2 copies of CFHR4. However, no 
significant decrease in CFHR4 levels was observed in these patients. 
Using CFHR4B in the standard curve resulted mean concentration values of 
~40 μg/ml in both the BTS and aHUS populations.  
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Figure 4.18: Detection of CFHR4 in human plasma 
A group of aHUS and BTS plasma controls were screened to detect CFHR4. Plates 
were coated with R4/244 at 5 μg/ml. Plates were then blocked with 1% BSA/PBS, 
followed by detection using a CFHR4 rabbit pAb. Final detection was achieved using 
an HRPO-conjugated goat anti-rabbit Ig. A Mann-Whitney test was used to determine 
whether there was a significant change between the 2 groups. Horizontal line refers to 
median value in each population.  
Key: ns; not significant. 
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4.5 Discussion 
The aim of this chapter was to produce a set of mAbs against rCFHR1, rCFHR3 
and rCFHR4B, and utilise their specificity to develop CFHR-specific detection 
assays using ELISA.  
The production of an anti-CFHR1 mAb (R1/1037) was successful. However, 
cross-reactivity testing revealed that R1/1037 cross-reacts with native CFHR2. 
As R1/1037 does not cross-react with CFH, this suggests the binding epitope 
lies within CFHR1 SCR domains 1-2. Due to high degree of homology between 
SCR domains 1-2 of CFHR1 and CFHR2 (~99%), it is difficult to identify the 
particular location, or binding epitope of R1/1037. 
Unfortunately, the dual binding capacity of R1/1037 means it is not suitable to 
specifically measure rCFHR1 protein concentration in human serum. To be 
used as a capture Ab, CFHR2 is also going to competitively bind and influence 
the signal result when using either a CFH or CFHR1 polyclonal. It could be 
argued that the ratio of CFHR1/CFHR2 binding to the R1/1037 coat is going to 
be maintained at a certain ratio. However, as we do not know the exact 
concentration of CFHR1 or CFHR2 in human serum, this ratio is difficult to 
determine. However, as I have produced both these proteins recombinantly 
there is the possibility of experimenting with different ratios in the standard 
curve. 
It appears the only way to build a truly specific CFHR1 ELISA is by targeting the 
Ab response directly to the single amino acid changes that occur between 
CFHR1 and CFHR2 (SCR domain 1), and CFHR1 and CFH (SCR domains 4-5 
and 19-20, respectively). My early work on producing CFHR1-specific mAbs did 
focus on the latter two fragments. However, after a failed attempt it was deemed 
more suitable to use full-length rCFHR1 to immunise, as this would result in a 
larger repertoire of mAbs, binding to a selection of epitopes. 
I would conclude that immunisations using peptide fragments would be the most 
suitable approach to gain highly-specific mAbs against CFHR1.  
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The production of mAbs against CFHR4B was also successful. After specificity 
testing, it became clear that R4/244 was highly-specific for CFHR4, both the 
recombinant (rCFHRB) and native CFHR4A. 
However, western blot data yielded an unusual result, whereby only CFHR4A 
was detected, but not CFHR4B. In human serum there are two isoforms of 
CFHR4 due to alternative splicing of the CFHR4 RNA gene transcript. The 
resulting transcripts are referred to as CFHR4A and CFHR4B. Therefore, once 
translated CFHR4A consists of a duplication of SCR domains 1-4, at SCR 
domains 5-8, with the addition of SCR domain 9165,166 (Figure 1.3). CFHR4B is 
identical to CFHR4A SCR domains 5-9. Based upon this sequencing data, 
CFHR4B was selected as the most suitable CFHR4 isotype for the aims of this 
work. Sequencing data suggests CFHR4B will contain the same antigenic 
peptides as CFHR4A, for use as an antigen for raising an Ab response and in 
detection of autoantibodies in aHUS patients (Chapter 5). It is currently 
unknown whether the duplication of SCR domains 1-4 in CFHR4A are involved 
in creating unique epitopes, relative to CFHR4B. Based upon structure/function 
models, it is thought that CFH does not have a tertiary protein structure, but 
rather the extended chain of SCR domains arrange themselves to recruit and 
secure CFH to the complement activated (C3b deposition) host cell surface125. 
There is currently no evidence to suggest the CFHR proteins have a tertiary 
structure that would result in a discontinuous antigen epitope from the 
interaction of different SCR domains (again, relative to CFHR4B). Additionally, it 
is well documented that the lower the molecular weight of a protein, the higher 
the chance of successful production in a recombinant system215-217. CFHR4B is 
essentially the latter part of CFHR4A, so an Ab response to CFHR4B should 
also result in cross-reactivity with CFHR4A. However, using CFHR4B allows the 
extra potential to produce a mAb to target CFHR4B, but not CFHR4A. 
Therefore, if the western blot result had detected CFHR4B, but not CFHR4A, 
this would fit with CFHR4B SCR domain 5-specificity.  
Aside from antigenicity, it may be due to the availability of CFHR4B on the 
western blot, due to CFHR4B existing at a lower concentration (undetectable 
via western blot) in human serum, or the splice-variant may only be produced 
under certain conditions (e.g. under specific immunological signalling). Recent 
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evidence suggest CFHR4 plays a role in promoting complement activation168, 
rather than regulating like its family members CFH, CFHR1 and CFHR5. There 
may be a role of CFHR4B that is only required when complement is activated. It 
remains unclear why CFHR4A would be detected, over its immunogen 
counterpart. However, the other CFHR4B mAbs, also cross-react with CFHR4B. 
It is clear that between R4/277 and R4/123, there is large difference between 
the band intensity between the two blots. This suggests these mAbs may bind 
CFHR4B with a different level of intensity. This is some evidence to suggest 
CFHR4B exists as a homodimer166, which would explain the larger band. The 
difference between CFHR4A and a potential CFHR4B dimer is one SCR 
domain; the dimer will contain an additional SCR 9. This only confers a 6-7 kDa 
change in molecular weight so is not going to resolve on a 10% SDS-PAGE gel. 
However, reducing, boiling and treating serum with SDS failed to breakdown 
potential CFHR4B homodimers. 
R1/1037 was essentially deemed unsuitable for use in a sandwich ELISA for 
determination of CFHR1 concentration, due to cross-reactivity with CFHR2 (as 
previously described). However, the reagent was fortuitously useful in the 
detection of rCFHR2, resulting in the progression of this work. We now have a 
full panel of CFHR proteins available for autoantibody screening of aHUS and 
IgAN patient sera. The Ab is also a useful reagent to have in purifying CFHR1 
from human serum. Clearly, CFHR2 is also purified, but a second round of 
purification via a high resolution gel filtration column would separate out these 
proteins. Alternatively, the Ab could be used to purify CFHR2 from CFHR1 
deficient serum (CFHR1-/- aHUS patients). Additionally, R1/1037 Ab may prove 
useful for creating CFHR1/2 deficient serum, allowing experimental focus to be 
placed upon other CFH family proteins. R4/244 could also be used in this way, 
and in conjunction with R1/1037. 
The mAbs produced can also be utilised in the identification and purification of 
CFH family fusion proteins. NAHR is commonplace within the RCA gene 
cluster, resulting in copy number variation and fusion events in CFH family 
genes. One of the difficulties with assessing the functionality of gene fusions is 
the difficulty in purifying them from patient serum. R1/1037 is another potential 
mAb that can be used to study the effect of fusion proteins, enabling specific 
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purification of CFH/CFHR1 fusions with a suitable CFHR1 binding epitope 
(without cross-purification of CFH). Any CFHR2 cross-reactivity can again be 
addressed using high resolution gel filtration. 
The specificity of the R4/244 mAb was used in an optimised sandwich ELISA to 
detect plasma CFHR4. R4/244 was used as the coating/capture Ab, and rabbit 
anti-CFHR4 polysera (produced in-house) used to for detection. Based upon 
the specificity testing data, this Ab is only detecting CFHR4A, but not native 
plasma CFHR4B. However, R4/244 does detect the rCFHR4B antigen to which 
it was raised. It remains unclear why native CFHR4B is not detectable, as 
R4/277 and R4/123 appear to detect it successfully. Potentially, the single point 
mutation in the rCFH4B is recognised by R4/244 which would influence its 
affinity in binding to native CFHR4B. This effect may be offset by the tertiary 
structure of native CFHR4A, allowing a higher affinity interaction. Domain 
swaps and epitope mapping could be used to address this theory. 
It is important to recognise that using rCFHR4B to create a standard curve for 
this assay may not yield the most accurate results for measuring CFHR4 
concentration. The primary reason being that CFHR4 exists as CFHR4A and 
CFHRB, and potentially as a CFHR4B homodimer (as previously described). 
Therefore, when measuring CFHR4 concentration it is difficult to ascertain how 
these variables will compare to a standard curve using just one CFHR4 species. 
However, using this assay to compare a patient and a normal control group is 
still a viable assay as the data from each group is relative. Taking these 
confounding variables into consideration, the R4/244 sandwich ELISA was able 
to detect CFHR4 at levels consistent with a previously reported CFHR4 
concentration (~40 μg/ml)168. 
The remaining CFHR4 mAbs, R4/277 and R4/123 are yet to be testing as 
capture Abs. Based upon the specificity testing results, R4/277 would also 
serve as a suitable candidate capture Ab in this type of assay. However, R4/123 
cross-reacts with CFH so could not be used in conjunction with the rabbit anti-
CFHR4 polysera (also binds CFH). 
In summary, several mAbs have been produced which can be readily utilised in 
a variety of experiment procedures within this research laboratory, including 
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ELISA and western blot analysis of tissue culture, purified, and plasma proteins. 
Based upon the research aims of this chapter, future work will involve further 
optimisation of the CFHR1 detection ELISA (using R1/1037), and screening of 
larger cohorts of disease and control plasma. 
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Chapter 5 
5. CFH family autoantibodies in aHUS and IgAN 
5.1 Introduction 
CFH autoantibodies have been described in approximately 10% of aHUS 
patients162,178,218,219. Based upon the high level of amino acid sequence 
homology between CFH and the CFHR proteins, the CFHRs are therefore also 
candidates for an autoantibody response; either as the primary trigger for the 
Ab response, or as secondary to CFH autoantibody cross-reactivity. There is 
evidence to suggest CFH autoantibodies are functionally significant in aHUS 
disease pathogenesis, i.e. the Ab binding is predominantly to the C-terminus of 
CFH where aHUS associated mutations are known to cluster162,220. Additionally, 
CFH autoantibodies have been shown to disrupt CFH-mediated complement 
regulation in AP haemolytic assays221. The degree to which autoantibodies are 
involved in disease outcome is currently unclear. However, based upon the 
evidence presented to-date, CFH autoantibodies are likely to be a contributing 
factor in the pathogenesis of a subset of aHUS patients179.  
Autoantibodies targeting CFHR1 have been identified, but only in the DEAP-
HUS (Section 1.6.6) sub-population of patients179,222. Autoantibodies against 
the remaining CFHR proteins are yet to be found. CFH autoantibody positive 
plasma has been screened for cross-reactivity to the CFHR proteins, but with 
no further evidence of cross-reactivity with CFHR proteins 2-5. However, there 
is a currently no data presented whereby a full aHUS cohort (CFH autoantibody 
positive and negative patients) has been screened against each CFHR protein. 
In IgAN patients, IgA Abs are found deposited on the mesangial surface of 
kidney glomeruli. However, the antigen-specificity of these IgA Abs is currently 
unknown. The IgA found deposited is polymeric IgA1 (pIgA1). It is well 
documented that pIgA1 in IgAN patients is abnormally glycosylated at the hinge 
region of the Ab heavy chain. This glycosylation results in increased affinity for 
the mesangium, hence deposition.  
Complement proteins (activatory and regulatory) are found co-localised with 
deposited pIgA1, suggesting IgA deposition may be resulting in complement 
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activation. IgA is a poor activator of complement so could not be solely 
responsible for triggering activating complement. However, IgG (and IgA) 
autoantibodies against pIgA1 were also found in the immune complexes, 
suggesting IgG as the activator of complement via the CP. 
The pIgA1 complex may also be deposited on the mesangium due to antigen 
binding, related to an autoimmune response to mesangial-associated antigens. 
Therefore, screening for autoantibody-specificity is an important step in 
understanding the complexity of IgAN. 
There may be a role for the CFHR proteins in the pathogenesis of IgAN. CFHR5 
has been found deposited in the glomerulus of IgAN patients, suggesting a role 
for the protein in protecting or damaging the glomerulus. CFHR5 has been 
shown to exhibit both cofactor and decay-accelerating activity, so the role in 
IgAN is more likely to be protective (regulating complement activation). 
However, regulation does not appear to be efficient enough to stop the 
progression of disease. In CFHR5 nephropathy, a duplication of CFHR5 SCR 
domains 1-2 appears to be the only triggering factor that correlates with 
disease. This suggests CFHR5 may play a role in protecting the kidney from 
complement-mediated attack. 
The detection of IgA and IgG deposited on the mesangial surface may not be 
restricted to the autoimmune response to abnormally glycosylated pIgA1. There 
may also be autoantibodies targeting other mesangial surface antigens, namely 
complement regulatory proteins.  
There is increasing evidence of autoantibody responses against complement 
regulators in renal disease. Therefore, it is reasonable to hypothesise this about 
IgAN, a disease where there is evidence of autoantibodies and altered 
complement regulator expression in the diseased kidney82-84,105. 
As CFH has shown significant antigenicity in ‘autoimmune’ aHUS, CFH and the 
CFHR proteins are suitable candidates for IgA autoantibody screening. The 
pIgA1 Ab is also found in the circulation, so blood screening is a suitable place 
to begin. 
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5.2 Chapter Aims 
To develop ELISA protocols for screening human plasma for autoantibodies 
against CFH family proteins allowing aHUS and IgAN patient cohorts to be 
screened for the presence of autoantibodies to CFHR1, CFHR2, CFHR3, 
CFHR4B and CFHR5. 
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5.3 Results 
5.3.1 CFH fragment screening: CFH autoantibody binding specificity 
The presence of CFH autoantibodies were first identified in a French aHUS 
patient cohort162 However, it was unclear whether these autoantibodies were 
involved in the pathogenesis of disease, or were merely an epiphenomenon 
seen in ~10% of aHUS patients. To begin to understand the potential role that 
CFH autoantibodies play in aHUS pathogenesis, truncated CFH fragments were 
used to assess which region of CFH was being targeted. Previously defined 
CFH autoantibody positive patients from our Newcastle aHUS cohort were used 
in this analysis162. CFH fragments consisting of SCR domains 1-4, 8-15 and 19-
20 (kind gift from Prof. Paul Barlow, Edinburgh University) were coated in 
equimolar concentrations to an ELISA plate, followed by washing and blocking 
as previously described (Section 2.3.4.1). CFH autoantibody positive plasma 
samples were applied in-triplicate at a 1/50 dilution, followed by detection with 
HRPO-conjugated sheep anti-mouse IgG. 
From the 12 patients tested, 6 have a CFH autoantibody response which 
targets the CFH19-20 fragment (P2, P4, P7, P8, P10, and P11), 1 patient had 
specificity for CFH1-4 (P6), 1 patient for CFH8-15 (P12), and 3 patients with no 
specificity for the CFH fragments presented (Figure 5.1). These results 
indicated that in at least 50% of CFH autoantibody positive aHUS patients, the 
Ab is targeting the C-terminal SCR domains 19-20. This is main region involved 
in CFH binding to heparin, or the cell surface223,224.  
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Figure 5.1: CFH autoantibody binding to CFH fragments  
ELISA plates were coated with equimolar concentrations of CFH fragments, CFH1-4, 
CFH8-15, CFH19-20 and CFH4-5. Plates were blocking with 1% BSA/PBS, followed by the 
addition of a 1/50 dilution of patient sera. CFH IgG autoantibodies were detected using an 
HRPO-conjugated goat anti human IgG secondary Ab (1/4,000). 
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5.3.2 CFH autoantibody detection ELISA optimisation 
A full panel of rCFHR proteins were produced (Chapter 3) to screen human 
plasma for the presence of autoantibodies to CFH family proteins. As previously 
observed in our group, using human plasma in ELISA requires careful 
optimisation. For each rCFHR protein, a unique ELISA optimisation was 
completed to select the most suitable conditions for each screen (Section 
2.5.2). Data from the optimisation of the rCFHR1 ELISA screen has been 
selected as a typical representation of the optimisation process (Figure 5.2-3). 
5.3.2.1 CFHR1 autoantibody ELISA optimisation (Stage 1) 
A multiplex-ELISA was designed to assess the binding efficiency of CFH to 3 
different ELISA plate surfaces, using 3 different coating buffers and a range of 
rCFHR1 coat concentrations, as previously described (Section 2.5.2). Bound 
rCFHR1 was detected using an antigen-specific primary Ab. Binding of the 
primary Ab to the coated antigen (i.e. rCFHR1) may be altered depending on 
the biophysical interaction of the antigen with the plate surface. Therefore, this 
preliminary optimisation step is a guide to choosing the most appropriate 
coating buffer and coat concentration. Any potential autoantibodies are not 
necessarily going to bind to the same epitope as this primary Ab.  
The results indicate the highest signal, with the lowest concentration of coated 
rCFHR1 comes from using the ‘flexiplate’ in-conjunction with PBS buffer 
(Figure 5.2). The rCFHR1 signal was saturated at 1 μg/ml (A280 = 2.253), which 
is ~17% higher than the nearest rival plate/coating buffer combination at 1 
μg/ml. These rCFHR1 coating conditions were used in ‘Stage 2’ of the 
optimisation procedure.  
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Figure 5.2: Stage 1 of rCFHR1 autoantibody ELISA optimisation 
Stage 1 assessed rCFHR1 coating to 3 different plate surfaces (Flexiplate, Perkins Elmer and Maxisorb), with 3 different 
antigen coating buffers (PBS, ‘Coating Buffer’, and carbonate buffer), using a range of rCFHR1 coating concentrations (0.1-10 
μg/ml). Plates were coated overnight with rCFHR1, then blocked with BSA blocking buffer (PBS, 1% BSA, pH 7.4). Coating 
efficiency was assessed using C18/3 (1/2,000 dilution), followed by detection with HRPO-conjugated sheep anti-mouse IgG. 
The highest absorbance reading prior to signal saturation was considered the most appropriate conditions to carry forward to 
‘Stage 2’ testing. 
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5.3.2.2 CFHR1 autoantibody ELISA optimisation (Stage 2) 
Optimal conditions for coating rCFHR1 to the ELISA plate surface were 
established above. However, optimisation was required to assess how the plate 
blocking and human plasma would interact in these assays and determine the 
level of background binding seen. Therefore, the same 3 plates surfaces were 
assessed, in-conjunction with 3 different blocking reagents, and the addition of 
human plasma diluted 1/50 (essentially, serving as primary Ab). Based on the 
study by Moore et al. (2010)162, 99% of Blood Transfusion Service (BTS) 
plasma collected from healthy blood donor controls are found negative for CFH 
autoantibodies. Therefore, 10 test samples (BTS1-10) were selected to identify 
conditions whereby the proposed negatives give low, or no response in the 
assay. An IgG CFH autoantibody positive plasma sample was used as a 
positive control for binding to rCFHR1. 
After calculating the mean value of each BTS population in each set of 
conditions, the mean value closest to zero (A280) came from conditions using 
the ‘flexiplate’ surface in-conjunction with 1% BSA blocking buffer (Figure 5.3). 
As a secondary measure for condition selection, the CFH autoantibody positive 
control values across all conditions were assessed. The highest signal came 
from the ‘flexiplate’ surface, using 1% BSA blocking buffer (as before).  
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Figure 5.3: Stage 2 of rCFHR1 autoantibody ELISA optimisation 
‘Stage 2’ assessed 3 different plate surfaces (Flexiplate, Perkins Elmer and Maxisorb), 
with 3 different blocking buffers, (1% BSA, 1/5 dilution of ‘Ultrablock’, and 0.1% 
Tween20), using plasma from 10 BTS controls dilution 1/50 with PBS (serving as ‘primary 
Ab’). Bound IgG was detected using HRPO-conjugated goat anti-human IgG. ‘Stage 2’ 
testing included non-coated duplicate plates (to assess background signal) which was 
then subtracted from rCFHR1 coated plate data. The data presented is background 
subtracted. Controls: CFH autoantibody positive plasma (CFH+), C18/3 positive coat 
control (Control 1), secondary only HRPO-conjugated goat anti-human IgG (Control 2), 
and secondary only HRPO-conjugated sheep anti-mouse IgG (Control 3). The BTS 
population mean closest to zero (A280), and the highest ‘CFH+’ positive control value were 
considered when selecting the most appropriate conditions to use for autoantibody ELISA 
screening. 
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Figure 5.3: Stage 2 of rCFHR1 autoantibody ELISA optimisation 
‘Stage 2’ assessed 3 different plate surfaces (Flexiplate, Perkins Elmer and Maxisorb), 
with 3 different blocking buffers, (1% BSA, 1/5 dilution of ‘Ultrablock’, and 0.1% 
Tween20), using plasma from 10 BTS controls dilution 1/50 with PBS (serving as ‘primary 
Ab’). Bound IgG was detected using HRPO-conjugated goat anti-human IgG. ‘Stage 2’ 
testing included non-coated duplicate plates (to assess background signal) which was 
then subtracted from rCFHR1 coated plate data. The data presented is background 
subtracted. Controls: CFH autoantibody positive plasma (CFH+), C18/3 positive coat 
control (Control 1), secondary only HRPO-conjugated goat anti-human IgG (Control 2), 
and secondary only HRPO-conjugated sheep anti-mouse IgG (Control 3). The BTS 
population mean closest to zero (A280), and the highest ‘CFH+’ positive control value were 
considered when selecting the most appropriate conditions to use for autoantibody ELISA 
screening. 
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5.3.3 Screening for autoantibodies against CFH family proteins 
The presence of anti-CFH autoantibodies (IgG detection) had previously been 
assessed in our laboratory, and the results were subsequently published162. 
This, and previous studies, suggested a level of cross-reactivity with CFHR1 
and therefore, aHUS IgG autoantibody screening was carried out against each 
of the CFHR proteins. 
Autoantibodies detection in IgAN patient plasma is more focused upon IgA 
detection, on account of IgA (pIgA1) deposition in kidney glomeruli, and also in 
fluid-phase circulation. The antigenicity of pIgA1 is currently unknown, but 
based upon the co-localisation of both C3 and CFHR5 in the mesangium of 
IgAN patients suggests an involvement of complement proteins. The similarities 
between aHUS and IgAN suggest the possibility that autoantibodies to CFH or 
CFHR5 could arise or be associated with IgAN. In order to test this hypothesis, 
patients from both cohorts were screened.  
5.3.3.1 Screening for CFHR1 autoantibodies in aHUS and IgAN 
The terminal SCR domains of CFH and CFHR1 share a high degree of 
sequence homology (as previously described), so the previously observed CFH 
autoantibody response against CFH SCR domains 19-20 and CFHR1 domains 
4-5 (Figure 5.1) suggested full length rCFHR1 may also yield a positive result in 
these patients. 
The ELISA screen was completed using the methodology previously described 
(Section 2.3.4.1), using the predetermined parameters previously outlined. The 
74 patients in this screen were aHUS patients with a confirmed diagnosis, from 
Newcastle aHUS cohort162. To determine a threshold between a positive and 
negative result, 100 blood donor controls were screened and the A450 
population mean value, plus 2 standard deviations determined. Any absorbance 
reading above this threshold was considered positive, and any below was 
considered negative. Based upon these criteria, the aHUS cohort yielded 3 
positive patient samples (Figure 5.4a). These patients had been previously 
been identified as CFH autoantibody positive, with specificity for CFH19-20 and 
CFHR14-5. Within this cohort of 74 aHUS patients, there was one other CFH 
autoantibody positive patient sample expected to be CFHR1 autoantibody 
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positive. However, analysis of patient plasma during this screen yielded a 
negative result. This patient was positive for full-length CFH, and positive for the 
rCFH19-20, and rCFHR14-5 fragments, so it unclear why the plasma sample is 
negative for full-length rCFHR1. 
An IgAN patient cohort of 22 patients was randomly selected and screened 
against rCFHR1, testing for the presence of either IgG (Figure 5.4b) and IgA 
autoantibodies (Figure 5.4c). As previously described, a panel of 100 BTS 
controls were screened to determine a threshold for positivity in the ELISA. The 
results show no autoantibodies, of either IgG or IgA subclass, could be detected 
against rCFHR1 using this ELISA screen. 
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 Figure 5.4: rCFHR1 autoantibody screen in aHUS and IgAN patients 
rCFHR1 was coated to ELISA flexiplates, followed by blocking with 1% BSA blocking buffer. 
Patient and control plasma were diluted 1/50 and applied in-duplicate to the coated and non-
coated plates. No coat plate absorbance readings were subtracted from rCFHR1 coat readings 
and plotted above. (a) CFHR1 IgG autoantibodies in aHUS and BTS. (b) IgAN and BTS control 
plasma cohorts were screened for CFHR1 IgG autoantibodies. (c) IgAN and BTS control 
plasma cohorts were screened for CFHR1 IgA autoantibodies.  
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5.3.3.2 CFHR1 autoantibody screen in aHUS patient plasma 
As noted above, the aHUS screen for anti-CFHR1 autoantibodies yielded 3 
positive results (Figure 5.4a). To support previous data of rCFHR1 
autoantibody positivity, patient plasma was tested via western blot. The rCFHR1 
protein was loaded onto a 10% SDS-PAGE gel and transferred to nitrocellulose, 
followed by blocking with NFDM blocking buffer. The nitrocellulose was cut into 
strips and each strip incubated with the ELISA positive patient plasma, as 
previously described (Section 2.3.6). The strips were then washed and probed 
for the presence of bound human IgG. 
All 3 positive patients from the ELISA screen were also found to be positive in 
the western blot screen (Figure 5.5). This provides further validation of an anti-
CFH/rCFHR1 autoantibody response in these patients. It also validates the 
ability of the rCFHR1 autoantibody ELISA protocol to detect positive patients. It 
is important to note, each of these positive patients had the characteristic 
CFHR3/1 gene deletion162. Therefore, this is an anti-CFH autoantibody 
response, not an anti-CFHR1 response. Cross-reactivity is merely coincidental 
based up the sequence homology between the two proteins. No aHUS patients 
were found with solely with an anti-CFHR1 autoantibody positive response. 
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Figure 5.5: Western blot screen of rCFHR1 autoantibodies in aHUS 
rCFHR1 autoantibody positive plasma samples from the ELISA screen were re-screened via 
Western blot. rCFHR1 was separated on a 10% SDS-PAGE gel, transferred to nitrocellulose 
and lanes were cut into individual strips. Each strip was individually incubated with each 
rCFHR1 autoantibody positive plasma (diluted 1/50), followed by detection with HRPO-
conjugated goat anti-human IgG (1/10,000 dilution). aHUS patients are numbered 1-4, as before 
(Figure 5.4a) The strip blots shown are from film exposed for 30 secs. 
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5.3.3.3 CFHR2-4B autoantibody screens in aHUS and IgAN plasma 
Autoantibody ELISA screens were completed against rCFHR2, rCFHR3 and 
rCFHR4B using the protocol and parameters previously described (Section 
2.5.2). The results for IgG and IgA autoantibody detection in both patient 
cohorts yielded negative results for CFHR2 (Figure 5.6), CFHR3 (Figure 5.7) 
and CFHR4B (Figure 5.8).  
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 Figure 5.6: rCFHR2 autoantibody screen in aHUS and IgAN patients 
rCFHR2 was coated to ELISA flexiplates, followed by blocking with 1% BSA blocking buffer. 
Patient and control plasma were diluted 1/50 and applied in-duplicate to the coated and non-
coated plates. No coat plate absorbance readings were subtracted from rCFHR2 coat 
readings and plotted above. (a) CFHR2 IgG autoantibodies in aHUS and BTS. (b) IgAN and 
BTS control plasma cohorts were screened for CFHR2 IgG autoantibodies. (c) IgAN and 
BTS control plasma cohorts were screened for CFHR2 IgA autoantibodies.  
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Figure 5.7: rCFHR3 autoantibody screen in aHUS and IgAN patients 
rCFHR3 was coated to ELISA flexiplates, followed by blocking with 1% BSA blocking buffer. 
Patient and control plasma were diluted 1/50 and applied in-duplicate to the coated and non-
coated plates. No coat plate absorbance readings were subtracted from rCFHR3 coat 
readings and plotted above. (a) CFHR3 IgG autoantibodies in aHUS and BTS. (b) IgAN and 
BTS control plasma cohorts were screened for CFHR3 IgG autoantibodies. (c) IgAN and 
BTS control plasma cohorts were screened for CFHR3 IgA autoantibodies.  
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 Figure 5.8: rCFHR4B autoantibody screen in aHUS and IgAN patients  
rCFHR4B was coated to ELISA flexiplates, followed by blocking with 1% BSA blocking 
buffer. Patient and control plasma were diluted 1/50 and applied in-duplicate to the coated 
and non-coated plates. No coat plate absorbance readings were subtracted from rCFHR4B 
coat readings and plotted above. (a) CFHR4 IgG autoantibodies in aHUS and BTS. (b) IgAN 
and BTS control plasma cohorts were screened for CFHR4 IgG autoantibodies. (c) IgAN and 
BTS control plasma cohorts were screened for CFHR4 IgA autoantibodies.  
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5.3.3.4 CFHR5 autoantibody screens in aHUS and IgAN patient plasma 
No IgG subclass autoantibodies against CFHR5 could be detected when 
plasma samples from aHUS (Figure 5.9a), or IgAN (Figure 5.9b) patients were 
screened. However, in the IgAN patient screen, when detecting IgA subclass 
autoantibodies, 2 patient samples gave positive results (P5 and P14), 
equivalent to ~9.1% of this population (Figure 5.9c).  
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 Figure 5.9: rCFHR5 autoantibody screen in aHUS and IgAN patients 
rCFHR5 was coated to ELISA flexiplates, followed by blocking with 1% BSA blocking 
buffer. Patient and control plasma were diluted 1/50 and applied in-duplicate to the coated 
and non-coated plates. No coat plate absorbance readings were subtracted from rCFHR5 
coat readings and plotted above. (a) CFHR5 IgG autoantibodies in aHUS and BTS. (b) 
IgAN and BTS control plasma cohorts were screened for CFHR5 IgG autoantibodies. (c) 
IgAN and BTS control plasma cohorts were screened for CFHR5 IgA autoantibodies.  
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5.3.3.5 Western blot screening of CFHR5 autoantibodies in IgAN plasma 
To confirm the presence of anti-CFHR5 in IgAN patients, plasma from the 
positive patients were tested for reactivity with rCFHR5 via western blot, as 
previously described (Section 5.3.3.2). As the IgAN cohort is made up of just 
22 samples, it is was manageable to analyse all patient samples using this 
method and determine the relative advantages compared to ELISA.  
Plasma from 14 IgAN patients (1-2, 4, 8-16, 19-20) displayed reactivity 
(showing visible bands) in the rCFHR5 western blot screen (Figure 5.10). 
However, the band size in these 14 samples is significantly larger than 
estimated molecular weight of rCFHR5, and suggests this interaction is not to 
rCFHR5 but to a contaminating protein in the preparation. Initially, these results 
were considered false-positives. However, P5 displayed IgA reactivity to 3 
distinct bands on the blot, with the strongest signal from the ‘false-positive’ band 
(labelled ‘y’). The other bands corresponded to rCFHR5 (labelled ‘z’), and a 
potential homodimer isoform of rCFHR5 (labelled ‘x’). Therefore, at least 1 out 
of 22 IgAN patients appeared to exhibit an IgA autoantibody response to 
rCFHR5 in both the Western blot analysis, and the previous ELISA testing. 
The high level of false positives in this screen raised questions regarding the 
level and source of the contamination in the rCFHR5 sample. It is not unusual 
that a purified protein sample would contain trace amounts of contaminating 
proteins. As highlighted in Chapter 3, any potential for interference is reduced 
when the sample is diluted for use in the ELISA screen. Aside from this, 
interference should be nullified by the combination of the ELISA and 
confirmation via western blot. Therefore, it was deemed essential to determine 
the origin of these contaminating proteins and therefore we had the rCFHR5 
sample analysed using peptide mass fingerprinting (PMF). 
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 Figure 5.10: Strip blot of IgAN IgA autoantibodies against rCFHR5 
(a-c) rCFHR5 was loaded on three 10% SDS-PAGE gels, transferred to nitrocellulose and 
lanes were cut into strips. Each strip was incubated with a 1/50 dilution of IgAN plasma (2ml 
volume), followed by detection with an HRPO-conjugated rabbit anti-human IgA (1/10,000 
dilution). IgAN patients are numbered 1-21. A secondary only negative control was also 
included (2nd only). The strip blots shown are from film exposed for 10 min. (d) Patient 11 
from panel (b) has been selected and compared to an SDS-PAGE separation of rCFHR5 
(with Coomassie staining), after over-loading the protein to highlight contaminating protein 
bands. These bands were cut from the gel and identified via peptide mass fingerprinting 
(PMF). Band was named x, y and z prior to identification via PMF.  
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5.3.3.6 Identification of proteins in CFHR5 protein sample 
To identify the origin of the contaminating bands in the purified rCFHR5 sample, 
the sample was ‘overloaded’ onto a 10% SDS-PAGE gel, separated by 
electrophoresis and Coomassie stained. This highlighted three bands (Figure 
5.10d), each of which was individual cut from the gel and sent for PMF 
(Pinnacle, Newcastle University). 
The PMF results identified band ‘x’ and ‘z’ as CFHR5, providing further 
confirmation of homodimeric and monomeric conformations of the protein, 
respectively. However, band ‘y’ was identified as bovine CFH. Bovine CFH will 
be a constituent of the CHO/rCFHR5 tissue culture SN, which is supplemented 
with 10% FCS. Bovine CFH is not routinely purified during a HisTag purification 
(at least at these levels) based upon other purifications of rCFHR proteins. This 
suggests that native bovine CFH (no HisTag) has complexed with human 
rCFHR5 and is subsequently, HisTag purified. The importance of this finding 
remains to be established.  
Taking into consideration the homology between human and bovine CFH 
(~73%), the previous conclusion regarding the detection of 14 false-positive 
results (Section 5.3.3.7) is likely correct as 13 of the 14 patients do not have a 
CFHR5 autoantibody phenotype, but may interact with exogenous bovine CFH. 
Exposure to bovine CFH in milk or meat products could explain this reactivity. 
Again, the importance of such a finding is unclear. The anomalous false-positive 
results suggest screening IgAN plasma against human CFH and purified bovine 
CFH. 
5.3.3.7 ELISA Screening for CFH autoantibodies in IgAN patient plasma 
Optimisation of the ELISA screen for CFH was unable to identify suitable 
conditions for the ELISA screen of IgA autoantibodies. Further investigation is 
required to find suitable conditions for this assay.  
5.3.3.8 Western blot screening of CFH autoantibodies 
Due to the problematic ELISA screen, and research time constrains, IgAN 
patients were screened against human CFH via western blot, as previously 
described (Section 5.3.3.2). 
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The results of the Western blot screen show CFH IgA autoantibodies present in 
the plasma of 7 out of 22 IgAN patients (3, 6, 10, 17, 20, 21 and 22), accounting 
for 31.8% of this cohort. However, only patient 10 and 20 shared an IgA 
autoantibody response to both bovine and human CFH. However, all 3 BTS 
controls were CFH IgA autoantibody positive. This suggests the CFH IgA 
autoantibody response is also present within the normal population. However, 
conclusions cannot be drawn from this preliminary data regarding the 
significance of this CFH IgA autoantibody response in IgAN patient plasma.  
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 Figure 5.11: Strip blot of IgAN IgA autoantibodies against human CFH 
CFH was loaded on 4x 10% SDS-PAGE gels, transferred to nitrocellulose and lanes 
were cut into a strips. Each strip was incubated with a 1/50 dilution of IgAN plasma (2ml 
volume), followed by detection with an HRPO-conjugated rabbit anti-human IgA 
(1/10,000 dilution). IgAN patients are labelled P1-22, and normal controls, C11, C20 and 
C22. L20/3 (1/2,000) was used as a CFH positive control (pos). A secondary only 
negative control was also included (neg). The strip blots shown are from film exposed for 
10 min.  
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5.4 Discussion 
Autoantibody screening of aHUS plasma did not detect an autoantibody 
response to CFHR proteins 2-5. Screening against CFHR1 confirmed the 
presence of 3 autoantibody positive patients. However, all 3 patients had 
previously been tested and identified as CFH autoantibody positives, with 
specificity for CFH19-20, and CFHR14-5 domain fragments. Additionally, each 
patient was previously determined as homozygous deficient for CFHR1 via 
MLPA and western blot162. Therefore, this positivity can be considered as a 
CFH autoantibody response and not against CFHR1. These data demonstrate 
that the CFH autoantibody response in aHUS patients is restricted CFH, as no 
observable cross-reactivity with the CFHR proteins exists. Additionally, the are 
no patients with a novel CFHR-specific autoantibody phenotype (i.e. CFHR 
autoantibody positive, but CFH autoantibody negative). We have previously 
shown the CFH autoantibody response in aHUS primarily targets the C-terminal 
cell surface recognition domain, and it is this interference that precipitates with 
aHUS162. Therefore, no evidence of CFHR autoantibodies in aHUS suggests 
the CFHR proteins are not involved the ‘cell surface’ regulation of complement 
activation that appears to be key to the pathogenesis of this disease. 
While the CFHR autoantibodies do not appear to be involved in aHUS, it is 
important to consider them in other diseases with a CFH autoantibody 
phenotype. In particular, MPGN2 patients present with mutations and CFH 
autoantibodies that predominantly bind the regulatory domain of CFH. As 
previously described, deficiency of CFH regulatory activity is what drives the 
progression of CFH-associated MPGN. The CFHR proteins exhibit C3/C5 
convertase regulatory activity, and/or C3b binding capability, so their role in the 
pathogenesis of MPGN should be considered. Therefore, autoantibody 
screening in these patients is important for future work, particularly CFHR5 as 
at-risk gene variants are associated with MPGN2174.  
In my analysis of CFHR autoantibodies in aHUS, only IgG autoantibodies were 
considered, as previously reported CFH autoantibodies were of this 
isotype163,178,218,220. IgM screening could be considered, but this may include 
detection of ‘natural’ Abs which not necessarily play a role in pathogenesis. The 
detection of IgA autoantibodies is also a consideration, especially considering 
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the role of IgA in IgAN, another form of glomerulopathy, as previously 
described. 
The western blot autoantibody screen of IgAN patients highlighted Ab 
responses against bovine CFH (n=14), human CFH (n=7), and rCFHR5 (n=2-4). 
When these results presented, a hypothesis was made regarding bovine CFH 
positives most likely resulting in a human CFH IgA autoantibody response. 
However, of the patients tested, only 2 patients (10 and 20) were positive to 
both species variants of CFH. The human CFH data yielded lower band 
intensities, relative to the bovine CFH results. Interesting, the human CFH 
protein is approximately 10x more concentrated than the contaminating bovine 
CFH (1 μg to 0.1 μg, respectively), yet the IgAN autoantibody response is far 
greater for bovine CFH.  
The disparity between binding to bovine and human CFH was an unexpected 
result, but it does raise some interesting questions regarding the autoantibody 
status of IgAN patients. The high bovine CFH signal relative to human CFH, 
suggests bovine CFH may be a triggering antigen in the development of this 
response. In triggering an IgA response suggests contact with an antigen that 
comes into contact with the mucosal immune system, such as a gastrointestinal 
(GI), urogenital or respiratory infection, or GI food antigen. Sampling of the GI 
tract by M cells has the potential to trigger an autoimmune response via 
‘molecular mimicry’. As bovine CFH is presented to immune cells (e.g. antigen 
presenting cells, B-cells) in the lamina propria, a pAb response against bovine 
CFH could ensure. B-cell receptors with cross-reactivity for epitopes within 
human CFH are then selected and immunological tolerance is broken. This may 
also explain why a CFHR5 IgA autoantibody response is present; selection of 
self-antigen epitopes from a polyclonal B-cell response against a highly 
homologous xenogeneic protein. 
In IgAN patients there is an increase prevalence of coeliac disease when 
compared to the healthy population, leading to the hypothesis that food 
antigens may serve as a trigger for IgAN onset and progression225. This 
supports the hypothesis of bovine CFH potentially being involved in disease 
pathogenesis, at least within a sub-population of IgAN patients. 
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While several IgAN patients have been identified with an IgA response to CFH 
and CFHR5, it remains that there is also an antigenic response to these 
proteins in BTS normal control population. This may suggest the IgA 
autoantibody response is a naturally occurring Ab found in a percentage of the 
population. After all, bovine-based food products are a significant part of the 
western diet. Therefore, it is important to establish whether there is a 
statistically significant difference in IgA autoantibodies in IgAN patients verses a 
normal control population. 
The CFHR5 IgA autoantibody ELISA screen highlighted 2 positive patients. 
Further confirmation came from the rCFHR5 IgA autoantibody western blot 
screen. However, the ELISA screen failed to detect 12 out of the 14 positives, 
as found in the western blot. This is most likely due to the bovine CFH 
contaminant being diluted to an undetectable level on the ELISA coating 
surface. To provide further clarification of these results, both the ELISA and 
western blot screen of IgAN plasma would benefit from using a CFHR5 sample 
with a higher level of purity. 
As previously described, rCFHR5 purification also led to the purification of a 
significant amount of bovine CFH in the sample (~20%, as measured via 
densitometry). This level of contamination was not seen until the protein was 
‘over-loaded’ on an SDS-PAGE gel. It appears that the contaminating bovine 
CFH has been purified with rCFHR5, suggesting the proteins have complexed 
together in some way. It is unlikely this is a coincidental result, as rCFHR5 was 
purified from a solution containing a multitude of different bovine serum 
proteins. Yet, bovine CFH was the selected protein. It is well documented that 
there is a high degree of sequence conservation in CFH, across mammalian 
species. Bovine CFH itself has been shown to regulate human complement 
activation via C3b binding226. If bovine CFH is able to complex with human 
CFHR5, its human counterpart may have the capacity to do the same. If there 
was an interaction between the proteins, this may suggest a dual or support role 
in a complement regulatory process. This could be investigated in future work. 
In summary, there is currently no evidence of a novel CFHR autoantibody 
process in aHUS patients, suggesting the CFHR proteins are not involved in a 
complement regulatory process in this disease. However, in a preliminary 
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cohort of IgAN patients, IgA autoantibodies against CFH and CFHR5 have been 
identified in ~32% and ~9% patients, respectively. Interestingly, IgA Abs against 
bovine CFH were identified in >60% of IgAN patients.  
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Chapter 6 
6. Conclusion and Future Work 
6.1 Project Summary  
During this research project, I have successfully generated a full panel of 
recombinant human CFHR proteins, produced in a mammalian expression 
system and purified using HisTag affinity chromatography (Chapter 3) 
CFHR1, CFHR3 and CFHR4B were selected to produce mAbs, for use to 
develop ELISA tests to specifically measure CFHR concentration in aHUS and 
normal control plasma (Chapter 4). CFHR-specific mAbs would also be utilised 
as general reagents within our research group for detection of native and 
recombinant CFHR proteins. Immunisations with CFHR1 and CFHR4B were 
completed first due to antigen availability. However, as work progressed, it 
became clear there would not be sufficient time to complete the CFHR3 mAb 
production.  
I was able to successfully produce 1 x CFHR1 (R1/1037), and 3 x CFHR4 
(R4/244, R4/123 and R4/277) mAbs, and fully characterise their function. After 
specificity testing, R1/1037 showed cross-reactivity for CFHR2, so was deemed 
unsuitable for use in a sandwich ELISA to specifically detect CFHR1 
concentration, unless the standard curve is sufficiently optimised to include 
ratios of rCFHR1 and rCFHR2. In the plasma test samples, R1/1037 would bind 
CFHR1 and CFHR2 at an unknown ratio, so comparing this to a CFHR1 only 
standard curve could deliver spurious and inconsistent results. However, 
R4/244 and R4/277 showed evidence of specificity for CFHR4. R4/244 was 
selected and used to initially develop an ELISA for specific detection of CFHR4. 
Western blot analysis of R4/244 was only detecting CFHR4A, yet CFHR4B was 
the antigen being used to create the standard curve. This was deemed an 
inefficient system for the exact quantification of plasma CFHR4A/B, but 
considered suitable for comparing disease and control group data as the result 
from each group are relative.  
An ELISA was set up using R4/244 to assess if there was a difference in 
CFHR4 levels between 10 x BTS controls, compared with 10 x aHUS samples, 
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including three patients with the novel CFHR1/4 deletion162. No significant 
difference was seen between the two groups. Further testing is required on a 
larger population of plasma samples, the data presented is considered 
preliminary. 
As part of the aforementioned screening methodology, after producing a panel 
of recombinant CFHR proteins, the proteins were used to screen both aHUS 
and IgAN patient plasma for the presence of CFHR autoantibodies (Chapter 5). 
In the aHUS cohort, there were no novel findings presented regarding CFHR 
autoantibodies, apart from the expected CFHR1 autoantibody response in three 
CFH autoantibody positive patients. As previously described, these patients are 
CFHR1 homozygous deficient so should never have been exposed to CFHR1. 
To have found an autoantibody response targeting CFHR1 only, (no CFH cross-
reactivity) was one of the aims of screening a full aHUS cohort, rather than only 
the CFH autoantibody positive patients. 
As there was no evidence of CFHR autoantibodies in the aHUS patient cohort, 
and it remains unclear whether the CFHR proteins play a role in complement 
regulation (in vivo), either in the kidney, or elsewhere in the body. There have 
been some recent findings which indicate CFHR5 may be involved in 
complement regulation in the kidney. CFHR5 nephropathy suggests CFHR5 is 
involved in complement regulation197. In vitro analysis shows CFHR5 has both 
decay-accelerating and cofactor activity172, and the extended CFHR5 mutant 
protein correlates with this renal nephropathy175,227,228. Additionally, CFHR5 was 
recently screened in a cohort of aHUS patients, and 3 novel heterozygous 
missense mutations were discovered associated with the disease173. Another 
set of CFHR5 mutations were also shown in a US aHUS cohort229. It appears 
there is sufficient genetic evidence to implicate CFHR5 variants in disease, but 
protein functional analysis is required to clarify these findings. 
A small cohort of IgAN patients were screened for CFHR autoantibodies. Due to 
the involvement of IgA Abs in this disease, IgA and IgG detection was 
investigated. There were no CFHR IgG autoantibodies detected. However, 
there were some interesting results from the IgA screen against CFHR5. The 
results from the ELISA were inconsistent with the western blot analysis. 
However, the western blot data was able to offer a better interpretation of the 
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autoantibody positive results. Western data (Figure 5.10) highlighted IgA 
autoantibody positivity against CFHR5 in at least 2 of the patients (11 and 16), 
with 2 others displaying a faint band in the position the CFHR5 dimer (patients 
19 and 20). These preliminary data suggest that a selection of IgAN patients 
have IgA autoantibodies targeting CFHR5. This is sufficient data to test a larger 
population of IgAN patients for the presence of IgA CFHR5 autoantibodies. 
However, in these analyses cross-reactivity with contaminating bovine CFH 
influenced the presentation of results., thus highlighting the need to further 
purify rCFHR5 from the contaminating elements in the sample. A high resolution 
chromatography column may be able to separate out these proteins. 
Alternatively, growing the established CHO/rCFHR5 cell clone in serum-free 
media would serve as a less expensive method for increasing rCFHR5 purity. It 
would not be advisable to only screen plasma using western blot, using the 
contaminated CFHR5 sample, as a secondary mechanism to clarify results is 
important for consistency and relative accuracy between tests. 
From the perspective of future work with CFHR5, it would be interesting to see 
whether human CFH is able to complex with human CFHR5 in an in vitro assay, 
as suggested by co-purification of rCFHR5 and bovine CFH in the HisTag 
purification protocol. If this were the case, it may suggest CFH and CFHR5 are 
working together in some way to regulate complement. As bovine CFH was 
eliciting a positive IgA autoantibody response, this led to testing the cross-
reactivity with human CFH. In ~32% of the IgAN plasma screened, western blot 
data showing IgA autoantibodies against human CFH. As before, this is 
sufficient evidence to begin screening a larger population of IgAN patients, and 
normal controls. CFH screening via ELISA proved unsuccessful. For further 
optimisation, there are now CFH IgA autoantibody positive controls so ELISA 
parameters can be selected around the upper limits of these positive controls. 
Finding CFHR5 and CFH autoantibodies in IgAN, potentially highlights another 
dimension in the pathogenesis of the disease. If the autoantibodies were 
blocking the complement regulatory function of CFHR5 and/or CFH, this would 
help explain why there is scattering of C3 on the mesangial surface. It would be 
interesting to screen complement genes in IgAN patients, to assess whether 
there is evidence of a link between the disease and complement dysregulation 
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at a genomic level. CFH has been screened in a small cohort of patients, but no 
susceptibility factors were found100. However, more recent evidence identified a 
novel mutation in the CFH N-terminal region to be associated with IgAN. It 
appears there is a role of CFH and/or CFHR5 in the pathogenesis of IgAN. 
The complement regulator CFH was first identified as major risk factor in aHUS 
in 1983230. Since this seminal discovery, our understanding of the complexity of 
aHUS, and several other disease states has become much clearer and more 
manageable to present a coherent disease model. CFH is just one component 
of a much wider community of proteins involved in the complement system, but 
understanding its involvement in disease has led to the development of a 
standard methodology for screening aHUS patients for risk-associated features 
of the disease, including screening for rare and common variants in 
complement regulatory and activatory genes, genomic rearrangements and 
autoantibodies. Results have highlighted several other risk-associated genetic 
variants in other complement regulators (CD46, CFI and TMBD), and 
complement activators (CFB and C3)118-120,123. CFH autoantibodies appear in 
~10% of aHUS patients, and correlation with CFHR3/1 (or CFHR1/4) 
deletion162. However, since evidence of a potential autoimmune aspect to aHUS 
was first published in 2005218, CFH autoantibodies have also been described in 
MPGN (type I and II), where the autoantibody response was targeted to the 
regulatory domain of CFH231. We were able to identify CFH autoantibodies in 
AMD, in association with the CFHR3/1 deletion, but age-matched controls had a 
higher mean CFH autoantibody titre139. This suggested the CFHR3/1 deletion 
was conferring protection against the development of an autoantibody 
response. More recently, CFH autoantibodies were found associated with 
rheumatic diseases, SLE and RA232. Most interesting is that the autoantibody 
response in rheumatic disease also presents with a deficiency of CFHR3/1. 
Prior to this study, this had only been observed in aHUS and AMD patients. 
However, the autoantibody response in these patients was scattered across 
several epitopes of CFH, compared with C-terminal clustering in aHUS. This 
suggests that individuals with a CFHR3/1 deficiency have an increased risk of 
developing a CFH autoantibody response, but the specificity of Ab binding is not 
always geared towards the C-terminal region as suggested by aHUS data. 
Therefore, the CFH autoantibody C-terminal clustering is precipitates with 
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aHUS. This further implicates the CFH autoantibodies as being involved in a 
pathogenic process in aHUS, rather than a mere epiphenomenon that develops 
secondary to other disease-associated factors. 
6.2 Future Work 
To further establish a robust CFHR-specific detection ELISA, the specificity of 
the mAb response needs to be driven a protein fragment. The previous 
methodology aimed to produce hybridomas secreting a selection of Ab clone to 
target different regions of each protein. However, this process has proved 
unsuccessful in generating an appropriate CFHR-specific monoclonal. There 
are limitations to using fragment for immunisation (e.g. restricted antigen 
profile), but this appears to be the only option to increase the chances achieving 
targeted specificity for such an assay. Any cross-reactivity is going to interfere 
with the accuracy of the results. As more disease states are presenting with a 
CFH autoantibody phenotype, in-conjunction with a CFHR3/1 deletion, the 
demand for such a test may increase. 
While we have CFHR4-specific mAbs, the accuracy of detecting CFHR4 using 
CFHR4B in the standard curve may present us with an inaccurate 
measurement of each protein (as previously described). As presentation of the 
CFHR4/1 deficiency has only been shown in three aHUS patients to-date, it 
may be more sensible to focus on CFHR1 and CFHR3 for screening to further 
establish whether CFHR1 deficiency is primarily responsible for triggering the 
CFH autoantibody presentation. Screening of CFHR proteins in aHUS is 
complete, so the detection of autoantibodies should now focus on other proteins 
that are yet to be screened, but have been identified as conferring and 
increased risk of disease, such as TMBD, CFB and C3. 
As previously described, a larger cohort of IgAN patients should now be 
screened against CFH and CFHR5, to assess the frequencies of this 
autoantibody phenotype between disease and normal controls. This is an 
essential next step, as ratio of positive results within the population needs 
careful consideration before association with disease can be attributed. 
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 Appendix I: pDEF/rCFHR plasmid constructs 
The pDEF/L5H6 plasmid was used as the base construct to build each rCFHR expression 
plasmid. Each inserted rCFHR cDNA was inserted excluding the native stop codon, resulting 
in the addition of the L5H6 motif to the C-terminus of each recombinantly expressed CFHR 
protein. (a-d) rCFHR1-4B cDNA were inserted using XbaI and BamHI RE sites. (e) rCFHR5 
cDNA was inserted using SpeI and BamHI RE sites.  
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Appendix II: mAb and pAbs used 
Supplier Code Ab 
Santa Cruz Biotech sc-47685 C18/3 (anti-CFH mAb; IgG1) 
Santa Cruz Biotech sc-47686 L20/3 (anti-CFH mAb; IgG1) 
AbD serotec MCA509G OX24 (anti-CFH mAb; IgG1) 
Calbiochem OB05-100UG Anti-His•Tag® (mAb; IgG1) 
Calbiochem 341276 Goat anti-CFH pAb 
Jackson ImmunoResearch 115-035-003 HRPO-conjugated goat anti-mouse IgG 
(H+L)  
Jackson ImmunoResearch 515-035-071 HRPO-conjugated sheep anti-mouse IgG 
(γ-chain specific) 
Jackson ImmunoResearch 115-006-075 HRPO-conjugated goat anti-mouse IgM 
(μ-chain specific) 
Jackson ImmunoResearch 115-006-071 HRPO-conjugated goat anti-mouse IgG 
(γ-chain specific) 
Jackson ImmunoResearch 109-035-008 HRPO-conjugated goat anti-human IgG 
(γ-chain specific) 
Jackson ImmunoResearch 309-035-011 HRPO-conjugated rabbit anti-human IgA 
(α-chain specific) 
Jackson ImmunoResearch 111-035-045 HRPO-conjugated goat anti-rabbit IgG 
(H+L) 
 
 
Name Antigen Cross-reactivity 
R1/1037 (mAb; IgG1) rCFHR1 CFHR2 
R4/244 (mAb; IgG1) rCFHR4A None 
R4/277 (mAb; IgG1) rCFHR4A/B None 
R4/123 (mAb; IgG1) rCFHR4A/B CFH 
Rabbit anti-CFHR4B 
polysera  
(IgG response) 
rCFHR4B CFH 
CFHR3 
CFHR4A 
CFHR4B? 
Rabbit anti-CFHR5 
polysera 
(IgG response) 
rCFHR5 CFH 
CFHR1 
CFHR2 (low level binding) 
CFHR4A 
CFHR5 
(b) mAb and pAb Abs produced in-house 
(a) Commercial primary and secondary Abs 
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Appendix III: Presentations and Publications 
 
Presentations 
1.  European Meeting on Complement in Human Disease; Visegrad, Hungary 
(5th-8th September 2009). “Towards a highly specific Factor H ELISA for 
rapid screening of patient sera” (poster presentation). 
2. ICM Research Day, Newcastle University, Newcastle upon Tyne, UK (23rd 
June 2010).“Assessing the function of the CFHR proteins in health and 
disease” (poster presentation). 
3. ICM Research Seminar, Newcastle University, Newcastle upon Tyne, UK 
(6th December 2011). “Autoantibodies in complement-mediated kidney 
diseases” (talk presentation). 
 
Publications: 
1. Moore et al., (2010) Association of factor H autoantibodies with deletions of 
CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in 
patients with atypical haemolytic uremic syndrome. Blood 115:2;379-387. 
2. Dhillon et al., (2010) Complement factor H autoantibodies and age-related 
macular degeneration. Invest Ophthalmol Vis Sci 51:11;5858-63. 
3. Goodship et al., (2012) Factor H autoantibodies in membranoproliferative 
glomerulonephritis. Mol Immunol 52:3-4;200-6. 
4. Holmes et al., (2012) Determining the population frequency of the 
CFHR3/CFHR1 deletion in the regulation of complement activation (RCA) 
gene cluster at 1q32 (publication under review at time of printing thesis). 
Copies of each publication can be found at the back of this thesis, with notes 
outlining my contribution to each. 
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4. Holmes et al., (2012) Determining the population frequency of the 
CFHR3/CFHR1 deletion in the regulation of complement activation (RCA) 
gene cluster at 1q32 (publication under review at time of printing thesis). 
Contributions 
Tables 2-4: I conducted the analysis of MLPA results to determine CFHR3/1 
copy number within the UK control cohort. This data set is not included in this 
thesis. 
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